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Abstract 
 
Relapse to drug taking is a major factor contributing to the low success rate of opioid 
addiction treatment programmes. Recently, studies have revealed a 
buprenorphine/naltrexone combination had successfully increased the treatment 
retention rate (compared to naltrexone alone) among heroin addicts (with history of 
cocaine abuse) who had undergone detoxification. However, buprenorphine and 
naltrexone could not be administered as a single formulation due to their different 
bioavailability, which could create compliance issues. Therefore, in this project, we 
aimed to synthesise a series of ligands each having the pharmacological profile of 
the buprenorphine/naltrexone combination (partial agonist (ORL-1 receptors), 
antagonist (- and -opioid receptors)). Based on the group’s previous work, this 
profile can be achieved within the orvinols series. Compound BU127, a 
buprenorphine analogue with phenyl substituent (C20) is very close to the desired 
profile. Therefore, in order to optimize BU127’s profile, we designed and 
synthesised a series of aromatic analogues, including analogues with a small group 
attached to the aromatic system to increase the ORL-1 receptor efficacy, while 
retaining the low efficacy / antagonist activity at the -opioid receptor and antagonist 
activity at -opioid receptor. However, [35S]GTPS screening has shown a sudden 
increase of -opioid receptor efficacy with these modifications. The related 
compound BU10119, having a C7-methyl, met the desired profile at all targeted 
receptors in the [35S]GTPS screen. A few analogues were selected for further 
evaluation in functional assays in the isolated tissue preparations (rat vas deferens 
(for the ORL-1 and -opioid receptors) and mouse vas deferens (for the -opioid 
receptor)) to estimate their binding affinity (KB) and potency (pA2) of the compounds 
relative to buprenorphine, using Schild analysis and Schild equation. Of the 
analogues synthesised, only compounds BU127 and BU10119 have met the desired 
profile at the targeted receptors (competitive reversible at the ORL-1 and -opioid 
receptors) and having binding affinity at each receptor similar to buprenorphine 
(ORL-1, - and -opioid receptors). Based on these results, at this point, the 
optimum features of buprenorphine analogues in order to achieve the targeted 
profiles are having a small group at C7 and a 6-membered aromatic substituent at 
C20 without any substituent group attached to the aromatic ring.  
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1.1 General Introduction 
 
Drug addiction is a chronic brain disorder and illness characterized by the persistent 
compulsive drug-seeking and drug-taking behaviours regardless of the harmful 
consequences (Feltenstein et al., 2008; Trigo et al., 2010). Substances that cause 
addiction usually share similar characteristics such as having reinforcing effects.  
According to the National Institute on Drug Abuse (NIDA), the commonly abused 
substances are opioids / morphine derivatives (eg: heroin), stimulants (eg: cocaine, 
amphetamine-type stimulants (ATS)), alcohol (ethanol), cannabinoids (eg: 
marijuana), dissociative drugs (eg: ketamine) and hallucinogens (eg: lysergic acid 
diethylamide (LSD)) (NIDA, 2010). 
.  
In 2008, the United Nations Office on Drugs and Crime (UNODC) estimated that 
3.5-5.7% (155-250 million) of the world population aged 15-64 had used illicit 
substances at least once, with the highest usage reported for marijuana (2.9-4.3%), 
followed by ATS (0.3-1.2%), cocaine (0.3-0.4%) and opioids (0.3-0.5%) (UNODC, 
2010). Alcohol was not included in this report. Based on the UNODC latest report 
(2010), the treatment demands for opioids ranked the highest among the list of drug 
problems (opioids, cannabis, cocaine-type, ATS) being treated in the European 
countries and Asia region in 2008, with the percentage of 57% and 62% 
respectively. These data which were based on delivery of treatment services for 
problem drug users indirectly reflects the main type of drug abuse in those regions 
(opioids) (UNODC, 2010). 
 
Various treatment options for opioid addiction are available, either detoxification 
followed by long term maintenance on substitution therapy (usually 2 years 
minimum) or rapid detoxification followed by relapse prevention (WHO, 2009). The 
three main types of opioid dependence treatment are opioid agonist (full and partial 
opioid agonist), opioid antagonist and -adrenergic agonist (eg: clonidine) 
(McLellan et al., 2000; WHO, 2009). The opioid agonists and the opioid antagonist 
act directly on the -opioid receptors, the same receptor on which abused opiates 
such as heroin, morphine and oxycodone act (Dole, 1988). Methadone (a long full 
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acting -opioid receptor agonist) acts in a similar manner to morphine and heroin 
and so is used in substitutions for illicit opiates for long-term maintenance therapy. 
Naltrexone (a non-selective opioid receptor antagonist) is used, after successful 
detoxification in attempt to prevent relapse, to directly block the -opioid receptor 
responsible for the reinforcing effects of illicit opioids (Kirchmayer et al., 2002). 
Clonidine, an -adrenergic agonist acts by decreasing the noradrenaline (NA) 
activity in the central nervous system, which is increased during withdrawal 
(Gossop, 1988; Nutt et al., 2008). As such, clonidine is most often used during 
detoxification to reduce the severity of withdrawal symptoms (Ponizovsky et al., 
2006; WHO, 2009). It is not widely used in the outpatient settings, especially 
because of the hypotension and sedation side effects (Mannelli et al., 2012).   
 
The principle behind the substitution (or maintenance therapy) with the -opioid 
agonist is to substitute and stabilize addicts with a safe and clinically controlled dose 
of opioid under medical supervision (MOH, 2005). Methadone and buprenorphine 
are equally recommended by the World Health Organization (WHO) for opioid 
agonist maintenance therapy (WHO, 2009). Since methadone is cheaper than 
buprenorphine and has been in use for longer, it is more widely used in many 
countries as the first line treatment for opioid-dependence (Saxena, 2010). 
However, there is not only a high drop-out rate from methadone maintenance 
treatment programmes, which was reported to be associated with concomitant use 
of cocaine and opioids (Montoya et al., 2004),  but the incidence of relapse back to 
taking illicit opiates is also high, with around 55-80% relapse rate within 1 year of the 
treatment completion (Tkacz et al., 2012).  
 
Even after receiving treatment, the majority of opioid addicts relapse back to drug-
taking following a period of abstinence. Furthermore, a large proportion of opioid 
addicts are addicted to more than one drug of abuse, termed ‘polydrug addiction’ 
(addiction to multiple substances from different pharmacological groups, eg: heroin 
and cocaine) (Downey et al., 2000; Leri et al., 2003; McCann, 2008; McLellan et al., 
2000; Minozzi et al., 2011). Various studies have shown that naltrexone was only 
clinically beneficial for highly motivated patients and the overall retention rate with 
this treatment agent was low due to the serious withdrawal side effects (Gerra et al., 
2006; Rothman et al., 2000). Moreover, post-hoc studies to review the effectiveness 
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of the naltrexone alone treatment to prevent relapse have shown that this single 
pharmacotherapy agent has no significant effects in preventing relapse to opioid use 
compared to placebo (Kirchmayer et al., 2002; Minozzi et al., 2011). Therefore, the 
current treatment programmes for opioid addiction are poorly effective, and there 
are no current effective treatments for polydrug addiction. 
 
Although buprenorphine is listed as one of the pharmacological options for opioid-
dependence treatment, due to its cost, the use of buprenorphine is believed to be 
less than optimal. Buprenorphine is an opioid with partial agonist activity at the -
opioid receptor. As such, as described above, it is used as an opioid substitution 
therapy. However, it has a more extensive pharmacology than methadone as it also 
acts as an antagonist at the -opioid receptor, an antagonist at the -opioid receptor 
and a partial agonist at the opioid receptor like (ORL-1) receptor (Bloms-Funke et 
al., 2000; Gerra et al., 2006; Leander, 1988; Lutfy et al., 2004; Martin et al., 1976; 
Montoya et al., 2004). The mixed agonist/antagonist profile of buprenorphine has 
made this drug unique compared to the other opioids used for substance abuse 
related pharmacotherapy. Not only has it a lower dependence liability, studies have 
also suggested that buprenorphine may be effective in treating cocaine addiction 
and alcohol dependence, leading to the idea that buprenorphine-based therapies 
may be beneficial for polydrug addiction treatment (Ciccocioppo et al., 2007; June et 
al., 1998; Kosten et al., 1989; Lutfy et al., 2004; Mello et al., 1993; Mello et al., 1989; 
Montoya et al., 2004).  
 
These two problems (relapse and polydrug addiction) have become the major 
concern among the healthcare providers and a challenge to the scientists to find 
solutions to overcome these matters. In this project, our main aim is to find a new 
drug lead to prevent relapse following successful detoxification. The 
pharmacological profile targeted may also have potential for the treatment for 
polydrug abuse. 
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1.2 Neurocircuitry of Drug Addiction 
 
All drugs of abuse exert their rewarding or euphoric effects by increasing dopamine 
(DA) release in the nucleus accumbens (NAcc) and frontal cortex (Figure 1.1) 
(Hollinger, 2008).  
 
 
Figure 1.1: Location of brain regions related to drug addiction (Thatcher et al., 2008). 
 
The cell bodies of the dopaminergic neurons responsible for the rewarding effects 
are located in the ventral tegmental area (VTA) in the mid brain (Spanagel et al., 
1999). The corticostriatolimbic circuits, where the end terminals of the dopaminergic 
neurons are projected include the limbic structures (eg: amygdala, ventral pallidum, 
hippocampus, NAcc) and corticol areas (eg: prefrontal cortex (PFC)), which are 
responsible for different characteristics of addiction-related behaviours (Table 1.1) 
(Feltenstein et al., 2008). In general, the mesolimbic pathway is responsible for the 
acute reinforcing effects of the addictive drugs and learning-engaged process of 
addiction, which in the animal models is seen as a conditional response to the 
environment paired with the drug-cues; while the mesocortical pathway is 
associated with the compulsive drug-seeking and drug-taking behaviours 
(Feltenstein et al., 2008).  
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Similar to most of the other neurotransmitters, the vesicle-contained dopamine is 
released through Ca2+-dependent exocytosis from the presynaptic nerve terminals 
during neuronal depolarisation (Rang et al., 2007). Although the commonly abused 
drugs have very different pharmacologies, they act similarly in increasing the 
extracellular DA levels during acute exposure, mainly in the NAcc (Duvauchelle et 
al., 2000; Pontieri et al., 1995; Spanagel et al., 1999).  For example, stimulants (eg: 
cocaine, amphetamine) increase the levels of extracellular DA at presynaptic end 
terminals by inhibiting the dopamine transporter (DAT) in the presynaptic neurons 
while opioids act by inhibiting the GABAergic interneurons in the VTA of the brain 
(Brown et al., 2009; Spanagel et al., 1999). The hyperpolarization of these 
interneurons by -opioid agonists blocks the inhibitory synaptic input to the 
dopamine cells, thus increasing dopaminergic neurons excitatory in the VTA 
(Johnson et al., 1992; Spanagel et al., 1999). The results of this activity will cause 
an increase in the extracellular dopamine in the NAcc.  
 
Table 1.1: Addiction-related function of different brain regions in the corticostriatolimbic 
circuits. 
Brain region Addiction-related behaviour 
Nucleus accumbens (NAcc) 
Ventral pallidum 
Primary reinforcing effects, cue-induced reinstatement 
Amygdala 
Ventral hippocampus 
Stimulus-reward associations 
Dorsal hippocampus Stimulus-stimulus associations (contextual learning) 
Prefrontal cortex (PFC) Emotional response, cognitive control 
  
Long term exposure to abused drugs causes disruption of the neurons signalling 
pathway in the brain (Christie, 2008; Weiss et al., 2001). Dependence and tolerance 
to the addictive drugs can develop following chronic drug use. The reward pathway 
becomes less sensitive to drug stimuli and a larger dose is required to achieve the 
similar euphoric experience (Hollinger, 2008). This phenomenon is known as drug 
‘tolerance’. Not only is the dopamine release reduced, but the opioid receptor 
signalling also becomes less efficient (Hollinger, 2008). The cellular 
neuroadaptations that slowly develop in response to the chronic drug exposures are 
needed to restore the homeostatic function of the cells (Christie, 2008). This 
7 
 
happens due to the overstimulation of neurotransmitters and neurochemicals in the 
brain when the drugs are present in the body system (Feltenstein et al., 2008).  For 
example, the downregulation of the dopaminergic signalling pathways is needed in 
order to counteract the excessive dopaminergic neurons stimulation that happen 
during acute phase of addiction (Trigo et al., 2010). The reduction of the 
extracellular dopamine and also the decrease in the opioid receptor signalling, 
especially the -opioid receptor will only become visible during drug abstinence 
period, especially after acute drug withdrawal (Feltenstein et al., 2008; Hollinger, 
2008). This is manifested by the negative mood symptoms (eg: dysphoria). 
 
1.3 Opioid Pharmacology 
 
1.3.1 General classification of opioid receptors 
 
Three major receptors have been identified and widely discussed for their significant 
interaction with opioid ligands. The classical receptors are mu-opioid receptor (), 
kappa-opioid receptor () and delta-opioid receptor (). All of these opioid receptor 
subtypes differ in function, distribution and affinity towards various ligands, although 
there is overlap in activity responsible for producing analgesic effects (Atcheson et 
al., 1994). Principally there are two classes of opioid ligand which compete at the 
same receptor; opioid agonists stimulate the activity of receptor and opioid 
antagonists block the activity of agonists (Casy et al., 1986). There are four main 
endogenous (or natural) ligands, all agonists, for opioid receptors which are -
endorphin which acts non-selectively on all the opioid receptors (-, - and -), leu-
enkephalin and met-enkephalin which act mainly on -opioid receptor and dynorphin 
(Corbett et al., 1982), the main ligand that interact with the -opioid receptor. All the 
endogenous ligands may also cross-interact with other opioid receptors having 
different degrees of selectivity (Lord et al., 1977).  
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Activation of the -opioid receptors exert the -agonist characteristic effects such as 
morphine-like analgesia, euphoria, constipation, respiratory depression, tolerance 
and physical dependence. Activation of the -opioid receptors can cause dysphoria, 
sedation, meiosis, diuresis and also analgesia (Johnson et al., 2005). On the other 
hand, activation of the -opioid receptor can also cause analgesia as well as 
immune stimulation (Bidlack, 2000). Activation of the -opioid receptor can also 
induce convulsion, especially with a potent -opioid agonist (Broom et al., 2000). Of 
these receptors, the -opioid receptor is the target receptor for most opioid drugs, 
including for analgesia. The -opioid receptors are widely distributed in the brain 
regions including the cortex, thalamus, hippocampus, locus coeruleus (LC), ventral 
tegmental area (VTA), nucleus accumbens (NAcc) and amygdala. It is the receptors 
located in the last three brain regions that are thought to be most responsible in 
mediating the rewarding and additive properties of opioid drugs (Feltenstein et al., 
2008).  
 
Recently, the opioid receptor like (ORL-1) receptor has been identified as a new 
receptor sharing some similarities with opioid receptors (Meunier et al., 1995). The 
endogenous ligand of the ORL-1 receptor, nociceptin (also known as orphanin FQ) 
has a close homology to dynorphin A (the endogenous ligand for -opioid receptor, 
which is also a 17 amino acid-containing peptide (Bignan et al., 2005; Calo et al., 
2000). Compared to the other endogenous opioid ligands, nociceptin has a Phe1 
attached to the N-terminal of its peptide instead of Tyr1 amino acid (Reinscheid et 
al., 1996). Although the endogenous ligands for the classical opioid receptors do not 
significantly bind to the ORL-1 receptor, this receptor shares a similar mechanism of 
action at the cellular levels with the classical opioid receptors, by activating the Go/Gi 
G protein (Bignan et al., 2005; Lutfy et al., 2004). The actions of nociceptin at the 
ORL-1 receptor were not antagonized by classical opioid receptor antagonists such 
as naloxone, meaning that the ORL-1 receptor has a unique profile (Nicholson et al., 
1998; Zaveri, 2011). Previous studies have shown that ORL-1 receptor activation 
caused either hyperalgesia or analgesia, depending on the route of administration 
and the dose. In general, the supraspinal administration of nociceptin was reported 
to induce hyperalgesia while spinal administration caused analgesia (Mogil et al., 
2001; Zeilhofer et al., 2003). Nociceptin was also reported to have anxiolytic and 
antistress effects, believed to be due to the high distribution of ORL-1 receptors and 
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nociceptin in the amygdala and hippocampus in the brain region which were 
associated with learning ability and emotion (Bignan et al., 2005).  
 
1.3.2 Mechanism of action of opioids at the cellular level 
 
It is important to understand the mechanism of action of opioid drugs at the cellular 
level in order to understand how opioid drugs change the cells’ responses and 
produce their therapeutic effects. Besides, the knowledge about activity of opioid 
drugs at the cellular level also will help to better understand their side effects in 
different tissues expressing opioid receptors.(Connor et al., 1999). 
 
1.3.3 G-protein-coupled receptors (GPCRs) 
 
Opioid receptors are members of the G-protein-coupled receptor family (GPCR). 
GPCRs are transmembrane receptors that couple with G-proteins to transmit their 
signals (Shaqura et al., 2004). At the molecular level, the receptors have 7-
transmembrane-spanning domains linked by loops with the N-terminal exposed at 
the outer layer and the C-terminal exposed intracellularly. There are three 
extracellular loops and three intracellular loops and the G-protein is thought to be 
linked to the third intracellular domain (Hollinger, 2008). These proteins reside on 
the intracellular side of the cell membrane and freely diffuse in a planar movement in 
the cell membranes and are called G-proteins because they interact with guanine 
nucleotides (guanine diphosphate (GDP) and guanine triphosphate (GTP)) to 
regulate their activities. There are 3 subtypes of G-protein (,  and ) that all 
generally co-exist with a single GPCR as a heterotrimer structure. These 
polypeptides perform their duty as a carrier between the membrane and the central 
system in the cell (Sheehan and Elliot, 1993). They permit the signal transduction to 
occur between receptor on the membrane surface and the effectors in the cell either 
by affecting enzymes or ion-channels. 
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In the resting state, G-proteins form as a  trimer with an  subunit occupied by 
GDP, and the  complex. This  trimer freely diffuses in the planar membrane of 
cells. Once the receptor is activated by an agonist, the  trimer binds to the 
receptor causing the GDP bound to the -subunit to exchange with intracellular 
GTP. -GTP and the  complex then dissociate from each other and separately 
activate or inhibit their effectors. The signalling activities will be terminated when the 
-GTP is hydrolysed back to -GDP by GTPase. Finally, the -GDP subunit will 
recombine with the  complex into its original trimer formation to complete the cycle 
(Figure 1.2) (Harrison et al., 2003).  
 
 
Figure 1.2: The mechanism of G-protein activation. R, receptor; T, target protein. 
 
The G-proteins are further subdivided into three main subtypes depending on the 
downstream effectors that they interact with (Vauquelin et al., 2007). Gs (stimulatory) 
or Gi (inhibitory) are named after their interaction with adenylyl cyclase; Gs G-
proteins activate adenylyl cyclase and Gi G-proteins inhibit adenylyl cyclase 
(Vauquelin et al., 2007). The third family of G-protein which is known as Gq 
mediates the stimulation of phospholipase C and is responsible for phosphoinositide 
turnover (Sheehan et al., 1993). Receptors that couple to the Gi subtype of G-
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protein, also generally couple to the Go subtype of G-protein (Brody et al., 1998; 
Dean et al., 2009). As well as downstream effectors mediated by the  subunit, the 
 complexes can also signal by affecting various ion channels. 
 
Opioid and ORL-1 receptors share the same mechanism of action at the molecular 
level. They are all linked to Gi/o G-proteins, and their activation causes inhibition of 
adenylyl cyclase, activation of certain potassium channels and inhibition of certain 
calcium channels (Trigo et al., 2010). The different effects of activation of each 
opioid receptor subtypes is therefore largely dependent on their localization in the 
body. 
 
1.4 The Roles of Opioid and ORL-1 Receptors in Drug Addiction 
 
The main aim of this project is to find a new drug lead that can be used during the 
abstinence period, after the patient has been successfully stabilized with the 
tapering down dose of substituting opioid (eg: methadone). As mentioned earlier, 
relapse is most likely to happen during this phase, and treatment with naltrexone 
alone failed to reduce the relapse incidence following successful detoxification 
(Minozzi et al., 2011). It is exacerbated by the problem of polydrug abuse (McCann, 
2008), and therefore, an additional function of the new drug lead is needed in this 
population of patients. Therefore, the ideal pharmacological profile of drug that is 
suggested to achieve these purposes is having a low efficacy / antagonist at the -
opioid receptor, antagonist at the -opioid receptor and partial agonist at the ORL-1 
receptor (McCann, 2008).  
 
1.4.1 Lower - / -opioid receptor antagonism to reduce dependence liability 
 
One of the proposed pharmacological profiles of the proposed new lead is to be a 
low efficacy agonist, or antagonist at the -opioid receptor. Therefore, due to 
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minimal efficacy at the -opioid receptors, this new lead will not have a similar 
function as the primary substituting opioid that primarily acts as a -opioid receptor 
agonist (eg: methadone and buprenorphine) (Mattick et al., 2008). Although it is 
indirectly suggesting that this profile is achievable by the naltrexone only treatment 
(opioid receptor antagonist), it is important to emphasize that this new drug lead will 
have a combination profiles at three targeted opioid receptors as previously 
described, and the overall activity is not solely reliant on one activity or another.  
 
Although there will be a concern regarding the withdrawal side effects as the result 
of suppressing this receptors (Ko et al., 2006; Martin et al., 1976), this new drug 
lead is planned to replace the primary substituting opioid only after the patient has 
been stabilized with the lower dose of -opioid agonist (MOH, 2005). Considering 
the activity of this new drug lead on the -opioid receptor alone, the compliance 
issue will be a potential problem, if the new lead is an antagonist at the -opioid 
receptor as seen with naltrexone. By completely blocking the -opioid receptor, the 
addictive nature of any opioid agonists subsequently taken (eg: heroin) would be 
avoided (Crabtree, 1984; Minozzi et al., 2011), but this will also block the effects of 
endogenous opioids which can cause aversive and negative motivational effects 
(Mucha, 1990; Mucha et al., 1985). Besides, there is still the possibility that the 
patient will experience some degree of withdrawal symptoms even though the 
primary substituting opioid agonist is weaned-off at the lower dose. Therefore, a 
slight -opioid receptor efficacy might be an advantage compared to a complete -
opioid receptor antagonist in order to minimize these problems, and importantly, 
promote compliance. 
 
Despite the compliance issue associated with the use of a -opioid receptor 
antagonist in opioid addiction, this pharmacological approach was found to be highly 
beneficial in some other substance abuse-related problems (eg: alcohol and 
cocaine) (Lobmaier et al., 2008; Schmitz et al., 2001), which means by antagonizing 
the -opioid receptor, the problem of polydrug abuse also could be treated. 
Naltrexone is used as an adjunct therapy in alcohol-dependence patients (Lobmaier 
et al., 2008). This was also confirmed by previous animal studies where treatment 
with naltrexone reduced alcohol-seeking behaviour and alcohol relapse (Boyle et al., 
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1998; Dhaher et al., 2012; Middaugh et al., 2000). Pharmacologically, the similarities 
of opioid and alcohol dependence are the involvement of -endorphin in the opioid 
system which is stimulated in both types of dependencies (Lobmaier et al., 2008). 
Therefore the treatment principle applied for naltrexone for opioid addiction is also 
applied to alcohol dependency where the antagonistic activity of naltrexone is 
believed to block the rewarding effects of alcohol consumption (McLellan et al., 
2000) through competitive opioid receptor binding. 
 
Together with the -opioid receptor antagonist (which will be discussed in the next 
paragraph) it is hopeful that the problems seen with naltrexone alone therapy, 
particularly in opioid dependence patient (Minozzi et al., 2011) can be avoided, and 
the co-occurring polydrug addiction problems can be treated with this proposed new 
drug lead.  
 
1.4.2 -antagonism to prevent relapse and drug seeking behaviour 
 
The hyperactivity of the -opioid receptor system in the brain has been linked to the 
high tendency to relapse following drug discontinuation, and therefore one of the 
suggested treatment approaches to prevent relapse to drug taking is by 
antagonizing the -opioid receptor. Earlier studies had indirectly shown the 
involvement of the -opioid receptor system in mediating relapse, as activation of 
the receptors has been shown to increase various behavioural responses (stress, 
dysphoria and other psychotomimetic symptoms) (Pfeiffer et al., 1986).  
 
For example, Rothman (2000) has suggested the “-overdrive syndrome” 
phenomenon to explain the high incidence of relapse seen with heroin addicts after 
completing opioid detoxification (with clonidine) which was shown by negative mood 
symptoms (eg: dysphoria) during naltrexone maintenance therapy. The -overdrive 
syndrome relates to the body’s own homeostatic system to compensate for any 
abnormal changes that occur within the internal environment (Rothman et al., 2000). 
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According to this theory, a chronic exposure to a potent exogenous opioid (eg: 
heroin) will cause an overstimulation of the -opioid receptor, and therefore the drug 
addicts will experience excessive feeling of pleasure (euphoria). The long term 
effects of opioid use will cause imbalance between - and -opioid receptors 
stimulation. As a consequence of chronic drug exposure, the endogenous -agonist 
dynorphin will increase in order to stimulate the activity of -opioid receptor to 
compensate for overstimulation of -opioid receptors. However, if addicts stop 
consuming the drug (eg: heroin, methadone), the -opioid receptor will no longer be 
stimulated leaving the upregulated -opioid receptor to exert the major effect. The 
sudden increase in activity of the -opioid receptor will cause dysphoria and 
psychotomimetic symptoms which are unpleasant. This mood disturbance will be 
worst during naltrexone therapy where the -opioid receptor is suppressed. During 
this prolonged abstinence period and post-detoxification, relapse is more likely to 
happen because the endogenous opioid system fails to adequately compensate for 
the sudden loss of the exogenous opioid (Gold et al., 1981; Tkacz et al., 2012).  One 
of the ways to overcome this mood breakdown is through self-medicating (usually by 
returning to the illicit drug-taking habits) to overcome chronic dysphoria (Rothman et 
al., 2000). Therefore, it is believed that by suppressing the -opioid receptor during 
this abstinence period dysphoria can be overcome and prevent relapse to drug 
taking, which is shown by buprenorphine/naltrexone combination (a functional -
opioid receptor antagonist) (Gerra et al., 2006). 
 
Rothman’s (2000) study was based on clinical observations, where the involvement 
of dynorphin system cannot be determined, although the possible involvement of the 
-opioid receptor was suggested based on the clinical symptoms presented by the 
patients. The later studies conducted using animal models of drug reinstatement 
(drug seeking behaviour) had proved dynorphin is partly responsible in drug-relapse 
(Beardsley et al., 2005). Interestingly, not only in opioid addicts (Shaham, 1996), the 
activity of dynorphin was also found to increase with other type of drugs 
dependence including cocaine (Ahmed et al., 1997; Beardsley et al., 2005; Redila et 
al., 2008) and ethanol (Le et al., 1998).  
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If the Rothman (2000) study relates the -opioid receptor hyperactivity with negative 
mood symptoms (eg: dysphoria), animal studies have linked relapse to stress 
(Beardsley et al., 2005; McLaughlin et al., 2003). Although the behavioural 
endpoints were quite different, the similarities between these two are the increase in 
dynorphin activity. A study has been conducted in mice to investigate the relation 
between stress and behavioural measures of drug seeking behaviour using the 
conditioned-place preference (CPP) model (McLaughlin et al., 2003). In this model, 
drug-seeking behaviour can be induced by a stressful stimulus. The prodynorphin 
level (precursor for dynorphin) is believed to increase following a stressful event 
(forced swim test) which was proved using an indirect method that compared the 
stress induced analgesia between the wild-type mice and the dynorphin knock-out 
mice (McLaughlin et al., 2003). In this study also, the effects of the selective -opioid 
receptor antagonist, norbinaltorphimine (nor-BNI) in reducing the cocaine-seeking 
behaviour in mice after exposure to the stressful event (forced swim stress) was 
compared to the group of stress-induced but non-pretreated mice (did not received 
nor-BNI).  From this study, it was found that nor-BNI significantly reduced the time 
spent in the drug-paired compartment for the stress-induced treatment group 
compared to the stress-induced non-pretreated group. The differences in the time 
spent in the drug-paired compartment between the stress-induced non-pretreated 
group was also compared against the unstressed group. There was no significant 
difference in these two groups which indicates that nor-BNI has successfully blocked 
the stress-induced prodynorphin released following the forced swim test. This 
suggests the potential role of -opioid receptor antagonists in reducing relapse 
incidence following stressful events which is suggested to be associated with an 
increased in the endogenous -opioid agonist activity (prodynorphin) (McLaughlin et 
al., 2003).  
 
In both cases discussed above, it is clear that chronic drug use causes activation of 
the -opioid system, regardless of drug classes. And by selectively blocking the -
opioid receptor, drug-relapse can be prevented. It is already known that different 
drugs of abuse have different modes of action, which depends on their 
pharmacological classification. Similar to the case of dopamine, where all the 
abusive drugs increased the extracellular dopamine levels during drug exposure 
(Duvauchelle et al., 2000), this overlapping also happens with the -opioid receptor 
16 
 
system. Therefore, the downstream cellular activity following chronic drug exposure 
is the key to explain how -opioid receptor is involved. 
 
Once dopamine is released in the nucleus accumbens (NAcc) it acts 
postsynaptically by activating dopamine receptors (principally D1 and D2 types). 
Following D1 receptor activation, adenylyl cyclase (AC) is activated leading to 
enhanced levels of cAMP and activation of protein kinase A (PKA). One of the 
downstream effects of this is phosphorylation of the gene transcription factor, cAMP 
Response Binding Element (CREB). Indeed, phosphorylated CREB (pCREB) has 
been reported to increase in the NAcc following chronic drug exposure of cocaine 
and amphetamine (Edwards et al., 2007; Yin et al., 2006) and during withdrawal 
from opioids (Chartoff et al., 2003). CREB regulates the transcription of many 
proteins, and pCREB has been shown to increase synthesis of prodynorphin (Briand 
et al., 2010). In this way, as all drugs of abuse act to increase dopamine release in 
the NAcc, all drugs of abuse will in turn lead to enhanced synthesis of prodynorphin.  
 
The -opioid receptor is expressed in distinct areas throughout the brain, including 
the VTA and NAcc (DePaoli et al., 1994). For example, -opioid receptors are 
located on the mesocorticolimbic dopaminergic neurons themselves. As activation of 
the -opioid receptor is generally inhibitory, this leads to a general, and prolonged, 
decrease in dopamine release in the NAcc and frontal cortex, which is thought to 
lead to long-term negative mood symptoms seen in abstinent addicts, enhancing the 
risk of relapse to drug-taking. This explains how dynorphin is increased during 
chronic drug exposure, and why by blocking the -opioid receptor, the relapse 
associated with hyperactivity of the -opioid receptor system which was shown by 
negative mood symptoms and stress during drug abstinence can be prevented. 
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1.4.3 ORL-1 as a new target for treatment of drug addiction  
 
The ORL-1 activity of most interest in this project was the role in the treatment of 
substance abuse, not only for opioid, but also including other reinforcing drugs (eg: 
cocaine) and also alcohol (Toll et al., 2009). The anti-addiction properties shown in 
animal models of drug reward were limited but promising. A number of studies have 
demonstrated that ORL-1 receptor activation reduced the rewarding effects of 
reinforcing drugs (eg: morphine, cocaine) (Marquez et al., 2008; Rutten et al., 2010; 
Toll et al., 2009). At the molecular level, intracerebroventricular (i.c.v) administration 
of nociceptin (30 nmol/10 l) given 5 minutes before cocaine (10 mg/kg 
intraperitoneally) significantly decreased extracellular dopamine levels in rats, 
measured using dialysis samples collected from the nucleus accumbens brain 
region (NAcc), compared to cocaine controls (Lutfy et al., 2001). In a CPP model of 
drug reward, the intraperitoneal (i.p) administration of Ro65-6570 (a non-peptide 
ORL-1 receptor agonist) was found to reduce the time spent in the drug-paired 
compartment in rats when administered 15 minutes prior to opioid drugs (eg: 
morphine, heroin) and stimulant (eg: cocaine) (Rutten et al., 2010). A separate 
study, also conducted in rats found that the ORL-1 receptor antagonist, J-113397 
reduced the dose required for morphine to induce CPP which proved that ORL-1 
receptor agonist activity reduced the drug rewarding effects (Rutten et al., 2011). In 
this study, the sensitivity of morphine to induce reinforcing effects was also found to 
be higher in the ORL-1 knockout rats compared to their wild-types which further 
proved the involvement of ORL-1 receptor in modulating drug rewards. The 
attenuation of the rewarding effects after acute cocaine exposures was also 
reported in the ORL-1 knockout mice compared to their wild-type littermates 
(Marquez et al., 2008). When J-113397 was given 15 minutes prior to cocaine to 
block the ORL-1 receptors in the wild-type mice, the rewarding effects of cocaine 
was increased compared to the control group. All of these evidence pointed that the 
ORL-1 receptor agonist can be a potential target for ‘polydrug addiction’ with lower 
abusive properties due to its anti-rewarding effects compare to the -opioid receptor 
agonist. 
 
To date, there is no single pharmacotherapy agent available in the market that has 
all of these listed pharmacological profiles that is suggested to be an ideal drug to 
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prevent relapse to drug taking, that also may be beneficial for the polydrug abusing 
patient population. However, buprenorphine has the closest pharmacological profile 
needed (-opioid receptor antagonist and partial ORL-1 agonist), but with a partial 
-opioid agonist activity. 
 
1.5 Buprenorphine 
 
Buprenorphine was first brought to market as a long-acting analgesic agent in an 
injectable dosage form (buprenorphine hydrochloride) (Cowan, 2007; Johnson et al., 
2005) but has since become better known as a treatment agent for opioid abuse 
(WHO, 2009). To date, buprenorphine also available in oral formulation (sublingual 
tablet) either contains buprenorphine alone (2 mg or 8 mg buprenorphine free base; 
Subutex®) or in combination of buprenorphine/naloxone in a 4:1 ratio (2 mg/0.5 mg 
or 8 mg/2 mg free bases; Suboxone®) (Cowan, 2007; Lacy et al., 2005). For a long 
time it has been the long-lived partial agonist activity at the -opioid receptor 
(Cowan et al., 1995; Martin et al., 1974) that has attracted interest to this compound 
and led to its current uses. Based on the data by NIDA, buprenorphine’s maximum 
effects are at the dose of 32 mg (base) with no further increase in response when 
the dose was further increased (SAMHSA, 2004). The effects are sustained for 48 
hours (Walsh et al., 1994) which gives advantage on dosing schedule for the patient 
with alternate day dosing (Amass et al., 2000) compared to methadone which 
requires strict daily dosing (Dole, 1988; MOH, 2005). The long duration of action of 
buprenorphine is related to its high lipophilicity and slow dissociation from the 
receptor (Johnson et al., 2005). Recently the -opioid receptor antagonist and 
possible ORL-1 agonist activity of buprenorphine have also been suggested as 
being important to its pharmacological profile (Gerra et al., 2006; Rothman et al., 
2000). The ceiling effects which occur with buprenorphine may also be due to its 
activity at the ORL-1 receptor (Lutfy et al., 2003a). This ‘ceiling effect’ also explains 
why buprenorphine cannot replace methadone as the first line treatment for heroin-
substitution therapy because a patient with high dependence history of heroin needs 
higher efficacy than buprenorphine can provide (Mattick et al., 2008; SAMHSA, 
2004). If given parenterally and intramuscularly, buprenorphine bioavailability ranges 
between 40% to more than 90% and undergoes a very fast initial distribution (t1/2d = 
2-5 minutes) based on its pharmacokinetic data (Johnson et al., 2005). 
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Buprenorphine undergoes extensive first pass hepatic metabolism by N-dealkylation 
at cytochrome P450 (CYP450)  to produce a polar metabolite, norbuprenorphine 
(Johnson et al., 2005).  
 
1.5.1 Pharmacology of buprenorphine 
 
Buprenorphine is an opioid with a mixed agonist/antagonist profile at opioid 
receptors, with partial efficacy at the -/ORL-1 receptors and antagonist actions at 
the -opioid receptor. In receptor binding assays conducted either in rodent brain 
homogenates or in cloned receptors in cell lines, buprenorphine is highly bound to 
the classical -, - and -opioid receptors, and has moderate binding affinity 
towards the ORL-1 receptor (Huang et al., 2001; Lutfy et al., 2004; Spagnolo et al., 
2008; Toll et al., 1998). Although buprenorphine is also highly bound to the -opioid 
receptor, it is believed to have no significant impact on buprenorphine 
pharmacological activity (Johnson et al., 2005). Due to the complexity of 
buprenorphine’s receptor profile, the discussion on its clinical and preclinical efficacy 
as an analgesic drug, its use in the treatment of drug addiction and also its effects 
on respiratory depression will be discussed separately.  
 
1.5.1.1 Buprenorphine and analgesia 
 
As an analgesic drug, buprenorphine is more potent than morphine (0.1 mg/kg/day 
buprenorphine = 10 mg/kg/day morphine), has a rapid onset (parenterally) and also 
has a longer duration of action (Martin et al., 1976). The longer duration of action of 
buprenorphine is also believed to be due to its high lipophilicity that causes slow 
dissociation once buprenorphine is bound to the receptors (Boas et al., 1985). The 
superiority in terms of buprenorphine’s potency over morphine is varied, and 
depends on the types of stimuli and species. For example, a study conducted in 
mice to measure the response to visceral pain in a phenylquinone-induced writhing 
test has revealed subcutaneous and intraperitoneal buprenorphine were 25-40 times 
more potent compared to morphine (Cowan et al., 1977a). In the tail-flick test 
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conducted in mice to measure acute pain associated with noxious stimuli (thermal), 
buprenorphine is only 5-9 times more potent than morphine (Christoph et al., 2005; 
Cowan et al., 1977b; Cowan et al., 1971). However the differences in terms of 
potency between these two drugs is only 2-fold when tested in rats (Cowan et al., 
1977a). For a long time, buprenorphine’s pharmacological profile has been 
described as an analgesic that produced a ‘bell-shaped’ (inverted u-shaped /      
curvilinear) dose-response curve, due to the response observed in rodents exposed 
to noxious stimuli (55°C) in a tail dip test (Christoph et al., 2005; Cowan, 2007). 
Later, the preclinical studies, conducted in animal models of pain, show that the 
efficacy of buprenorphine depends on many factors, for example the selection of 
test and the nature of noxious stimuli (Cowan, 2007). Based on the commonly used 
animal models of pain, the bell-shaped dose response curve was reported in acute 
pain models (tail-flick, hot plate, and flexor reflex test) and the inflammatory pain 
model (formalin test) where the analgesic effects tends to decrease when the dose 
is increased after it reached the maximum response (1-3 mg/kg/day) (Christoph et 
al., 2005; Cowan et al., 1977b; Cowan et al., 1971; Kamei et al., 1995; Kamei et al., 
1997; Martin et al., 1976). In contrast, linear dose-response relationships were 
observed in the animal models of visceral pain (writhing test) and in rat tail pressure 
test, which achieved ‘ceiling effects’ when the doses were further increased 
(Christoph et al., 2005; Cowan et al., 1977b). In the rat tail pressure test, 
buprenorphine achieved nearly full efficacy (90%) compared to morphine (100%), 
but the antinociceptive effects last longer with buprenorphine (Cowan et al., 1977b). 
The ‘ceiling effect’ is shown by a plateau of the dose-response curve when the 
response remained stable after the drug reached a maximal response (Johnson et 
al., 2005). In relation to analgesia, the ‘ceiling effect’ is not a barrier only if the pain 
is fully controlled (Johnson et al., 2005; Walsh et al., 1994). The previous clinical 
studies also have shown that buprenorphine was as effective as a full opioid agonist 
in controlling pain, including post-operative pain and some malignant-associated 
pain (Downing et al., 1977; Noda et al., 1989). 
 
1.5.1.2 Buprenorphine and respiratory depression 
 
Both morphine and buprenorphine have been shown to cause respiratory 
depression. However, the depression was significantly greater in morphine-treated 
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subjects compared to the buprenorphine group (measured from the arterial partial 
CO2 (PCO2) and partial O2 (PO2) values) (Cowan et al., 1977a; Kishioka et al., 
2000). A clinical study conducted in non-opioid dependent healthy subjects shows a 
dose-dependence for the analgesic effects of buprenorphine, but not for respiratory 
depression (Dahan et al., 2006). This shows that the ‘ceiling effect’ is clinically more 
important in relation to the respiratory depression, but not with its analgesic activity. 
The clinical advantage of having a ceiling effect in respiratory depression is more 
towards the safety margin of the drug. Respiratory depression is a life-threatening 
event which is usually associated with morphine and heroin toxicity. Buprenorphine 
has a wider therapeutic index (TI) (LD50/ED50) compared to morphine, which is about 
12000 and 460, respectively, measured from the rat tail pressure test to determine 
intraperitoneal buprenorphine-induced acute toxicity (respiratory depression) 
(Cowan et al., 1977a). 
 
In view of the physical dependence in relation to the -opioid agonist activity, 
buprenorphine withdrawal side effects were reported as mild at best with delayed 
appearance after buprenorphine cessation. For example, chronic treatment with 
subcutaneous buprenorphine for four consecutive days (0.5 mg/kg twice daily) only 
produced a weak sign of withdrawal (diarrhoea) following sudden drug 
discontinuation in some rats, while no other symptoms were observed (Dum et al., 
1981). This indicates that although buprenorphine has dependence-liability, it is to a 
lesser extent as compared to the full -opioid agonists. As a partial -opioid agonist, 
buprenorphine partially precipitated withdrawal and suppressed abstinence 
syndrome in chronic morphine-dependent dogs (Martin et al., 1976). A study 
conducted in morphine-dependent mice (subcutaneous (s.c) 75 mg morphine 
implant) shows a bell-shaped buprenorphine dose-effects in suppressing morphine-
induced withdrawal symptoms, with the maximum suppressive doses seen at the 
lower doses (0.01-0.5 mg/kg) and at the highest dose (50 mg/kg) buprenorphine 
(Lizasoain et al., 1991). 
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1.5.2 Buprenorphine for polydrug addiction 
 
Although as mentioned above, buprenorphine is largely used currently as 
substitution therapy for opioid addicts, there have been studies that suggest it may 
also be effective against other drugs of abuse. The potential effects of 
buprenorphine on cocaine addiction were initially revealed when some of the 
patients who were in a methadone-maintenance treatment programme for their 
heroin addiction problems, were switched to an alternative treatment agent, 
buprenorphine (Kosten et al., 1989). These patients had a history of both heroin and 
cocaine addiction prior to their enrolment into the treatment programme. However, 
during methadone treatment, it was noticed that cocaine use was substantially 
increased among these patients. This was later discovered to be associated with the 
longer ‘speedball effects’ achieved with methadone compared to heroin. It is quite 
common for the heroin users to take cocaine to achieve more pleasurable effects, 
although some patients claimed to take cocaine after methadone to overcome 
sedation and lethargy associated with methadone treatment. This ‘speedball effect’ 
was claimed to be ineffective during buprenorphine treatment. ‘Speedball effect’ is 
an increased feeling of pleasure or reinforcing value when an opioid (usually heroin) 
and cocaine are taken together (Duvauchelle et al., 1998; Leri et al., 2003). 
Therefore, the initial idea of substituting methadone (a full -opioid agonist) with 
buprenorphine (a partial -opioid agonist) was to reduce the increasing cocaine-
abusing habit among patients during methadone treatment programme (Kosten et 
al., 1989). 
 
In the clinical setting, it is hard to differentiate the effects of buprenorphine on 
cocaine addiction on its own since cocaine usually was taken together with heroin in 
order to get the synergistic effects (McCann, 2008). Studies performed in cocaine-
dependent rhesus monkeys have shown that intravenous buprenorphine 
significantly reduces cocaine self-administration in these subjects, either when 
buprenorphine is given alone or as a dual therapy with naltrexone (Mello et al., 
1993; Mello et al., 1989). Since better outcomes came from the group receiving 
buprenorphine alone, this suggests that the agonist component of buprenorphine 
was important in reducing cocaine-dependence (Mello et al., 1993). Buprenorphine 
and cocaine, not only have different drug classifications, but also have different 
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mechanism of actions at the cellular level, where buprenorphine acts mainly through 
the opioid receptor system while cocaine acts mainly through the dopaminergic 
system (Leri et al., 2003). However, neurochemical studies have shown that both 
drugs could indirectly cross-interact with the other system especially during chronic 
drug dependence (Leri et al., 2003; McLellan et al., 2000). 
 
1.5.3 Buprenorphine/naltrexone combination 
 
The high incidence of relapse following cessation of substitution therapy with the full 
opioid agonist methadone (of the order of 55-85% of addicts relapse within a year of 
treatment) is thought to be, at least in part, due to the -opioid receptor system 
overdrive syndrome (Minozzi et al., 2011; Rothman et al., 2000; Tkacz et al., 2012). 
Clinical evidence in support of this theory was provided when the 
buprenorphine/naltrexone combination significantly increased the treatment 
retention rate among patients following detoxification with clonidine compared to the 
group that received naltrexone treatment alone (Rothman et al., 2000). A recent 
discovery has suggested the positive outcome could also be contributed by the 
ORL-1 receptor partial agonist activity of buprenorphine (Bignan et al., 2005; Gerra 
et al., 2006; McCann, 2008; Rothman et al., 2000).  
 
Since a -opioid antagonist is not yet available for clinical studies, naltrexone was 
given together with buprenorphine to leave the functional -opioid receptor 
antagonist activity of buprenorphine dominant (Gerra et al., 2006; Rothman et al., 
2000). The objective of this combination was to unmask the -opioid antagonistic 
activity of buprenorphine by blocking the -opioid agonist activity of this drug, giving 
a functional -opioid antagonist. Changes of pupil diameters before and during 
treatment were used as a parameter to monitor the effects of -opioid receptor 
blockade in an effort to ensure that any positive outcome was not due to residual 
agonist activity at the -opioid receptor.  In other words, only the -opioid antagonist 
activity of buprenorphine can be seen. Using urine analysis and retention period 
during 12 weeks treatment, Rothman found that the retention rate with the 
buprenorphine/naltrexone combination treatment was 33% (compared to 10% 
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retention rate as reported by Crabtree, 1984) with 5 subjects successfully 
completing the study and 4 of them with negative urine sample for both opiate and 
cocaine throughout the 12 weeks observation (Crabtree, 1984; Rothman et al., 
2000). However, since there was no control group used in this study, Gerra and co- 
workers (2006) have come out with an improved study design by introducing a 
naltrexone only group as a control with almost the same pretreatment procedure 
and duration of observation used by Rothman, but with a few modifications on the 
methods and with more subjects recruited. The studies by Gerra supported the 
findings suggested by Rothman where they found that patients stay longer in 
treatment with this combination drug therapy with 73.33% compared to 40% 
subjects completing the 12 weeks study with p values of 0.019 (p < 0.05) which 
helps substantiate the theory suggested by Rothman that the 
buprenorphine/naltrexone combination does indeed appear to be better than 
naltrexone only treatment.  
 
1.6 Medicinal Chemistry 
 
1.6.1 Synthesising single compounds to mimic a buprenorphine/naltrexone 
combination 
 
There is growing evidence suggesting that -opioid antagonist activity would be 
important in preventing relapse and the ORL-1 receptor may also be a promising 
new target for drug addiction (Gerra et al., 2006; McCann, 2008; Rothman et al., 
2000). Evidence for this was provided by the buprenorphine/naltrexone combination, 
compared to naltrexone alone pharmacotherapy (Gerra et al., 2006). Although the 
suggestion of combining buprenorphine/naltrexone seems promising, 
pharmaceutically this combination is not ideal. This is because the bioavailability of 
these two drugs is very different, with buprenorphine having reasonable 
bioavailability via the sublingual route compared to naltrexone which can be taken 
orally. This may lead to non-compliance issues due to a complicated dosing 
requirement. Therefore a single compound that mimics this combination is desired 
(McCann, 2008). In this project, a series of buprenorphine analogues have been 
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synthesised and evaluated in the hope of developing a single compound to mimic 
the buprenorephine/naltrexone combination within a single compound. 
 
Buprenorphine (Figure 1.3 (c)) is a semi synthetic drug which belongs to the orvinol 
series of opioids. It is synthesised from thebaine (Figure 1.3 (a), (1)), one of the 
natural alkaloids of Papaver somniferum (opium poppy) (Blakemore et al., 2002). 
Compared to morphine (Figure 1.3 (b)) (the major alkaloid from opium), 
buprenorphine has a cyclopropylmethyl (CPM) attached at the N17 position while 
morphine retains a N-methyl as found in thebaine. There are also two major 
structural modifications to the morphinan C-ring. The introduction of an endoethano 
bridge and also the presence of an extended group at the C7 position and these are 
partly responsible for the change from morphine’s pharmacological profile, 
especially related to its potency (Loew et al., 1979).  
 
                       
Figure 1.3: Chemical structures of thebaine (a), morphine (b) and buprenorphine (c). 
 
In the 1960’s, the investigation of the structure-activity relationship (SAR) of the 
opioids was initially based on their in vivo antinociceptive activities measured using 
either the tail pressure or the tail flick test which was conducted in rats (Bentley et 
al., 1972). The antinociceptive (analgesic) activitiy of the new opioid drugs was 
compared against morphine by measuring the in vivo parameters such as the ED50 
and tail flick withdrawal latency. During this time, the only way to differentiate 
pharmacological activity between opioids was by comparing their analgesic potency 
relative to standards. The existence of multiple opioid receptors was first postulated 
from Martin’s study, where different pharmacological characteristics of morphine and 
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its analogues were identified (Martin et al., 1974). This study, which was conducted 
in chronic spinal dog, is considered as the major evolution in the opioid field leading 
to more focused SAR studies based on different opioid receptor types. Later in the 
1980’s, in vitro techniques were introduced and performed in isolated tissues to 
evaluate opioid functional activity at the different types of opioid receptors 
(Huidobro-Toro et al., 1981; Kajiwara et al., 1986). This has been followed by other 
in vitro techniques (eg: [35S]GTPγS) which used cell culture in place of isolated 
tissues (Chapter 1.7.2.1). The development of selective ligands, alongside the 
development of in vitro assays has allowed the terms ‘efficacy’, ‘potency’ and 
‘affinity’ to be used with some confidence to compare pharmacological profiles 
between different opioid drugs.  
 
1.6.2 Structure-Activity Relationship (SAR) of orvinols 
 
Although morphine is widely used as an analgesic drug to control moderate to 
severe pain, there are many issues with this drug especially related to its side 
effects. Besides causing tolerance and dependence following prolonged use, an 
overdose of morphine can cause respiratory depression which is fatal. Therefore, an 
analgesic with a safer clinical profile and improved pharmacological activity (eg: 
more potent, longer duration of action) is needed. It was initially thought to be 
achievable by designing analogues of morphine with more complex and rigid 
chemical structures (Bentley et al., 1967a). The Diels-Alder adducts of thebaine 
have been extensively explored by Bentley’s group in order to search for the 
desirable morphine analogues (Bentley et al., 1967a; Bentley et al., 1967b; Bentley 
et al., 1967d). The orvinols, the major products of this work will be discussed in this 
thesis since buprenorphine and the products synthesised in this PhD project belong 
to the orvinol series. The parent structures of orvinol (Figure 1.4 (a)) and 
buprenorphine analogues (Figure 1.4 (b)) synthesised in this project are shown in 
Figure 1.4 below: 
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Figure 1.4: Parent structures of orvinol (a) and buprenorphine analogues (b).  
 
The initial SAR investigations conducted by Bentley and his co-workers (1967) were 
mostly focussed on the orvinol (3-OH) and thevinol (3-OCH3) with a 6,14-
endoetheno bridge (Figure 1.4 (a)).  
 
Substituting the N-methyl with N-allyl in morphine significantly changed the 
pharmacological profile of morphine to become a morphine antagonist (nalorphine) 
(Figure 1.5), in the rat tail pressure test (Martin, 1967). 
 
 
Figure 1.5: Structure of nalorphine (N-allyl normorphine), a morphine antagonist. 
 
This prompted a similar study in the orvinol and thevinol series.  Bentley discovered 
a similar effect with the N-allyl and N-CPM having reduced analgesic potency in the 
rat tail pressure test (Cowan, 1995; Lewis, 1974; Lewis et al., 1971). In the tail flick 
test, some of the compounds that show lower analgesic potency in the previous rat 
tail-pressure test, antagonized morphine in the tail-flick test (Lewis, 1974). The tail-
flick test is a more sensitive assay to detect opioids with mixed agonist/antagonist 
activity (Cowan, 1995). Therefore, it was concluded that the N-allyl and N-CPM 
substituted analogues of orvinols and thevinols lead to the compounds mostly 
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having decreased efficacy towards -opioid receptors, and that -efficacies of the 
orvinols were lower than their thevinol analogues (Husbands (unpublished work), 
(Husbands et al., 2000; Lewis et al., 1971; Martin et al., 1974).  
 
Replacing the N-methyl with N-CPM also increased the binding affinity of the 
compounds towards the opioid receptors, particularly the - and -opioid receptors 
(Lewis, 1985; Magnan et al., 1982). While the efficacies of the analogues towards 
the -opioid receptors were greatly reduced, their efficacies at the -opioid receptors 
were only minimally affected (Katz et al., 1982). Therefore, the major effect resulting 
from replacement of the N-methyl with N-CPM was to change the predominant 
intrinsic activity of the analogues from µ- to -opioid receptors, which was evidenced 
in the rhesus monkeys with the oripavine derivatives (Cowan, 1995; Katz et al., 
1982). 
 
A major site of modification within the orvinol series has been at the R3 position 
(Figure 1.4 (a)). SAR within the orvinol series (R1 and R2 = Me) (Figure 1.4 (a)), 
showed that alkyl manipulation at R3 could markedly affect the potency of the 
analogues compared to morphine (Bentley et al., 1967b). With the straight alkyl 
substituents (n-alkyl), the analgesic potency (ED50), of the analogues increased 
when the size of n-alkyl was increased and achieved its peak activity between        
n-propyl and n-butyl. After reaching these limits, the analgesic potency of the 
analogues decreased if the n-alkyl chain was further lengthened. The relationship 
between the size of the n-alkyl substituent (R3) and the analogues analgesic 
potency at the -opioid receptor was also seen in vitro in the rat vas deferens 
preparation (Lewis et al., 2004). For the R3 cycloalkyl substituents, cyclopentyl and 
cyclohexyl were reported to produce relatively higher analgesic potencies compared 
to morphine (70-fold and 3400-fold respectively). In conclusion, the relative order for 
potency in the orvinol series (Figure 1.4) with R3 alkyl manipulation (R1 = R2 = 
Methyl (Me) is as follows (Bentley et al., 1967b): 
 
n-Butyl (n-Bu) > n-Propyl (n-Pr) > Cyclohexyl > Cyclopentyl > Ethyl (Et) > Me 
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Branching in the side chain adjacent to C20 appears to reduce efficacy, particularly 
at -opioid receptors (Lewis et al., 2004). The effect of introducing a methylene 
spacer (n-alkyl) between the C20 and branched alkyl groups has also been recently 
investigated. As well as increasing the binding affinity of the compounds towards the 
- and -opioid receptors (from nanomolar to subnanomolar), introducing a 
methylene spacer in between the C20 and the branched alkyl group has increased 
the efficacy of the compounds at both of these opioid receptors (Husbands 
(unpublished work)). With this modification, the -opioid receptor agonist activity 
becomes visible. A further increase of the methylene spacer (-(CH2)2-) increased the 
predominant -opioid receptor efficacy of the compounds (Husbands (unpublished 
work)). For example, although both isobutyl orvinol (R = CH2(CHCH3)2) and 
isopentyl orvinol (R = (CH2)2(CHCH3)2) (Figure 1.4 (b)) were equipotent analgesics, 
the analgesic activity of isobutyl orvinol was higher than the isopentyl orvinol in the 
presence of the selective -opioid receptor antagonist, nor-BNI. This suggests that 
the analgesic activity of the former compound was partially mediated by the -opioid 
receptors, while the analgesic activity of the latter was predominantly mediated by 
the -opioid receptors. With these recent findings, Bentley’s (1967) previous results 
could be explained, where the analgesic potency of phenyl orvinol was greatly 
increased (35-fold) when an ethylene spacer was introduced between the C20 and 
the phenyl group at the R3 position (R1 = R2 = Me) (Figure 1.4 (a)) (Bentley et al., 
1967b). 
  
The effect of the side chain length is believed to be related to the compounds 
interaction with a lipophilic opioid receptor site. Since the maximum analgesic 
potency for the analogues as reported with the n-alkyl substituents (R3) (Figure 1.4 
(a)) was between C3-C4, it was concluded that this lipophilic receptor site is not more 
than 6 A° in distance from C7 (Lewis et al., 1971).   
 
Early work also suggested that besides the lipophilic component, the C20-hydroxyl 
group also has an important role in the analgesic potency of thevinols and orvinols, 
by forming an intramolecular hydrogen bond with the C6-methoxy group and/or  
binding with the opioid receptor binding site (Figure 1.6 (a)) (Bentley et al., 1972; 
Cowan et al., 1995). This theory suggested that the intramolecular hydrogen bond 
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helps to fix the alkyl group (Figure 1.6 (a)) towards the lipophilic opioid receptor 
binding site (Cowan, 1995; Loew et al., 1979). These components are not present in 
morphine and its close derivatives and was thought to explain the different analgesic 
potencies observed among these series (Figure 1.6 (b)) (Cowan, 1995). 
 
                                
Figure 1.6: Intramolecular hydrogen bond in orvinol between C20-OH and C6-Methoxy groups 
(a); Morphine chemical structure shows lack of C20 moeity (b). 
 
However, it was later proved that intramolecular hydrogen bonding is not crucial for 
the analgesic potency of these series as the C6-demethylated analogues still 
managed to retain their high analgesic potency relative to morphine (Hutchins et al., 
1981; Knipmeyer et al., 1985).  
 
A further study conducted by Hutchins (1984) proposed the theory of synergistic 
hydrophilic/lipophilic opioid receptor binding sites to explain the change in analgesic 
potency seen when the C19 chiral center configuration is manipulated. Based on this 
study, the C20-OH (hydrophilic region) is not necessarily needed in order to obtain 
an analogue with high analgesic potency, but it may help fix the alignment of the 
alkyl group (lipophilic region) to the lipophilic opioid receptor sites (Hutchins et al., 
1984). According to Hutchins (1984), the lipophilic alkyl chain (C20) that determines 
the analgesic potency of the orvinol and thevinol analogues is located below C8 
(Figure 1.7) near to the 6,14-etheno bridge (Cowan et al., 1995; Hutchins et al., 
1984; Loew et al., 1979). This hypothesis was proved when the oripavine analogue 
(cyclohexane ring is constrained at C7-C8) showed 1000-fold higher potency than 
morphine even without the presence of C20-OH (Figure 1.7) (Hutchins et al., 1984).  
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Figure 1.7: Oripavine derivatives with cyclohexane ring constrained below C8 and near to the 
6,14-etheno bridge without the presence of C20-OH (1000-fold more potent than morphine). 
 
Preliminary work by Husbands’ group has found phenyl orvinol (BU127 (15)) to have 
a promising profile at the - and -opioid receptors, significantly different from all 
other compounds synthesised in the series, which includes branched alkyl (eg: 
isopropyl, isobutyl) or aryl alkyl such as benzyl and 
phenethenyl side chains (Figure 2.2) (Husbands 
(unpublished work)). BU127 (15) has shown low 
efficacy, but high affinity, at - and -opioid receptors 
(Figure 2.2) suggesting that the desired / profile 
has been achieved. Together, this evidence suggested that only direct aryl 
analogues of BU127 (15) would retain low /efficacy and that introduction of a 
spacer between the aryl ring and C20 would be detrimental to the desired profile. In 
addition, in the current work, the 6,14-endoetheno bridge (Figure 1.4 (a)) was 
reduced to 6,14-endoethano (Figure 1.4 (b)). The reduction of the bridge helps to 
lower the efficacy of the analogues at -opioid receptors (Husbands (unpublished 
work)), though the overall antagonist potency was only minimally affected by this 
reduction (Bentley et al., 1972).  
 
1.6.3 ORL-1 receptor pharmacophore 
 
This PhD project also aimed to increase the efficacy and binding affinity of the 
buprenorphine analogues toward the ORL-1 receptor. By comparing ORL-1 ligands 
that have already been synthesised, it is apparent that all ORL-1 ligands share 
common features, which are; having a basic nitrogen, a large cyclic lipophilic group 
attached to the basic nitrogen and also a heterocyclic moiety at least 3 carbons 
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distant from the basic nitrogen (Figure 1.8) (Zaveri et al., 2005). The heterocyclic 
group appears to play a significant role in increasing the compounds binding affinity 
towards the ORL-1 receptor.  
 
 
Figure 1.8: The important features of ORL-1 ligands that determine the compounds’ affinities 
and efficacies at the ORL-1 receptors. 
 
1.7 In Vitro Evaluation of Opioids (Principle and Mechanism)  
 
There are many parameters that can be used to completely define the 
characteristics of opioid related drugs, starting from their physicochemical properties 
(in vitro) to their dependence liability (in vivo) (Leslie, 1987). However, our current 
work is focusing on evaluating the characteristics of the novel compounds 
synthesised at the receptor level and to relate their chemical structure modifications 
with their activities at the targeted opioid receptors, compared to the reference drug. 
Therefore, the parameters that are used to define the characteristics of the 
compounds synthesised in this project are the binding affinity, efficacy and potency 
(antagonist potency) at different opioid receptors type. To ease the discussion, the 
word ‘ligand’ will be used in place of drug and compound to define all the 
parameters used in our assay.  
 
Binding affinity refers to the ability of a ligand to occupy a specific receptor type. The 
parameters that are usually used to describe the binding affinity of a ligand are IC50 
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and Ki. Both IC50 and Ki are used to define the binding affinity of a ligand derived 
from a receptor binding assay. IC50 refers to the concentration of competing ligand 
which displaces 50% of the specific binding of the radioligand (Sheehan et al., 
1993). Since the IC50 value of the test compound varies depending on the 
radioligand concentration used in the assay, the binding affinity can be converted to 
an absolute inhibition constant, Ki using the Cheng-Prusoff equation (Kenakin, 
2009). Another parameter that can be used to describe the affinity of a ligand is KB 
(dissociation constant of an antagonist) (Leslie, 1987), which is derived from the 
functional assay for a competitive antagonist (Kenakin, 2009; Motulsky, 2007). 
Theoretically, the Ki and KB value for the same antagonist is equal, provided the 
experimental conditions are the same (Sheehan et al., 1993). 
 
Efficacy is a term used to describe the extent of agonist activity of a ligand which 
has a direct proportional relationship with receptor occupancy. A high efficacy ligand 
only needs to occupy a low proportion of receptor to produce a maximal response, 
while a low efficacy ligand either needs a higher receptor occupation to produce 
similar response as the high efficacy ligand or sometimes only partially stimulates 
the receptor although all the receptor is occupied (and is therefore a partial agonist). 
There is no absolute value to show efficacy, except for an antagonist which has no 
efficacy (zero efficacy). However, theoretically, the efficacy value  can be described 
to lie between zero and large positive value (Stephenson, 1956). For agonists, the 
efficacy is generally between partial to full efficacy. Since the term of efficacy is quite 
subjective, the efficacy of a ligand is usually described as ‘relative efficacy’ and 
compared to a standard agonist (usually a full agonist) (Sheehan et al., 1993). The 
efficacy value is usually expressed as a percentage relative to the standard full 
agonist (where the full agonist is converted into 100% response). 
 
Potency is a term used to describe the effectiveness of a ligand, either as an agonist 
or an antagonist. Potency is measured from a functional assay. It is important to 
understand that unlike efficacy and binding affinity, potency does not provide any 
information about receptor occupancy (Leslie, 1987). The parameters that are 
usually used to compare potency in a functional assay for an agonist are EC50 (or 
IC50), or pEC50 or pIC50 (for an agonist) and for an antagonist, pKB and pA2 are 
commonly used. For example, EC50 refers to the molar concentration of an agonist 
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which produces 50% of the maximum possible response for that specific agonist 
(Sheehan et al., 1993), while for a functional assay, IC50 refers to the molar 
concentration of an agonist which produces 50% of its maximum possible inhibition. 
pA2 and pKB, the parameters used to describe antagonist potency, will be discussed 
later in more details. 
 
Therefore, it is important to understand the different assays and methods used to 
generate all these parameters before comparing the values and generalizing the 
results obtained by different labs. 
 
1.7.1 Binding assay 
 
1.7.1.1 Receptor binding 
 
Receptor binding assay is used to measure the binding affinity of a drug or 
compound to the receptor binding sites of a particular receptor type. The cells that 
are usually used in this assay are cell membrane homogenates that are known to 
contain high population of the receptor needed. For opioids, the commonly used 
cells are brain cell membranes (eg: guinea pigs) or cell lines transfected with cloned 
receptors (eg: Chinese hamster ovarian (CHO) transfected cells) (Toll et al., 1998). 
The receptor binding assay can measure the binding affinity of a compound 
regardless of its pharmacological activity (agonist or antagonist nature). For a 
compound with antagonist activity, the isolated tissue preparation also can be used 
to estimate the compound binding affinity, which will be explained in the next 
subchapter (Schild analysis and Schild equation).  
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Principle and mechanism of receptor binding assay 
 
There are three ways of conducting binding assays which are through saturation, 
displacement and kinetic binding. The main principles behind these three binding 
assays are the same where the fraction bound of the measured ligand (specific 
binding) is different from the fraction unbound (non-specific binding, nsb) (specific 
binding = total binding – nsb). The nsb refers to the fraction of ligand that is bound to 
the sites other than the receptors, which also include the test tube and the cell 
membranes. The differences between saturation, displacement and kinetic binding 
techniques are how the tracer ligand (ligand labelled with radioactive isotope / 
fluorescence species) is measured (Kenakin, 2009). Saturation binding directly 
measures the binding of tracer ligand to the receptors. The ligand used has to be 
traceable which only can be done to the radioactive or fluorescence molecules. The 
tracer ligand in this case is the test compound. The second method, displacement 
binding, measures the interruption or reduction of radioactive signals through 
competitive binding (displacement) by a nontraceable ligand. The reduction of 
radioactive signal of the tracer ligand caused by the competitive activity of the 
nontraceable ligand at the receptor is used to measure the binding affinity of the 
nontraceable ligand. In this case, the tracer ligand was a standard drug while the 
nontraceable ligand was the test compound. The last technique, kinetic binding, 
measures directly the decay of radioactivity of tracer ligand with time (Kenakin, 
2009). 
 
The method used by John Traynor’s lab that is presented in this thesis is the 
displacement binding technique. The detailed method used will be discussed in 
Chapter 3. Principally, the cells transfected with the specific receptor are              
pre-incubated with a constant (fixed) concentration of a tracer ligand (radiolabelled 
ligand), together with a high concentration of nonlabelled ligand to measure the nsb, 
in the presence and absence of varied concentration of another nonradiolabelled 
ligand (the test compound) (Kenakin, 2009). Theoretically, the test compound will 
compete with and displace the tracer ligand which will disrupt the radioactivity of the 
tracer ligand in a concentration dependent manner. The remaining radioactivity of 
the tracer ligand bound to the receptor is measured using a scintillation counter. The 
percentage of receptor displacement of the tracer ligand is plotted against the 
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concentration of the test compound (displacing ligand) in a log scale to get the IC50 
value (Traynor et al., 1995). The IC50 refers to the concentration of the test 
compound that causes 50% decrease in the radioactivity of the tracer ligand from 
the original (basal) value. This value is derived from the non-linear regression graph. 
This IC50 value is then fitted into the Cheng-Prusoff equation to calculate the binding 
affinity (Ki) value of the displacing ligand (test compound) (Kenakin, 2009). 
 
1.7.2 Functional assays 
 
1.7.2.1 [35S]GTPS binding 
 
[35S]GTPS refers to a non-hydrolyzable analogue of GTP that is tagged with a 
radioactive isotope of 35S, which can be measured by a liquid scintillation counter 
(Harrison et al., 2003; Traynor et al., 1995). The [35S]GTPS binding is a functional 
assay, usually conducted in cell lines transfected with a homogenous (isolated) 
receptor type. It is commonly used nowadays as a functional bioassay alternative to 
the isolated tissue preparations. Although the word ‘binding’ is used to describe this 
assay, it is not similar to the receptor binding assay because this assay is not 
directly quantifying the receptor occupancy, as in the receptor binding assay. The 
[35S]GTPS is a measures of receptor activation activity by an agonist as a result of 
agonist-receptor interaction (Harrison et al., 2003). Therefore, the ‘binding’ in this 
assay actually refers to the binding of the [35S]GTPS with the     -subunit of the 
activated G-proteins. 
 
Principle and mechanism of [35S]GTPS binding assay 
 
The [35S]GTPS assay measures the very first events of the G-protein’s activation by 
an agonist at the receptor level (Harrison et al., 2003). This event refers to the 
nucleotide exchange between the membrane bound -GDP subunit of the activated 
37 
 
 heterotrimer complex and the intracellular GTP (Figure 1.2, top (right)). In this 
assay system, the function of the intracellular GTP is replaced with a radiolabelled, 
non-hydrolyzable GTP analogue, [35S]GTPS (Harrison et al., 2003). Since the 
amount of [35S]GTPS added in the test tube is known, the percentage of the          
-[35S]GTPS complex bound to the cellular membrane during agonist occupation at 
the receptor can be measured (Figure 1.9) after filtering the membrane, to 
determine the efficacy of the agonist (expressed as % stimulation) and compared 
against standard agonist. The [35S]GTPS is a stable species and is not subject to 
hydrolysis by the intracellular GTPase activity (Traynor et al., 1995). Therefore once 
activated, it will accumulate in the cell membranes which enables the level of this 
membrane-bound species to be measured (Figure 1.9). 
 
 
Figure 1.9: Principle of [
35
S]GTPS binding assay and measurements. 
 
Since [35S]GTPS is an artificial assay system, the level of agonist expression (% 
stimulation) may vary between different labs, which depends on the experimental 
protocol. Besides the [35S]GTPS species, the important materials for this assay are 
the GDP, charged ions (Mg2+ and Na+), and membranes (which contains the protein 
receptor) (Harrison et al., 2003). The amount of these materials and the types of cell 
lines can be adjusted to achieve a bigger receptor stimulation, which explains why 

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      + 
        
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sometimes different labs have reported huge differences of % receptor stimulation 
by the same agonist (Alt et al., 2002; Bloms-Funke et al., 2000; Spagnolo et al., 
2008). 
 
1.7.2.2 Isolated (peripheral) tissue preparations 
 
Peripheral tissues have been widely used to pharmacologically characterize opioid 
drugs at different types of opioid receptors (Leslie, 1987). Since different tissues 
have different opioid receptor types, the selection of tissues to be used in the 
bioassay is important, especially for a drug which is known to have lower efficacy 
(Lord et al., 1977). The most commonly used tissues for the evaluation of opioid 
ligands are the guinea pig ileum, GPI (for - and -opioid receptors) (Leslie, 1987) 
and mouse vas deferens, MVD (-opioid receptors) (Lord et al., 1977). Although the 
mouse vas deferens has all the three opioid receptors (-, - and -), they are more 
sensitive to the -opioid receptor agonist activity (Leslie, 1987). The MVD 
preparation however is more sensitive in detecting the antagonist activity of an 
opioid with a partial agonist activity (eg: cyclorphan) or an opioid that has a mixed 
agonist/antagonist activities, compared to the GPI preparation (Kosterlitz et al., 
1973; Magnan et al., 1982). Due to its higher potency, cyclorphan, a partial -opioid 
agonist, shows full efficacy in the system with a higher -opioid receptor reserve 
(GPI) (Kosterlitz et al., 1973).  
 
In this project, rat vas deferens (RVD) was used to determine the binding affinity of 
the compounds synthesised at the - and ORL-1 receptors. Since RVD does not 
have -opioid receptors (Smith et al., 1983), and our compounds have shown a 
substantial efficacy at the -opioid receptor during the [35S]GTPS screening (Figure 
3.2), it is an advantage to conduct assays using this preparation without 
complications caused by the potential -opioid receptor activity of the compounds. 
Furthermore, RVD has a lower -opioid receptor population compared to MVD 
(Smith et al., 1983), therefore some compounds that show efficacy (-opioid 
receptor mediated) in the MVD were antagonist in the RVD preparation (eg: 
buprenorphine) (Spagnolo et al., 2008), which allows the potency and binding 
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affinity of the compound at the -opioid receptor to be determined using this tissue. 
This procedure will be discussed in greater details in Chapter 3. 
 
The effects of receptor reserve in isolated tissue assays 
 
Two major factors that determine the activity of drugs in each model / system are 
the density of receptor, which will determine the receptor reserve in the system and 
the efficacy of the drug (Kenakin, 2009). Receptor reserve is more common with 
drugs that elicit their response on smooth muscle contraction compared to other 
types of receptor mediated responses (Stephenson, 1956). Receptor reserve or 
spare receptors refers to the percentage of receptors that are not required to 
produce the maximal response (Kenakin, 2009). In general, the more potent the 
drug, there will be a greater receptor reserve available in the system. A potent and 
highly efficacious drug does not need to occupy a high percentage of receptors in 
order to produce the maximal response. The availability of the receptor reserve is a 
really important issue to highlight because it will determine the behaviour of the drug 
in the system, especially when using a drug with low efficacy. For example, [D-
Ala2,N-Me-Phe4,Gly5-ol]enkephalin acetate (DAMGO), a selective -opioid receptor 
agonist, has a different potency (IC50) when measured in mouse vas deferens  (311 
± 26 nM) compared to rat vas deferens (2640 ± 410 nM) (Miller et al., 1986). The 
difference in the potency of the drug in the two systems depends on both the 
efficiency of the drug-receptor coupling mechanism to produce the response in the 
tissue and the receptor density in that particular model (Kenakin, 2009). The density 
or number of -opioid receptor is higher in the mouse vas deferens compare to rat 
vas deferens which explains why DAMGO was found to be more potent in mouse 
vas deferens compared to rat vas deferens (Smith et al., 1983). 
 
The binding affinity of a drug is system-independent but the potency of drug 
uniquely depends on the system (Kenakin, 2009). Although both DAMGO and 
morphine show high binding affinity at the -opioid receptor, DAMGO has a higher 
efficacy or intrinsic activity compared to morphine. Therefore, DAMGO acts as a full 
-opioid receptor agonist even in a system with low -receptor reserve. For 
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example, in rat vas deferens, DAMGO produced a maximal response (Emax) 
between 70-100% (Sheehan et al., 1988). On the other hand, morphine behaved as 
a complete antagonist in rat vas deferens (Schulz et al., 1979) but demonstrated full 
-opioid agonist activity in guinea pig ileum (GPI) and in mouse vas deferens (MVD) 
(Hutchinson et al., 1975).  
 
In order to evaluate the -opioid receptor activity of our buprenorphine analogues, it 
was important to use a highly efficacious standard agonist in our assay, especially in 
the rat vas deferens since this system has low -opioid receptor density (Smith et 
al., 1983). This issue will be discussed throughout this thesis when the behaviour of 
the buprenorphine analogues is compared to the other drug in the same assay 
system and also between different assay systems. This problem will be more 
prominent when we compare the results obtained from the isolated tissue assays to 
the results obtained from Traynor’s group in the [35S]GTPγS functional assay. 
 
Opioids agonist activity on the smooth muscle (vas deferens) 
 
There are two main receptors that are responsible for the contraction of smooth 
muscle in the vas deferens which are P2X receptor (purinergic) and -adrenoceptor 
(adrenergic) (Westfall et al., 2001). The purinergic receptors (for ATP) were reported 
to occupy mainly the prostatic end while adrenergic receptors (for noradrenaline) 
were mainly distributed at the epididymal end of the vas deferens (Westfall et al., 
2001). This is the reason why, in the present study, 20% of the vas deferens was 
removed at the prostatic end during tissue preparation since it was occupied by  
non-adrenergic receptor, to isolate noradrenergic responses (Andrews et al., 2010). 
In the isolated vas deferens preparation, as well as the smooth muscle, there are 
also axons and nerve terminals of postganglionic sympathetic neurons. As such, 
when the isolated vas deferens is electrically stimulated, the postganglionic 
sympathetic axons are activated and the noradrenaline (NA) stored in the vesicles at 
the nerve terminals is released by exocytosis and binds to the postjunctional         
-adrenoceptor on the smooth muscle cells (Westfall et al., 2001). The -
adrenoceptor is a Gq-coupled GPCR, so activation of the receptor leads to activation 
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of the phospholipase C enzyme (effector for Gq G-protein). 
Inositol(1,4,5)trisphosphate (IP3) is one of the key products of hydrolysis activity of 
phospholipase C which in turn acts on its specific IP3 receptor (a ligand-gated 
calcium channel) located on the sarcoplasmic reticulum. Activation of the IP3 
receptor will then release the Ca2+ which is stored in the endoplasmic reticulum into 
the cytosol and activates the calcium binding protein, calmodulin. The                
Ca2+-calmodulin will then activate myosin through the activity of myosin light-chain 
kinase (MLCK) and causes contraction of the vas deferens (Berridge, 2008). At the 
later stage, IP3 can also be phosphorylated into inositoltetrakiphosphate (IP4) which 
will induce the opening of calcium channel located at the cell membranes, and 
therefore cause influx of extracellular Ca2+ into the cells (Figure 1.10) (Vauquelin et 
al., 2007).  
 
In the vas deferens tissue, the opioid receptors are located at the presynaptic nerve 
terminals of the sympathetic nervous system (Leslie, 1987; Westfall et al., 2001). 
Opioid drugs inhibit the electrically evoked contraction of vas deferens by inhibiting 
the NA release from the postganglionic sympathetic nerves in a concentration-
dependent manner (Henderson et al., 1976; Leslie, 1987). As mentioned earlier 
(Chapter 1.3.3), the opioid receptors belong to Gi/o G-protein subtypes (Brody et al., 
1998; Connor et al., 1999). Although the opioid receptors couple to both Gi and Go 
G-protein subtypes, their effects in altering the cellular activities will depend on 
which effector is expressed by that particular cell (Connor et al., 1999). The main 
effects of opioid receptor activation in the vas deferens are the inhibition of voltage-
gated calcium channels and inducing the opening of potassium channels (Satoh et 
al., 1995). These happen directly through the coupling of  subunits of Go G-
proteins to the ion channel without the involvement of other second messenger 
systems (Connor et al., 1999). NA is released from vesicles through exocytosis as a 
response to increasing intracellular Ca2+ during neuronal depolarisation (Cunnane, 
1984). Therefore, the inhibition of Ca2+ influx through the inhibition of voltage-gated 
calcium channel by opioid agonists will cause inhibition of the NA release from the 
vesicles (Westfall et al., 2001). Similarly, opening of potassium channels by 
activation of opioid receptors will lead to hyperpolarization of the nerve terminal 
membranes, decreasing the opening of voltage-gated calcium channels.  As a 
result, there will be a reduction of NA in the synapse to interact with the 
postjunctional -adrenoceptors such that activation of opioid receptors causes 
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inhibition of the electrically-evoked vas deferens contraction in a concentration-
dependent manner (Figure 1.10).  
 
 
Figure 1.10: Cellular mechanism of electrically evoked and inhibition of vas deferens 
contractions mediated by noradrenaline and opioid agonist. AC, adenylyl cyclase; CaM, 
calmodulin; SR, sarcoplasmic reticulum; MLCK, myosin light-chain kinase; OP, opioid 
agonist; OR, opioid receptor; PK, protein kinase; PLC, phospholipase C.  
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1.7.3 Advantages, strengths and limitations of different assay systems 
 
Different assay systems have their own advantages, strengths and limitations. 
Therefore, careful consideration needs to be made before interpreting and 
comparing the results, not only between different assay systems, but also between 
different labs. This is because the experimental protocols might be different which 
have impact on the values reported.  
 
Amongst all the three in vitro techniques that have been discussed above, the 
isolated tissue preparations is at least the closest to mimic the in vivo environment. 
Although the environment is artificial (the organ bath), the tissues are still intact 
(Leslie, 1987). In our experiment, the isolated tissue preparation was used to 
evaluate the potency of the test compounds relative to buprenorphine and to 
estimate their binding affinity in a more physiological environment (Kenakin, 2009; 
Leslie, 1987). The end physiological response shown by the tissue (eg: inhibition of 
muscle contraction) is a result of a series of biochemical events starting from the 
receptor activation at the cell membranes and intracellular effectors response (eg: 
activation / inhibition of ion channels / cyclic adenosine monophosphate (cAMP)) 
(Lemaire et al., 1978). In contrast to the [35S]GTPS, the receptor stimulation shows 
is not a translation of the downstream biochemical events of the cells (Harrison et 
al., 2003). 
 
The [35S]GTPS binding can also be used to evaluate the potency of the test 
compounds and offers some advantages compared to the isolated tissue 
preparation (Traynor et al., 1995). For example, there will be less physiological 
obstacles (eg: drug diffusion) for the test compounds to reach the receptor binding 
site compare to the intact tissue and it can be performed in a cell cultures with 
homogenous receptor type (Leslie, 1987). The density of the receptor also can be 
adjusted and other materials can be quantified to achieve bigger receptor 
stimulation. The [35S]GTPS binding also is a sensitive assay that can be used to 
measure efficacy of the compound tested. Although this function also can be shown 
in isolated tissue preparations, the ability of a compound to show efficacy (especially 
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for a lower efficacy compound), will depend on the receptor reserve available in the 
tissue (Smith et al., 1983). Therefore in some tissues a compound can be agonist, 
but it may be an antagonist in a different tissue. This is discussed in greater detail in 
the Chapter 3. 
 
For an artificial system (eg: [35S]GTPS), not only the amount of the component 
added (GDP) will influence the result, but the expression levels of the receptor will 
also have a significant impact on the outcome of the assay. Often the cell culture 
itself is modified in order to achieve very high expression levels to achieve a robust 
result (Law et al., 1982). This is proven when buprenorphine, which is known as 
having partial efficacy at the ORL-1 receptor at most in vivo and in isolated tissue 
assays, can show full efficacy, as efficacious as the standard full agonist, nociceptin 
in CHO cells with high receptor expression levels (Wnendt et al., 1999). Although 
the isolated tissue does not fully represent the actual environment in vivo, the 
receptor expression levels, signal transduction pathways, and internal tissue 
environment are as they are in vivo.  
 
1.8 Schild Analysis and Schild Equation 
 
Schild analysis is a powerful tool to measure the affinity of an antagonist in a 
functional system (to obtain the value of KB) (Kenakin, 2009; Leslie, 1987). After the 
affinity of an antagonist has been determined, the relative potency of different 
antagonists acting at the same receptor type can be compared.  The two important 
criteria that are essential in order to achieve an accurate Schild analysis are that the 
concentration range of antagonist tested has to be wide and the slope of the 
regression line is equal to unity (Leslie, 1987). For Schild analysis, a series of at 
least three concentration ratios (CRs) of an agonist in the absence and in the 
presence of known concentrations of antagonist that produced equivalent responses 
are calculated (Kenakin, 2009). The x-intercept that derives from the linear 
regression line with slope equal to 1 gives the pKB value of the antagonist. If this 
slope is not significantly different from unity, the antagonist can be assumed to be 
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competitive and reversible, and constraining the slope to 1 gives a more accurate KB 
value (Kenakin, 2009).  
 
KB is the equilibrium dissociation constant of the antagonist-receptor complex, and 
also refers to the concentration of antagonist that occupies 50% of the measured 
receptor, and therefore in this case KB is equal to Ki which also is a parameter to 
measure binding affinity of a ligand (antagonist in this case) (Kenakin, 2009). pKB is 
also commonly referred to as pA2, a concentration of antagonist that caused a 
twofold shift of agonist concentration-response curve (characteristic of simple 
competitive antagonism) (Kenakin, 2009). The KB or pA2 values are independent of 
the agonist and the system used (Leslie, 1987). The only differences between KB 
and Ki is the assay used to measure this value in which Ki was obtained from a 
radioligand binding assay whereas KB was measured from a functional assay. In 
contrast, in the case when the slope is significantly different from unity, pKB cannot 
be assumed as pKi (Motulsky, 2007).  
 
In the cases that the Schild plot slope is not significantly different from 1, but there is 
a significant decrease in the maximum agonist response in the presence of higher 
concentrations of antagonist, this pattern may suggest noncompetitive behaviour of 
the antagonist. Alternatively it could be due to hemi-equilibrium conditions where the 
agonist and antagonist do not achieved equilibrium with the receptor (Kenakin, 
2009). If this is the case, Schild analysis still can be used to estimate the antagonist 
potency of the test compound (Kenakin, 2009).  
 
There are also cases where Schild analysis is no longer a valid method to estimate 
the potency of the antagonist. For example, in cases where either the Schild slope 
was found to be significantly less than unity or in the case where only a single 
concentration of antagonist was compared to an agonist. In either case, the single 
concentration method (Schild equation) can be used to empirically estimate the 
potency of an antagonist without defining the molecular model of antagonism of 
antagonist in a particular system studied (Kenakin, 2009). This equation use pA2 as 
a parameter, assuming that the value measured is a prediction of antagonist 
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concentration that produced a twofold shift of agonist concentration-response curve. 
Another limitations of the Schild equation is the general assumptions that the 
antagonist tested is following a simple competitive antagonism model and the 
receptor-antagonist-agonist equilibrium is achieved, although this is sometimes not 
always right (Leslie, 1987). Therefore, according to Gaddum (1954), in order to 
ensure the prediction of pA2 is reliable, the value of CR-1 has to be at least 5 or 
greater  (Gaddum et al., 1954). However, Kenakin (2009) suggests that log (CR-1) 
has to be a positive value (not specified) and Schild equation analysis should use a 
minimum concentration of antagonist that produced a twofold shift of agonist 
concentration response-curve.  
 
Despite these disadvantages, the single concentration method offers a few 
advantages, as it is a faster method to estimate the antagonist affinity and potency 
especially if the antagonist tested has affinity to multiple opioid receptors that can 
present in a single tissue (eg: buprenorphine in mouse vas deferens, MVD) (Leslie, 
1987; Spagnolo et al., 2008). Not only related to the antagonist, the problem with 
agonist receptor selectivity can also be avoided with the single concentration 
method. Although agonists with high receptor selectivity are commercially available, 
it is rarely possible to maintain their selectivity at a higher concentration (Leslie, 
1987). This will cause a problem especially when a high concentration of antagonist 
is used during the Schild analysis. Therefore, the selection of a high affinity and 
potent agonist as a standard drug is important, together with the selective antagonist 
to block the unwanted receptor present in the isolated tissue. Furthermore, if the 
agonist used has slow wash-out, or is such that concentration-response curves can 
only be constructed non-cumulatively, Schild plot analysis (requiring four or more 
concentration-response curves on the same tissue) is not possible. 
 
Another example of where Schild plot analysis is not possible, and so the single 
concentration Schild equation approach is preferred is with competitive reversible or 
pseudo-irreversible antagonism. 
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A compound is defined as being a competitive antagonist if it competes at the same 
binding site on the receptor as the agonist to achieve effect (Kenakin, 2009). The 
ability of either the agonist or the antagonist to occupy the binding sites depends on 
its relative binding affinity and concentration (Kenakin, 2009). The reversibility 
(surmountability) of the antagonist is shown by a dextral displacement (parallel shift 
to the right) of the agonist concentration-response curve without causing significant 
diminution (suppression) of the maximal response. Or alternatively if the agonist 
manages to regain its baseline response after the antagonist is washed from the 
tissue (Kenakin, 2009; Motulsky, 2007). Ideally, the agonist, antagonist and the 
receptor are allowed to achieve re-equilibrium before the tissue response to agonist 
is measured in the presence of antagonist (Kenakin, 2009). However, there is a 
case where the re-equilibria is hardly achieved due to the slow offset of antagonist 
from the receptor during this period and therefore the pattern of the concentration-
response curve shows diminution of agonist maximal response in the presence of 
this antagonist. If this is the case, the compound that was competing with the 
agonist is concluded as having a pseudo-irreversible behaviour of antagonism 
(Kenakin, 2009).  
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1.9 Objective of Studies 
 
1.9.1 General objectives 
 
To synthesize several single compound(s) similar in activity to 
buprenorphine/naltrexone combination with higher activity at the ORL-1 and -opioid 
receptor to treat psychological dependence (reduce relapse) related to drug 
addiction. 
 
1.9.2 Specific objectives 
 
1) To synthesis several new orvinols (Figure 1.11 (a)) closely related to the lead 
compound BU127 by introducing a small substituent group (methyl) at different 
positions of the C20-phenyl (Figure 1.11 (b)). 
2) To introduce a heterocyclic group (thiophene including substituted 
thiophenes) at the C20-position of the orvinols (Figure 1.11 (c)) and to compare the 
receptor profiles of these ligands with the BU127 analogues (Figure 1.1 (b)) and 
buprenorphine. 
3) To assess the receptor behaviour and the relative potency of the analogues 
against buprenorphine in the isolated tissue preparation (rat vas deferens (- and 
ORL-1 opioid receptors) and mouse vas deferens (-opioid receptor)). 
4) To assess the receptor behaviour and the relative potency of the analogues’ 
having methyl substituent at C7 position of orvinol compared to the analogues 
without methyl at this position. 
49 
 
 
               (a)                                            (b)                                              (c) 
Figure 1.11: Structure modification of orvinols; (a) General structure of orvinols; (b) BU127 
and its analogues; (c) thiophene analogues.  
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2.1 Introduction 
 
2.1.1 BU127 as the lead buprenorphine/naltrexone single compound alternative 
 
 
                                        (15)       
        
Figure 2.1: Left, parent structure of buprenorphine analogues with point of modification at 
C20. Right, lead compound of buprenorphine/naltrexone analogues, BU127 (15) (R = phenyl)  
 
Of all the orvinols synthesized within the group, varying the R-substituent (eg: 
branched alkyl, cycloalkyl and aryl (eg: phenyl) substituents) and the 
stereochemistry at C20, BU127 (15) (Figure 2.1) is one of the only examples to have 
little to no efficacy at the -opioid receptor and substantially lower efficacy at the -
opioid receptor than buprenorphine (Figure 2.2).  
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Figure 2.2: Comparison of relative efficacies ([
35
S]GTPS binding) of buprenorphine 
analogues (compared to full opioid agonists DAMGO and U69593) at - and -opioid 
receptors conducted in CHO transfected cells (Husbands (unpublished work)). 
 
Due to the interesting profile of BU127 (15) to this project, we have targeted close 
analogues having a substituted phenyl ring and those having alternative aryl groups 
(Figure 2.3). All of the compounds were designed using compound BU127 (15) as a 
lead due to its successful profile observed at all of the targeted receptors (-, -, and 
ORL-1 receptor). Compound BU127 (15) has a phenyl substituent at R position of 
C20 (Figure 2.3). Compounds BU10101 (16), BU10092 (17) and BU10135 (18) are 
the closest analogues to BU127 (15) with a methyl group attached to the phenyl 
(BU127 (15)) at ortho (o-), meta (m-) and para (p-) positions respectively (Figure 
2.3). The idea of introducing and varying the methyl group on the phenyl ring was to 
investigate whether introducing a small amount of bulk, the pharmacological profile 
at the opioid receptors would improve. We aimed to investigate the effects of the 
methyl position on the phenyl ring compared to BU127 (15). On the other hand, 
compounds BU08026 (19), BU11001 (22), BU10093 (20) and BU10136 (21) also 
have aromatic substitution at R position (Figure 2.3) but contain a sulphur atom in 
the heterocyclic system. The aim of these compounds was to study if a small 
heterocyclic system had any implication on the pharmacological activity of this 
orvinol series at the main opioid receptors. Compound BU08026 (19) is a 2-
thiophene whereas compound BU11001 (22) is a 3-thiophene. Compound BU10093 
(20) was similar to BU08026 (19) but with a methyl side change attached to the 
thiophene ring. Instead of a small alkyl group, compound BU10136 (21) has a 
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halogen atom (chloro) attached to the heterocyclic system (Figure 2.3). We aimed to 
observe the effects of relocation of the sulphur in the aromatic ring and the effects of 
introducing different substituents. 
 
 
 
Figure 2.3: Buprenorphine analogues. 
 
2.2 Results and Discussion 
 
All of the compounds have been synthesised using thebaine (1) as the starting 
material, except for the first compound (phenyl orvinol (15)) where M5028 
(dihydrothevinone, 3) was used. Both of these starting materials were obtained from 
Reckitt Benkinser. 
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2.2.1 Diels-Alder reaction of Thebaine (1) to give Thevinone (2) 
 
 
(1) (2) 
 
Thevinone (2) was prepared from thebaine (1) under reflux through a Diels-Alder 
reaction with methyl vinyl ketone which acts as the dienophile in this reaction. The 
cycloaddition of the methyl vinyl ketone with the conjugated diene system is a 
stereospecific reaction (a cis addition) (Fessenden et al., 1986) which produces an 
adduct (thevinone / 6,14-endo-ethenotetrahydrothebaine) (2) having an -acetyl 
group at C7 (regiospecific) as the major product (Casy et al., 1986). The formation of 
the regioisomer of the adduct (acetyl at the C8 position) is unlikely to occur, due to 
the polarizing electronic effects of electrons between the oxygen in the C6-methoxy 
group and the diene system in the morphinan rings and also the steric effects of the 
morphinan skeleton (Hutchins et al., 1981; Knipmeyer et al., 1985). This is a high 
yield reaction which in our case, gave 76% total adduct of 7-ketone and the 
remainder was identified as the starting material (thebaine (1)) which was confirmed 
with 1H-NMR. The final percentage yield obtained from our experiment was slightly 
lower than previously reported which was 96.3% (7-ketone) and 1.5% (7-ketone) 
(Bentley et al., 1967a). In Bentley’s (1967a) study, the main adduct isolated was 
93% and the remaining crops were isolated from the insoluble 7 epimer through 
repeated recrystallization of the mother liquors with methanol (60°C). According to 
Bentley (1967a), the presence of 7 epimer could be detected from both the thin 
layer chromatography (TLC) and 1H-NMR (Bentley et al., 1967a). The 7-ketone is 
less polar than its epimer and the 5-H appears in a different chemical shift for both 
epimers which can be easily detected using the 1H-NMR (Bentley et al., 1967a; 
Fulmor et al., 1967). Bentley (1967a) has reported that the 5-H signals for the    
7- ketone appears at the lower field (4.55) whereas at a slightly higher field for its 
7 epimer (4.98). The 5-H signal appears at the higher field for the 7 epimer due 
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to the anisotropy of the acetyl group (Hutchins et al., 1981). In our current work, 
69% of the main adduct was purified from the first crop.  The 5β-H signal appears at 
4.56 which was in line with Bentley’s (1967a) findings. Our experiment also shows 
no evidence of 7 epimer detected from the remaining mother liquors, proved by 
both TLC and 1H-NMR.  
 
2.2.2 Catalytic hydrogenation of Diels-Alder adduct (Thevinone) (2) to give 
Dihydrothevinone (3) 
 
 
                             (2)                                                                 (3) 
 
The hydrogenation of thevinone (2) was conducted using a mild temperature 
(slightly above the room temperature) to overcome the shielding effects on the 
etheno bridge by the COCH3 group at C7 (Bentley et al., 1967d). This catalytic 
hydrogenation was conducted with a slightly modified procedure by referring to 
Bentley’s (1967b) and Grivas’ (1995) previous works. The initial reaction was 
conducted using 0.01% wequiv. of 10% Paladium on Carbon (Pd/C) in ethanol, 
under 65 psi which only gave 59% yield of dihydrothevinone (3), and 27% was 
identified as the starting material, thevinone (2) based on the 1H-NMR (Grivas, 
1995). It was later noticed that the starting material, thevinone (2) was not fully 
dissolved in the ethanol, which is thought to contribute to the low yield percentage. 
This procedure was modified by dissolving the thevinone (2) into a mixture of 
ethanol and ethyl acetate (1:1), increasing the amount of catalyst (0.1% wequiv.) 
(Bentley et al., 1967d) and performed under a higher pressure (200 psi). With these 
modified procedures, the yield increased to 86%. The adduct (2) formed a 
suspension in ethanol even when heated at 50°C but fully dissolved into a clear 
orange solution after ethyl acetate was added. Although thevinone (2) is fully 
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dissolved in ethyl acetate, alcohol (eg: ethanol) is needed in order to dissolve the 
hydrogen gas necessary for this reaction. 
 
2.2.3 Demethylation of Dihydrothevinone (3) to give Dihydronorthevinone (4)  
 
 
                                  (3)                                                      (4) 
 
The reagents that are commonly used for N-demethylation are cyanogen bromide 
(CNBr) and azodicarboxylic acid ((:N.CO2H)2) (Casy et al., 1986; Kroutil et al., 2000; 
Marton et al., 1997). Azodicarboxylic acid (eg: diethyl azodicarboxylate (DEAD), 
diisopropyl azodicarboxylate (DIAD)) is more preferable for a lab scale productions 
compared to CNBr which is usually used for industrial scale. Although                    
N-demethylation with CNBr was reported to produce a higher yield of (4) compared 
to azodicarboxylic acid (DEAD) (92% vs 71%) (Marton et al., 1997), CNBr is a highly 
toxic reagent due to its volatility which is readily absorbed through skin upon direct 
contact and also during inhalation. 
 
 
Figure 2.4: Diisopropyl azodicarboxylate (DIAD). 
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The N-demethylation of tertiary amines to secondary amines by DIAD (Figure 2.4) 
initially involves nucleophilic attack by the nitrogen atom of the tertiary amine then 
formation of a reactive ylide, followed by a two-step intermediate (ylide) 
rearrangement (3(a) and 3(b)) (Figure 2.5 (a) and Figure 2.5 (b)) (Kenner et al., 
1952; Smissman et al., 1973). The acid hydrolysis (weak acid) of the unstable 
adduct (3(c)) (Kenner et al., 1952) gave an intermediate hydrochloride salt, which 
was reported by Smissman (1973) containing an NH group and two nonequivalent 
carbonyl group, detected using infrared spectroscopy (IR) from the reaction between 
a tertiary amine (N-methyl-piperidine) and a azocarboxylic acid (dimethyl 
azodicarboxylate). Although IR analysis was not performed in our experiment, the 
1H-NMR of dihydronorthevinone (4) has confirmed the disappearance of N-CH3 
signals which was previously seen with dihydrothevinone (3) 1H-NMR. The yield 
percentage of (4) obtained from our experiment with DIAD was 69.3% which is 
nearly similar to the yield that has been previously reported with DEAD (71%) 
(Marton et al., 1997). The N-demethylation of tertiary amines with azodicarboxylic 
acids were reported to consistently gave good yields of the N-demethylated amines 
(> 70%) as the main adducts (Kroutil et al., 2000). According to Kroutil (2000), the 
side products of this reaction when DIAD was used as the reagent were an 
aldehyde of the dealkylated group and also a diisopropyl hydrazinodicarboxylate 
(DIHD). However, we did not characterize the remaining side products in our current 
work. The suggested mechanism for the N-demethylation of (3) by DIAD, followed 
by acid hydrolysis by pyridinium chloride/ethanol is shown in Figure 2.5: 
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Figure 2.5 (a): N-demethylation of dihydrothevinone (3) by DIAD (Mechanism 1) 
 
 
 
Figure 2.5 (b): N-demethylation of dihydrothevinone (3) by DIAD (Mechanism 2) 
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2.2.4 Synthesis of N-CPM dihydronorthevinone (6)  
 
 
 
The alkylation of dihydronorthevinone (4) to its N-alkyl substituted derivatives is a 
high yield reaction which in the case of phenyl dihydronorthevinone (C20 = phenyl 
ketone) gave 72% yield with cyclopropylmethyl bromide (5) (Marton et al., 1997). 
The yield percentage obtained for (6) from our experiment was 83% which is higher 
than the value reported for phenyl dihydronorthevinone. This may be due to the 
steric hindrance caused by the phenyl substituent around the N17 and C20 region. 
The alkylation involves a simple nucleophilic substitution mechanism as shown 
(Figure 2.6):  
 
 
Figure 2.6: Alkylation of dihydronorthevinone (4) with cyclopropylmethyl bromide (5) to give 
N-CPM dihydronorthevinone (6) 
 
The cyclopropylmethyl bromide (5) (CPMBr) reagent used in this reaction (Cowan, 
1995) was prepared by bromination of the commercially available cyclopropyl 
methanol with phosphorus tribromide. Initial attack by oxygen to form an 
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intermediate with oxygen part of a better leaving group, as shown below (Figure 
2.7): 
 
 
Figure 2.7: Bromination of cyclopropyl methanol with phosphorus tribromide. 
 
2.2.5 Grignard addition to give Thevinol 
 
All the Grignard reagents (R-MgX) used in this reaction were commercially 
available. However, 3-thienyl magnesium bromide was prepared in the lab due to 
the stability issues of the 3-thienyl magnesium iodide that was previously purchased. 
The synthesis route of 3-thienyl magnesium bromide is shown below (Figure 2.8) 
(Nyberg et al., 1970); involving production of the aryl lithium species and reaction of 
this with MgBr2, prepared from treatment of magnesium with dibromoethene. 
 
 
 
Figure 2.8: Synthesis of 3-thienyl magnesium bromide from 3-bromothiophene. 
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The Grignard addition to the ketone (N-CPM dihydronorthevinone, (6)) is a 
stereospecific reaction, yielding an almost pure tertiary alcohol (thevinol) with the 
alkyl group (R) adding from the upper face (major product of Grignard reaction) 
(Bentley et al., 1967d).  
 
 
 
During the transition state of the Grignard addition, a six-membered intermediate is 
believed to have formed (Figure 2.9) (Bentley et al., 1967b). The rate of addition, of 
the R group, during this transition state versus rate of deprotonation of C7-H or 
Grignard reduction, will determine the proportion of the major product obtained from 
this reaction.  
 
 
Figure 2.9: A six-membered intermediate was formed during transition state of Grignard 
addition. 
 
Although; in many cases, a minor product of Grignard reduction (2° alcohol) can 
also be produced from Grignard reaction (can account for up to 30% of the total 
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product), it cannot happen in our particular series due to the absence of a reactive 
-hydrogen in the aromatic Grignard reagents used in our experiments (Bentley et 
al., 1967d). If the diastereomer of the major product (tertiary alcohol) or reduction 
side product is suspected, it can be initially detected by thin layer chromatography 
(TLC) and confirmed by infrared spectroscopy (IR) and 1H-NMR (Bentley et al., 
1967d; Fulmor et al., 1967). As expected, no evidence of secondary product was 
observed (after 22-44 hours). The low yield obtained in some of the reactions was 
due to bulkier nature of the Grignard reagent and unreacted starting material (6) was 
obtained at the end of reaction which was confirmed by TLC and 1H-NMR. When the 
starting material (6) was observed during TLC, extra Grignard reagent was added to 
the reaction mixture and the reaction was left to go to completion for another 22 
hours. In some cases, especially when the rate of reaction was suspected to be 
slower than usual (eg: due to the steric hindrance at C20 during aryl addition), no 
further Grignard reagent was added. This action was taken to avoid base-catalyzed 
rearrangement which can occur as the Grignard reagent can also act as a base 
(Bentley et al., 1967c; Bentley et al., 1967d) (Figure 2.10). This was suspected to 
happen during o-tolyl magnesium bromide addition that contributes to the low yield 
of BU10101 (16). From the TLC of o-tolyl thevinol (8) reaction, a compound that is 
more polar than the starting material (6) was detected which was suspected to be 
the phenolic alcohol II (product of rearrangement) (Figure 2.10). 
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Figure 2.10: Base-catalyzed rearrangement during Grignard addition due to a slow rate 
Grignard addition and also in the presence of excess Grignard reagent. 
 
Over the range of Grignard reagents used, yields after silica gel chromatography 
ranged from 29-83% (Table 2.1). The lowest yield was o-tolyl thevinol (8), followed 
by 3-methyl-2-thienyl thevinol (12), indicating that the steric bulk of the o-methyl 
group was hindering the reaction. Best yields were with the less sterically 
demanding and more electron rich Grignard reagents such as 2-thienyl, m-tolyl and 
p-tolyl. The presence of electron withdrawal group (chloro) in 5-chloro-2-thienyl did 
not reduce the yield of reaction. The quite low yield obtained with phenyl magnesium 
bromide may be because this was the first example attempted. The yield percentage 
obtained from the previous work carried out in the Husbands’ group for phenyl 
magnesium bromide addition was 63% (BG1021). 
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Table 2.1: Percentage yields of Grignard addition to N-CPM dihydronorthevinone (6) from 
various reagents 
Grignard Reagent Product Percentage 
yield (%) 
Phenyl magnesium bromide Phenyl thevinol (7) 
 
 
42% 
o-tolyl magnesium bromide   o-tolyl thevinol (8) 
 
 
29% 
m-tolyl magnesium chloride m-tolyl thevinol (9) 
 
 
81% 
p-tolyl magnesium bromide p-tolyl thevinol (10) 
 
 
71% 
2-thienyl magnesium bromide 2-thienyl thevinol (11)  
 
 
83% 
3-methyl-2-thienyl magnesium bromide 3-methyl-2-thienyl thevinol (12) 
 
 
44% 
5-chloro-2-thienyl magnesium bromide 5-chloro-2-thienyl thevinol (13) 
 
 
79% 
3-thienyl magnesium bromide 3-thienyl thevinol (14) 
 
62% 
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2.2.6 3-O demethylation of Thevinols to Orvinols 
 
 
              
The O-demethylation with propanethiol is a selective reaction for thevinols, in which 
only 3-O demethylation occurs. Another alternative for a selective 3-O demethylation 
is by using potassium hydroxide (KOH), a strong nucleophile. However, KOH is 
highly corrosive and it also needs a higher temperature (200-215°C) to perform this 
reaction (Bentley et al., 1967b; Marton et al., 1997). These is in contrast to 
demethylation using some other reagents (eg: bromo tribromide (BBr3) and 
hydrobromic acid (HBr)) (Kopcho et al., 1986; Kotick et al., 1983; Rice, 1977) which 
cause 6-O demethylation and 3-O demethylation. 
 
The 3-O demethylation of thevinol with propanethiol is another example of SN2 
reaction where the formation of phenoxide intermediate is a rate limiting step. The  
3-O demethylation of the thevinols must be conducted under base conditions to 
avoid acid-catalyzed rearrangement of the alcohols (Bentley et al., 1967b; Casy et 
al., 1986). A highly polar aproctic solvent, hexamethylphosphoramide (HMPA) was 
used in this reaction. Although liquid ammonia and dimethylformamide (DMF) also 
can be used as solvents for the reaction, the advantage of using HMPA is its high 
polarity which makes the nucleophile (eg: propanethiolate) more nucleophilic, and 
also eases the electron transfer reaction, and therefore helps to increase the yield of 
reaction (Knipmeyer et al., 1985; Testaferri et al., 1982). Under anhydrous condition, 
an excess sodium hydride (NaH) deprotonates propanethiol, creating a strong 
nucleophile, propanethiolate (Michne, 1978; Testaferri et al., 1982). Propanethiolate 
is a strong nucleophile and will attack the 3-methoxy carbon which is electrophilic. 
Phenoxide is a leaving group in this reaction (Figure 2.11) (Testaferri et al., 1982) 
and the aromatic group (ring A) of morphinan will delocalize the negative charge of 
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phenoxide around the phenyl ring to make it a stable species and therefore likely to 
form. 
 
 
 
Figure 2.11: The formation of phenoxide sodium intermediate during 3-O demethylation with 
propanethiol. 
 
TLC was carried out 1 and 4 hour after the reaction was set up to detect the 
formation of product. If reaction was not proceeding (based on TLC), more sodium 
hydride was added to ensure all the propanethiol was deprotonated. The yield 
percentage obtained for the 3-O demethylation products (orvinol) in our experiments 
were varied (39-82%), partly depending of the dryness of the HMPA (Grivas, 1995). 
HMPA is commercially available, but requires distilling after prolonged storage. A 
previous study has also reported freshly distilling propanethiol before the reaction 
was performed in order to achieve a high yield (Knipmeyer et al., 1985). This was 
not done in the current project. It also seemed that some product was lost on the 
column during the purification process, especially when the purification was 
conducted manually. This could also explain the lower yield achieved with some of 
the orvinols synthesised. 
 
In summary, eight N-CPM orvinols (end products) have been successfully prepared 
(including BU127 (15) which were used as lead). These bases were converted into 
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their hydrochloric salts (as described in the experimental section) for 
pharmacological evaluation.  
 
2.3  Experimental 
 
2.3.1 Experimental techniques 
 
The NMR spectra (1H, 1H-COSY, 13C, DEPT) were recorded on either a JEOL Delta 
270 MHz or Varian Mercury 400 MHz spectrometer and referenced to external 
standards using the deuterium lock signal. All chemical shifts and coupling 
constants are given in ppm and Hz respectively.  
 
Low and high resolution mass spectra were obtained on ESIMS:micrOTOF 
(BRUKER). 
 
Elemental analysis were obtained on a Perkin-Elmer 240C analyzer. 
 
All reactions were monitored by either thin layer chromatography (Rf) on aluminium 
silica sheets coated with silica gel 60 F254 (Merck), or by proton NMR spectroscopy 
in the case of catalytic hydrogenation. 
 
All purifications were carried out by either gravity elution chromatography on Fluka 
silica gel 60, or flash column chromatography (Combiflash Rf) on silica RediSep Rf 
(12-24 g). 
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All reagents and solvents were used as supplied by commercial sources        
(Sigma-Aldrich, Fischer Scientific, Abcam) unless otherwise stated. 
 
All solvents used were dried according to literature methods (Armarego et al., 2003) 
whenever necessary. 
 
2.3.2 Synthetic procedures 
 
2.3.2.1 General procedures 
 
Procedure A : Diels Alder Reaction of Thebaine (1) to give Thevinone (2) 
A mixture of thebaine 1 (1 equiv.) and methyl vinyl ketone (1.2 equiv.) were heated 
at 70°C in anhydrous toluene (0.25 mmolml-1) for 24 hours. The solvent and excess 
methyl vinyl ketone were removed under reduced pressure to yield a viscous 
residue which was purified by recrystallisation in methanol. 
 
Procedure B : Catalytic Hydrogenation of Diels-Alder Adduct (Thevinone) (2) 
to give Dihydrothevinone (3) 
A solution of thevinone 2 in mixture of ethanol (0.63 mmolml-1) and ethyl acetate 
(0.63 mmolml-1), and 10% palladium on carbon (0.1 wequiv.) was hydrogenated at 
200 psi at 41°C for 6 days. The mixture was cooled to room temperature, the 
catalyst was removed by filtration over cellite and the solvent was evaporated under 
reduced pressure to yield a foam which was used without any further purification. 
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Procedure C : Synthesis of N-CPM dihydronorthevinone (6)  
A solution of dihydrothevinone 3 (1 equiv.) in acetonitrile (anhydrous, 5.0 mmolml-1 
of 3) and diisopropyl azodicarboxylate (DIAD, 2.8 equiv.) was heated at reflux 
(acetonitrile boiling point, 82°C) for 3 hours. The reaction mixture was then 
evaporated and the residue was dissolved in ethanol (3.3 mmolml-1 of 3). Pyridinium 
chloride (0.9 equiv.) was added and the mixture was stirred overnight at room 
temperature. The hydrochloride which precipitated was filtered off and washed with 
cold ethanol. The white isolated powder was dried under vacuum. The hydrochloride 
intermediate 4 obtained was dissolved in dimethylformamide, DMF (2 mmolml-1 of 4) 
and treated subsequently with anhydrous sodium hydrogen carbonate, NaHCO3 (4.5 
equiv.) and cyclopropylmethyl bromide 5 was added. The resultant mixture was 
heated at 90°C for 19 hours. The mixture was filtered to remove NaHCO3 before 
removing DMF under vacuum and the residue was then dissolved in water. The 
aqueous phase was then extracted with chloroform and washed with brine. The 
organic layers obtained were then dried over magnesium sulphate, filtered and 
evaporated. 
 
Procedure D : Synthesis of Cyclopropylmethyl bromide (5) 
Cyclopropyl methanol  (1 equiv.) was treated with phosphorus tribromide, PBr3 (0.37 
equiv.) in anhydrous diethyl ether at -78°C (0.3 mmolml-1). The reaction was stirred 
overnight and allowed to warm to room temperature. Water (10 ml) was added and 
the phases were separated. The aqueous phase was extracted with diethyl ether. 
The organic layers obtained were then dried over magnesium sulphate and filtered. 
Diethyl ether was removed under vacuum and the product obtained by distillation 
(80-100°C). 
 
Procedure E : Grignard Addition to give thevinols 
N-CPM dihydronorthevinone 6 (1 equiv.) was dissolved in anhydrous toluene (0.1 
mmolml-1). The appropriate Grignard reagent (2 equiv.) was added and the reaction 
mixture was stirred at room temperature for 22 hours. Thin layer chromatography 
(TLC) was done after 1, 4 and 22 hour(s) to detect the product. The reaction mixture 
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was quenched with saturated ammonium chloride (NH4Cl) and extracted with ethyl 
acetate, washed with brine and dried with magnesium sulphate (MgSO4). 
 
Procedure F : 3-O Demethylation of thevinols (3-methyl ethers) to give 
orvinols 
To a mixture of sodium hydride, NaH (3.5 equiv.) and thevinol (1 equiv.) in 
hexamethylphosphoramide, HMPA (0.20 mmolml-1) under nitrogen, 1-propanethiol 
(3.5 equiv.) was added drop wise. Once the addition had been completed the 
mixture was heated to 120°C under stirring for 5 hours before cooling to room 
temperature and adding a saturated aqueous solution of ammonium chloride, 
NH4Cl. The mixture was extracted with diethyl ether (3x) and then was washed with 
water (3x) and a saturated aqueous solution of sodium chloride (2x) and finally dried 
with magnesium sulphate, MgSO4. The extracts were evaporated to dryness under 
reduced pressure and the product was purified by chromatography. 
 
Procedure G : Preparation of salts 
Into a stirred solution of the freebase (1.0 equiv.) in methanol, hydrogen chloride in 
diethyl ether (2.0 equiv.) was added and stirred at room temperature for 30 minutes 
(until no further precipitation was observed). The solvent was then evaporated under 
reduced pressure. The salt was purified by recrystallisation from either ethanol or   
2-propanol. 
 
Procedure H : Synthesis of Grignard reagent (3-thienyl magnesiumbromide) 
3-thienyllithium was prepared from 3-bromothiophene (1.0 g, 6.13 mmol) in 
anhydrous diethyl ether (2.26 mmolml-1) and butyllithium (345.0 mg, 5.59 mmol) in 
anhydrous diethyl ether (0.67 mmolml-1) at -70°C and was subsequently added (at   
-70°C) under nitrogen to a well-stirred solution of magnesium bromide in ether-
toluene (anhydrous). The latter was prepared by carefully adding ethylene bromide 
(1.5 g, 8.0 mmol) in a mixture of anhydrous diethyl ether (2.20 mmolml-1) and 
anhydrous toluene (22.1 mmolml-1) to magnesium (300.0 mg, 12.1 mmol) in 
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anhydrous diethyl ether (6.74 mmolml-1). A clear solution of 3-thienylmagnesium 
bromide was formed. 
 
2.3.2.2 Experimental data 
 
Thevinone (2) 
Thebaine 1 (20.0 g, 64.2 mmol) and methyl vinyl ketone (6.4 ml, 77.1 mmol) in 
anhydrous toluene (150 ml) were treated as in general procedure A. The adduct 2 
(thevinone) was purified by recrystallisation from MeOH (18.5 g, 76%). Rf (5% 
MeOH.DCM-0.5%NH3) 0.38. H (400M Hz; CDCl3) 6.62 (1H, d, J 8.12, 2-H), 6.52 
(1H, d, J 8.12, 1-H), 5.89 (1H, d, J 8.88, 18-H), 5.56 (1H, d, J 8.84, 19-H), 4.56 (1H, 
s, 5-H), 3.81 (3H, s, 3-OCH3), 3.59 (3H, s, 6-OCH3), 3.21 (1H, d, J 19.12, 10-H), 
3.18 (1H, d, J 6.88, 9-H), 2.88-2.95 (2H, m, 7-H, 8-H), 2.49-2.53 (1H, m, 15/16-
NCH2CH2-), 2.40-2.44 (1H, m, 15/16-NCH2CH2-), 2.37-2.38 (1H, m, 10-H), 2.36 
(3H, s, 17-NCH3), 2.13 (3H, s, 20-OCH3), 1.93-1.97 (1H, m, 15/16-NCH2,CH2-), 
1.82-1.86 (1H, m, 15/16-NCH2,CH2-), 1.32-1.39 (1H, dd, J 10.84, J 6.08, 8-H); C 
(100.56 MHz; CDCl3) 209.12 (C20), 141.88, 135.99, 134.08, 126.10, 119.48, 113.54, 
95.23, 81.30, 81.29, 60.02, 56.66, 53.54, 50.70, 50.69, 47.55, 45.54 (CH2), 43.27, 
33.54 (CH2), 30.59, 30.02 (CH2), 22.47 (CH2); m/z 382 (M
+ + 1, 100%),  (Found: M+ 
+ 1, 382.2011. C23H28NO4 requires 382.2018).    
 
Dihydrothevinone (3) 
Adduct 2 (16.9 g, 44.3 mmol) and 10% palladium on carbon (1.7 g) was treated as 
in general procedure B (reaction time: 6 days) to yield 3 (14.7 g, 87%). H (400 MHz; 
CDCl3) 6.70 (1H, d, J 8.12, 2-H), 6.57 (1H, d, J 8.08, 1-H), 4.46 (1H, s, 5-H), 3.87 
(3H, s, 3-OCH3), 3.43 (3H, s, 6-OCH3), 3.09 (1H, d, J 18.44, 10-H), 3.00-3.04 (1H, 
dd, J 10.04, J 5.20, 9-H), 2.62-2.71 (2H, m, 7-H, 8-H), 2.41-2.45 (1H, m, 15/16-
NCH2CH2-), 2.27-2.30 (1H, m, 15/16-NCH2CH2-), 2.27 (3H, s, 17-NCH3), 2.25-2.27 
(1H, m, 10-H), 2.25 (3H, s, 20-CH3), 1.98-2.06 (1H, td, J 12.6, J 5.8, 15/16-
NCH2CH2-), 1.70-1.75 (1H, dd, J 13.08, J 6.20, 8-H), 1.64-1.68 (1H, m, 15/16-
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NCH2CH2-), 1.51-1.56 (2H, m, 2 x 18/19-H), 1.23-1.33 (1H, m, 18/19-H), 0.69-0.76 
(1H, m, 18/19-H). ); C (100.56 MHz; CDCl3) 210.68 (C20), 146.84, 141.82, 132.52, 
128.77, 119.21, 114.17, 94.71, 61.37, 56.84, 52.24, 49.65, 45.79, 45.24 (CH2), 
43.51, 35.61, 35.21 (CH2), 33.70, 30.40 (CH2), 28.60 (CH2), 22.02 (CH2), 17.46 
(CH2); m/z 384 (M
+ + 1, 100%),  (Found: M+ + 1, 384.2171. C23H30NO4 requires 
384.2175).         
 
Dihydronorthevinone (4) 
Dihydrothevinone 3 (14.0 g, 36.5 mmol), DIAD (20.7 g, 102.2 mmol) and pyridinium 
chloride (3.8 g, 32.9 mmol) was treated as in general procedure C to yield 4 (10.2 g, 
69%). Rf (40% EtOAc.Pet.Ether-0.5% NH3) 0.30.  H (400 MHz; CDCl3) 6.78 (1H, d, 
J 8.24, 2-H), 6.67 (1H, d, J 8.24, 1-H), 4.52 (1H, s, 5-H), 3.88 (3H, s, 3-OCH3), 
3.61-3.65 (1H, m),  3.42 (3H, s, 6-OCH3), 3.29-3.41 (2H, m), 3.05-3.13 (2H, m), 2.27 
(3H, s, 20-CH3), 1.98-2.03 (1H, m, 15/16-NCH2,CH2-), 1.85-1.90 (1H, m, 15/16-
NCH2,CH2-), 0.68-0.76 (1H, m) ); C (100.56 MHz; CDCl3) 210.60 (C20), 146.94, 
145.78, 142.75, 130.00, 124.58, 120.36, 115.20, 106.56, 93.83, 93.81, 81.35, 56.78, 
54.00, 52.51, 52.50, 48.64, 45.17 (CH2), 35.71, 34.06 (CH2), 34.02 (CH2), 30.98 
(CH2), 16.97 (CH2); m/z 370 (M
+ + 1, 100%),  (Found: M+ + 1, 370.2011. C22H28NO4 
requires 370.2018).     
 
Cyclopropylmethyl bromide (5) 
H (400 MHz; CDCl3) 3.31 (2H, d, J 8.00, CH2), 1.26-1.30 (1H, m, cyclopropyl-CH), 
0.73-0.75 (2H, m, cyclopropyl-CH2), 0.33-0.35 (2H, m, cyclopropyl-CH2) 
 
N-CPM dihydronorthevinone (6)  
Dihydronorthevinone 4 (2.2 g, 5.4 mmol), anhydrous NaHCO3 (2.1 g, 24.4 mmol) 
and cyclopropylmethyl bromide 5 (1.1 g, 8.1 mmol) was treated as in general 
procedure C to yield 6 (2.0 g, 83%). Rf (5% MeOH.DCM-0.5% NH3) 0.70. H (400 
MHz; CDCl3) 6.70 (1H, d, J 8.08, 2-H), 6.55 (1H, d, J 8.12, 1-H), 4.47 (1H, s, 5-H), 
3.87 (3H, s, 3-OCH3), 3.43 (3H, s, 6-OCH3), 3.02-3.06 (2H, m, includes 9-H), 2.95-
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3.00 (1H, d, J 18.32, 10-H), 2.70-2.77 (1H, m, 7-H), 2.60-2.64 (1H, dd, J 11.92, J 
5.24, 8-H), 2.28-2.34 (4H, m, includes 10-H), 2.26 (3H, s, 20-CH3), 1.99-2.07 (1H, 
m, 15/16-NCH2,CH2-), 1.70-1.75 (1H, dd, J 13.16, J 6.28, 8-H), 1.64-1.68 (1H, m, 
15/16-NCH2,CH2-), 1.52-1.56 (2H, m, 18/19-H), 1.26-1.33 (2H, m, 18/19-H), 0.68-
0.79 (1H, m, N-CH2CH(CH2-CH2)), 0.44-0.49 (2H, m, N-CH2CH(CH2-CH2)), 0.08-
0.09 (2H, m, N-CH2CH(CH2-CH2)); C (100.56 MHz; CDCl3) 211.08 (C20), 146.81, 
141.81, 137.11, 132.74, 128.85, 119.23, 113.92, 94.81, 59.88 (NCH2CH(CH2)2), 
58.43, 56.79, 52.34, 49.73, 46.53, 43.83 (CH2), 35.50 (CH2), 35.38, 33.88, 30.44 
(CH2), 28.74 (CH2), 22.82 (CH2), 17.55 (CH2), 9.55, 4.17 (CH2), 3.43 (CH2), ; m/z 
424 (M+ + 1, 100%),  (Found: M+ + 1, 424.2468. C26H34NO4 requires 424.2488). 
 
Phenyl thevinol (7)  
N-CPM dihydronorthevinone 6 (220.0 mg, 0.52 mmol) in anhydrous toluene (5.2 ml)  
was treated as in procedure E with phenyl magnesium bromide (1.5 ml, 1.04 mmol). 
Purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) (110.0 
mg, 42%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.7. H (270 MHz; CDCl3) 7.50 (2H, 
d, J 7.16, 2 x aryl.CH), 7.33 (2H, t, J 7.16, J 7.72, 2 x aryl.CH), 7.18-7.26 (1H, m, 1 x 
aryl.CH). 6.69 (1H, d, J 8.24, 2-H), 6.52 (1H, d, J 7.97, 1-H), 5.50 (1H, s, 20-OH), 
4.42 (1H, s, 5-H), 3.87 (3H, s, 3-OCH3), 3.61 (3H, s, 6-OCH3), 2.91 (1H, d, J 19.28, 
10-H), 2.86 (1H, d, J 7.16, 9-H), 2.39-2.44 (1H, m, 15/16-NCH2,CH2-), 2.11-2.55 
(5H, m, includes 10-H), 1.87-1.99 (1H, m, 15/16-NCH2,CH2-), 1.79-1.86 (2H, m, 
includes 15/16-NCH2,CH2-), 1.79 (3H, s, 20-CH3), 1.54-1.58 (1H, m), 0.77-1.07 (3H, 
m, includes 2 x 18/19-H, 8-H), 0.55-0.73 (1H, m, N-CH2CH(CH2-CH2-)), 0.33-0.39 
(2H, m, N- CH2CH(CH2-CH2-)), -0.10-(-0.03) (2H, m, N- CH2CH(CH2-CH2-)). C 
(100.56 MHz; CDCl3) 147.46, 146.94, 141.66, 132.76, 128.98, 127.92, 126.79, 
126.17, 119.18, 113.97, 97.14, 80.87, 59.54 (NCH2CH(CH2)2), 57.97, 56.90, 53.00, 
48.57, 46.95, 43.52 (CH2), 36.03, 35.70 (CH2), 32.65, 30.06 (CH2), 23.58, 22.72 
(CH2), 17.97 (CH2), 9.35, 4.18 (CH2), 3.32(CH2); m/z 502 (M
+ + 1, 100%), (Found: 
M+ + 1, 502.2958. C32H40NO4 requires 502.2957). 
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o-Tolyl thevinol (8)  
N-CPM dihydronorthevinone 6 (500.0 mg, 1.18 mmol) in anhydrous toluene (11.8 
ml) was treated as in procedure E with o-tolyl magnesiumbromide (2.95 ml, 2.95 
mmol). Purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
(120.0 mg, 29%). Rf (40% EtOAc.Pet.Ether-0.5%NH3) 0.85. H (400 MHz; CDCl3) 
7.21-7.24 (1H, m, 1 x aryl.CH), 7.08-7.15 (3H, m, 3 x aryl.CH), 6.69 (1H, d, J 8.12, 
2-H), 6.52 (1H, d, J 8.08, 1-H), 5.17 (1H, s, 20-OH), 4.42 (1H, s, 5-H), 3.88 (3H, s, 
3-OCH3), 3.59 (3H, s, 6-OCH3), 2.91 (1H, d, J 18.44, 10-H), 2.86 (1H, d, J 6.36, 
9-H), 2.76 (3H, s, 1 x aryl.CH3), 2.61-2.66 (1H, t, J 10.28, 7-H), 2.43-2.47 (1H, m, 
15/16-NCH2,CH2-), 2.10-2.20 (4H, m, includes 10-H, 1 x 15/16-NCH2,CH2-), 1.96-
2.04 (1H, m, 8-H), 1.83-1.88 (2H, m, 2 x 18/19-H), 1.84 (3H, s, 20-CH3), 1.78-1.81 
(1H, m, 15/16-NCH2,CH2-), 1.56-1.61 (1H, m, 15/16-NCH2,CH2-), 1.02-1.10 (1H, m, 
18/19-H), 0.80-0.86 (1H, dd, J 13.68, J 9.48, 8α-H), 0.71-0.77 (1H, m, 18/19-H), 
0.56-0.59 (1H, m, N-CH2CH(CH2-CH2-)), 0.29-0.41 (2H, m, N-CH2CH(CH2-CH2-)),   -
0.10-(-0.04) (2H, m, N- CH2CH(CH2-CH2-)); C (100.56 MHz; CDCl3) 145.52, 132.82, 
127.49, 126.85, 124.84, 119.54, 97.76, 79.69, 59.45 (NCH2CH(CH2)2), 57.91, 52.69, 
43.69, 36.11, 32.64, 31.93, 29.88 (CH2), 29.70, 29.36, 25.95, 22.86, 22.69 (CH2), 
18.25 (CH2), 14.11, 9.19, 4.09 (CH2), 3.17 (CH2);  m/z 516 (M
+ + 1, 100%), (Found: 
M+ + 1, 516.3119. C33H42NO4 requires 516.3114). 
 
m-Tolyl thevinol (9)  
N-CPM dihydronorthevinone 6 (560.0 mg, 1.32 mmol) in anhydrous toluene (13.2 
ml) was treated as in procedure E with m-tolyl magnesiumchloride (2.64 ml, 2.64 
mmol) to yield 9. Purification using column chromatography (30% EtOAc-Pet.Ether-
0.5%NH3) (551.0 mg, 81%). Rf (30% EtOAc-Pet.Ether-0.5%NH3) 0.59. H (400 MHz; 
CDCl3) 7.39 (1H, s, 2 x aryl.CH), 7.31 (1H, d, J 7.96,  1 x aryl.CH), 7.25 (1H, t, J 
7.44, 1 x aryl.CH), 7.09 (1H, d, J 7.32, 1 x aryl.CH), 6.74 (1H, d, J 8.12, 2-H), 6.57 
(1H, d, J 8.12, 1-H), 5.59 (1H, s, 20-OH), 4.47 (1H, s, 5-H), 3.93 (3H, s, 3-OCH3), 
3.64 (3H, s, 6-OCH3), 2.89 (1H, d, J 19.24, 10-H), 2.87 (1H, d, J 7.28, 9-H), 2.43-
2.45 (1H, m, 15/16-NCH2,CH2-), 2.42 (3H, s, 1 x aryl.CH3), 2.09-2.22 (5H, m, 
includes 7-H, 10-H, 1 x 15/16-NCH2,CH2-), 2.00-2.09 (1H, m, 15/16-NCH2,CH2-), 
1.84-1.92 (3H, m, includes 8-H, 1 x 15/16-NCH2,CH2-), 1.82 (3H, s, 20-CH3), 1.08-
1.17 (1H, m, 18/19-H), 0.90-0.98 (1H, dd, J 13.2, J 8.96, 8-H), 0.74-0.84 (1H, m, 
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18/19-H), 0.61-0.70 (1H, m, N-CH2CH(CH2-CH2-)), 0.35-0.46 (2H, m, N- 
CH2CH(CH2-CH2-)), -0.02-0.00 (2H, m, N- CH2CH(CH2-CH2-)). C (100.56 MHz; 
CDCl3) 147.41, 146.92, 141.62, 137.20, 132.77, 128.96, 127.58, 127.43, 126.77, 
123.23, 119.07, 113.98, 97.02, 80.81, 59.38 (NCH2CH(CH2)2), 57.81, 56.88, 52.88, 
48.36, 46.85, 43.55 (CH2), 35.96, 35.61, 32.57, 29.99 (CH2), 23.62, 22.65 (CH2), 
21.77, 18.00 (CH2), 9.24, 4.19 (CH2), 3.09 (CH2);  m/z 516 (M
+ + 1, 100%), (Found: 
M+ + 1, 516.3113. C33H42NO4 requires 516.3114). 
 
p-Tolyl thevinol (10)  
N-CPM dihydronorthevinone 6 (220.0 mg, 0.52 mmol) in anhydrous toluene (5.2 ml) 
was treated as in procedure E with p-tolyl magnesiumbromide (1.04 ml, 1.04 mmol). 
Purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) (190.0 
mg, 71%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.56. H (400 MHz; CDCl3) 7.39 (2H, 
d, J 8.16, 1 x aryl.CH), 7.14 (2H, d, J 8.04, 2 x aryl.CH), 6.70 (1H, d, J 8.08, 2-H), 
6.53 (1H, d, J 8.08, 1-H), 5.51 (1H, s, 20-OH), 4.25 (1H, s, 5-H), 3.88 (3H, s, 3-
OCH3), 3.60 (3H, s, 6-OCH3), 2.92 (1H, d, J 18.32, 10-H), 2.87 (1H, d, J 6.32, 9-
H), 2.42-2.46 (1H, m, 15/16-NCH2,CH2-), 2.34 (3H, s, 1 x aryl.CH3), 2.12-2.22 (4H, 
m, includes 7-H, 10-H), 2.08-2.11 (1H, m, 15/16-NCH2,CH2-), 1.95-2.02 (1H, m, 
15/16-NCH2,CH2-), 1.80-1.86 (3H, m, includes 8-H, 1 x 15/16-NCH2,CH2-), 1.76 
(3H, s, 20-CH3), 1.02-1.10 (1H, m, 18/19-H), 0.87-0.92 (1H, dd, J 13.24, J 5.2,     
8-H), 0.72-0.78 (1H, m, 18/19-H), 0.57-0.61 (1H, m, N-CH2CH(CH2-CH2-)), 0.35-
0.41 (2H, m, N-CH2CH(CH2-CH2-)), -0.05-0 (2H, m, N-CH2CH(CH2-CH2-)); C 
(100.56 MHz; CDCl3) 146.95, 144.54, 141.57, 135.95, 132.76, 128.94, 128.38, 
125.88, 118.98, 114.21, 96.96, 80.70, 59.43 (NCH2CH(CH2)2), 58.03, 56.90, 52.72, 
48.44, 46.78, 43.40 (CH2), 35.95, 35.58, 32.55, 29.93 (CH2), 23.49, 22.68 (CH2), 
20.91, 17.90 (CH2), 9.18, 3.91 (CH2), 3.12 (CH2). m/z 516 (M
+ + 1, 100%), (Found: 
M+ + 1, 516.3182. C33H41NO4 requires 516.3114). 
 
2-Thienyl thevinol (11)  
N-CPM dihydronorthevinone 6 (800.0 mg, 1.89 mmol) was treated in anhydrous 
toluene (18.9 ml) as in procedure E with 2-thienyl magnesiumbromide (3.78 ml, 3.78 
mmol). Purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
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(800.0 mg, 83%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.52. H (400 MHz; CDCl3) 
7.28 (1H, d, J 1.16, 1 x thienyl.CH), 6.94 (1H, t, J 5.04, 1 x thienyl.CH), 6.90 (1H, d, 
J 3.52, 1 x thienyl.CH), 6.72 (1H, d, J 8.12, 2-H), 6.56 (1H, d, J 8.08, 1-H), 5.78 (1H, 
s, 20-OH), 4.51 (1H, s, 5-H), 3.90 (3H, s, 3-OCH3), 3.62 (3H, s, 6-OCH3), 2.96 (1H, 
d, J 18.32, 10-H), 2.90 (1H, d, J 6.24, 9-H), 2.50-2.55 (1H, m, 15/16-NCH2,CH2-), 
2.18-2.25 (6H, m, includes 7-H, 10-H, 15/16-NCH2,CH2-), 1.85-1.89 (3H, m, 
includes 8-H, 1 x 15/16-NCH2,CH2-), 1.85 (3H, s, 20-CH3), 1.60-1.64 (1H, m, 
15/16-NCH2,CH2-), 1.05-1.13 (1H, m, 18/19-H), 0.95-1.01 (1H, dd, J 12.68, J 8.68, 
8-H), 0.75-0.81 (1H, m, 18/19-H), 0.66-0.69 (1H, m,  N-CH2CH(CH2-CH2-)), 0.40-
0.43 (2H, m, N-CH2CH(CH2-CH2-)), -0.05-0.02 (2H, m, N-CH2CH(CH2-CH2-)); C 
(100.56 MHz; CDCl3) 153.12, 146.99, 141.67, 132.72, 128.97, 125.84, 124.55, 
123.05, 119.14, 114.25, 98.99, 80.78, 59.58 (NCH2CH(CH2)2), 58.18, 56.95, 52.94, 
49.72, 47.06, 43.42 (CH2), 36.05, 35.67 (CH2), 32.67 (CH2), 29.93 (CH2), 24.12, 
22.80 (CH2), 17.86 (CH2), 9.35, 3.96 (CH2), 3.37 (CH2).  m/z 508 (M
+ + 1, 100%), 
(Found: M+ + 1, 508.2559. C30H38NO4S requires 508.2522). 
 
3-Methyl-2-Thienyl thevinol (12) 
N-CPM dihydronorthevinone 6 (600.0 mg, 1.42 mmol) in anhydrous toluene (14.2 
ml) was treated as in procedure E with 3-methyl-2-thienyl magnesiumbromide (5.68 
ml, 2.84 mmol). Purification using column chromatography (30% EtOAc.Pet.Ether-
0.5%NH3) (325.0 mg, 44%). Rf (30% EtOAc-Pet.Ether-0.5%NH3) 0.54. H (400 MHz; 
CDCl3) 7.04 (1H, d, J 5.08, 1 x thienyl.CH), 6.77 (1H, d, J 5.12, 1 x thienyl.CH), 6.71 
(1H, d, J 8.12, 2-H), 6.54 (1H, d, J 8.08, 1-H), 5.39 (1H, s, 20-OH), 4.43 (1H, s, 5-
H), 3.89 (3H, s, 3-OCH3), 3.59 (3H, s, 6-OCH3), 2.93-2.97 (1H, m, 10-H), 2.88-2.90 
(1H, m, 9-H), 2.50-2.52 (1H, m, 15/16-NCH2,CH2-), 2.49 (3H, s, 1 x thienyl.CH3), 
2.17-2.32 (5H, m, includes 7-H, 10-H, 15/16-NCH2,CH2-), 1.82-1.88 (3H, m, 
15/16-NCH2,CH2-, 2 x 18/19-H), 1.88 (3H, s, 20-CH3), 1.61-1.64 (1H, m, 15/16-
NCH2,CH2-), 1.23-1.28 (1H, m), 1.05-1.13 (1H, m, 8-H), 0.74-0.79 (1H, m, 18/19-
H), 0.63-0.69 (1H, m, N-CH2CH(CH2-CH2-)), 0.35-0.45 (2H, m, N-CH2CH(CH2-CH2-
)), 0.00-0.01 (2H, m,  N-CH2CH(CH2-CH2-)); C (100.56 MHz; CDCl3) 147.00, 
144.14, 141.65, 133.14, 132.74, 131.74, 129.01, 121.18, 119.15, 114.25, 97.18, 
80.49, 59.46 (NCH2CH(CH2)2), 57.93, 56.95, 52.85, 47.43, 47.00, 43.54 (CH2), 
36.02, 35.74 (CH2), 32.23 (CH2), 29.95 (CH2), 25.59, 22.75 (CH2), 18.00 (CH2), 
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16.03, 9.32, 4.13 (CH2), 3.12 (CH2).  m/z 522 (M
+ + 1, 100%), (Found: M+ + 1, 
522.2760. C31H40NO4S requires 522.7186).  
 
5-Chloro-2-Thienyl thevinol (13) 
N-CPM dihydronorthevinone 6 (250.0 mg, 0.59 mmol) in anhydrous toluene (5.9 ml) 
was treated as in procedure E with 5-chloro-2-thienyl magnesiumbromide (2.36 ml, 
1.18 mmol). Purification using column chromatography (30% EtOAc-Pet.Ether-
0.5%NH3) (254.0 mg, 79%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.56. H (400 MHz; 
CDCl3) 6.72 (1H, d, J 3.80, 1 x thienyl.CH), 6.70 (1H, d, J 8.12, 2-H), 6.61 (1H, d, J 
3.84, 1 x thienyl.CH), 6.54 (1H, d, J 8.12, 1-H), 5.82 (1H, s, 20-OH), 4.40 (1H, s, 5-
H), 3.88 (3H, s, 3-OCH3), 3.59 (3H, s, 6-OCH3), 2.95 (1H, d, J 17.56, 10-H), 2.92 
(1H, d, J 5.88, 9-H), 2.52-2.56 (1H, m, 15/16-NCH2,CH2-), 2.16-2.34 (5H, m, 
includes 7-H, 10-H, 15/16-NCH2,CH2-), 1.83-1.90 (3H, m, 15/16-NCH2,CH2-, 2 x 
18/19-H), 1.76 (3H, s, 20-CH3), 1.58-1.64 (1H, m,  15/16-NCH2,CH2-), 1.02-1.09 
(1H, m, 18/19-H), 0.87-0.96 (1H, m, 8-H), 0.71-0.81 (1H, m, 18/19-H), 0.67-0.70 
(1H, m, N-CH2CH(CH2-CH2-)), 0.40-0.45 (2H, m, N-CH2CH(CH2-CH2-)), -0.03-0.05 
(2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; CDCl3) 151.81, 146.75, 141.55, 
132.47, 129.06, 128.80, 124.93, 122.13, 119.10, 113.84, 96.91, 80.65, 59.52 
(NCH2CH(CH2)2), 57.84, 56.76, 52.99, 49.40, 47.00, 43.37 (CH2), 35.90, 35.53 
(CH2), 32.59 (CH2), 29.81 (CH2), 23.41, 22.55 (CH2), 17.69 (CH2), 14.16, 9.27, 4.07 
(CH2), 3.25 (CH2). m/z 542 (M
+ + 1, 100%), (Found: M+ + 1, 542.2161. 
C30H37ClNO4S requires 542.2132).    
 
3-Thienyl thevinol (14) 
N-CPM dihydronorthevinone 6 (288.0 mg, 0.68 mmol) in anhydrous toluene (6.8 ml) 
was treated as in procedure E with 3-thienyl magnesiumbromide  (4.80 ml, 1.36 
mmol). Purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
(215.0 mg, 62%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.58. H (400 MHz; CDCl3) 
7.27 (1H, d, J 3.00, 1 x thienyl.CH), 7.20 (1H, d, J 5.00, 1 x thienyl.CH), 7.16 (1H, d, 
J 1.80, 1 x thienyl.CH), 6.70 (1H, d, J 8.08, 2-H), 6.53 (1H, d, J 8.12, 1-H), 5.39 (1H, 
s, 20-OH), 4.43 (1H, s, 5-H), 3.89 (3H, s, 3-OCH3), 3.60 (3H, s, 6-OCH3), 2.94 (1H, 
d, J 18.28, 10-H), 2.85 (1H, d, J 6.44, 9-H), 2.48-2.52 (1H, m, 15/16-NCH2,CH2-), 
78 
 
2.12-2.26 (6H, m, 7-H, 8-H, 10-H, 15/16-NCH2,CH2-), 1.80-1.90 (3H, m, 15/16-
NCH2,CH2-, 2 x 18/19-H), 1.78 (3H, s, 20-CH3), 1.57-1.63 (1H, m,  15/16-NCH2,CH2-
), 1.01-1.09 (1H, m, 18/19-H), 0.87-0.95 (1H, dd, J 18.44, J 14.36, 8-H), 0.70-0.80 
(1H, m, 18/19-H), 0.60-0.70 (1H, m, N-CH2CH(CH2-CH2-)), 0.34-0.44 (2H, m, N- 
CH2CH(CH2-CH2-)), -0.06-0.03 (2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; 
CDCl3) 149.44, 146.97, 141.63, 126.42, 124.93, 120.42, 119.05, 114.32, 96.95, 
80.52, 59.46 (NCH2CH(CH2)2), 58.20, 56.91, 52.75, 48.21, 46.84, 43.39 (CH2), 
35.97, 35.58 (CH2), 32.45 (CH2), 29.89 (CH2), 22.84 (CH2), 17.81 (CH2), 9.16, 3.87 
(CH2), 3.28 (CH2). m/z 508 (M
+ + 1, 100%), (Found: M+ + 1, 508.2604. 
C30H37NNaO4S requires 530.2341).     
  
Phenyl orvinol (15) 
The thevinol 7 (103.0 mg, 0.21 mmol) was treated as in procedure F to yield orvinol 
15 after purification using column chromatography (30% EtOAcPet.Ether-0.5%NH3) 
(40.0 mg, 39%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.2. H (270 MHz; CDCl3) 7.50 
(2H, d, J 7.16, 2 x aryl.CH), 7.32 (2H, t, J 6.86, 7.97, 2 x aryl.CH),  7.18-7.26 (1H, m, 
1 x aryl.CH). 6.62 (1H, d, J 7.99, 2-H), 6.45 (1H, d, J 7.97, 1-H), 5.58 (1H, s, 20-
OH), 4.60 (1H, s, 3-OH), 4.42 (1H, s, 5-H), 3.56 (3H, s, 6-OCH3), 2.89 (1H, d, J 
17.87, 10-H), 2.84 (1H, d, J 4.43, 9-H), 2.40-2.42 (1H, m, 15/16-NCH2,CH2-), 
2.10-2.19 (5H, m, includes 10-H, 15/16-NCH2,CH2-), 1.90-2.08 (1H, m, 15/16-
NCH2,CH2-), 1.72-1.84 (3H, m, includes 15/16-NCH2,CH2-), 1.80 (3H, s, 20-CH3), 
1.54-1.58 (1H, m, 15/16-NCH2,CH2-), 1.02-1.10 (1H, m, 18/19-H), 0.89-0.94 (1H, dd, 
J 12.2, J 9.48, 8-H), 0.69-0.76 (1H, m, 18/19-H),  0.56-0.65 (1H, m, N-CH2CH(CH2-
CH2-)), 0.30-0.40 (2H, m, N-CH2CH(CH2-CH2-)), -0.1-0 (2H, m, N-CH2CH(CH2-CH2-
)); C (100.56 MHz; CDCl3) 147.27, 132.44, 127.93, 126.83, 126.14, 119.56, 116.51, 
97.39, 80.92, 59.52 (NCH2CH(CH2)2), 58.01, 52.91, 48.48, 47.24, 43.53 (CH2), 
36.10, 35.60 (CH2), 32.60, 29.95 (CH2), 23.59, 22.80 (CH2), 17.97 (CH2), 9.32, 4.15 
(CH2), 3.31(CH2) ;  m/z 488 (M
+ + 1, 100%), (Found M+ + 1, 488.2778. C31H38NO4 
requires 488.2801). 
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU127 (15). 
 
79 
 
o-Tolyl orvinol (16)  
The thevinol 8 (200.0 mg, 0.39 mmol) was treated as in procedure F to yield orvinol 
16 after purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
(159.0 mg, 81%). Rf (30% EtOAc-Pet.Ether-0.5%NH3) 0.30. H (400 MHz; CDCl3) 
7.16-7.23 (1H, m, 1 x aryl.CH), 7.10-7.16 (3H, m, 3 x aryl.CH), 6.68 (1H, d, J 8.04, 
2-H). 6.49 (1H, d, J 8.04, 1-H), 5.12 (1H, s, 20-OH), 4.64 (1H, s, 3-OH) 4.46 (1H, s, 
5-H),  3.58 (3H, s, 6-OCH3), 2.91 (1H, d, J 18.52, 10-H), 2.87 (1H, d, J 6.56,     
9-H), 2.76 (3H, s, 1 x aryl.CH3), 2.62-2.67 (1H, t, J 9.88, 7-H), 2.45-2.49 (1H, m, 
15/16-NCH2,CH2-), 2.13-2.21 (4H, m, includes 10α-H, 1 x 15/16-NCH2,CH2-), 1.97-
2.02 (1H, m, 8-H), 1.86-1.90 (2H, m, 2 x 18/19-H), 1.85 (3H, s, 20-CH3), 1.79-1.83 
(1H, m, 15/16-NCH2,CH2-), 1.59-1.63 (1H, m, 15/16-NCH2,CH2-), 1.02-1.10 (1H, m, 
15/16-NCH2,CH2-), 0.83-0.88 (1H, dd, J 13.56, J 9.36, 8-H), 0.70-0.76 (1H, m, 
18/19-H), 0.56-0.60 (1H, m, N-CH2CH(CH2-CH2-)), 0.32-0.40 (2H, m, N- 
CH2CH(CH2-CH2-)), -0.08-(-0.03) (2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; 
CDCl3) 145.55, 137.28, 136.92, 132.90, 128.43, 127.60, 126.95, 124.91, 119.57, 
116.42, 97.77, 80.90, 79.85, 59.51 (NCH2CH(CH2)2), 57.85, 52.84, 47.25, 43.70, 
43.61 (CH2), 36.12, 35.66 (CH2), 29.93 (CH2), 29.80, 25.99, 22.96, 22.72 (CH2), 
18.27 (CH2), 9.28, 4.11 (CH2) , 3.23 (CH2);  m/z 502 (M
+ + 1, 100%), (Found M+ + 1, 
502.3052. C32H40NO4 requires 502.2957). 
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU10101. 
Found: C, 69.70; H, 7.38; N, 2.46. C32H40ClNO4.0.75H2O requires C, 69.67; H, 7.58; 
N, 2.54%. 
 
m-tolyl orvinol (17) 
The thevinol 9 (530.0 mg, 1.03 mmol) was treated as in procedure F to yield orvinol 
17 after purification using column chromatography (30% EtOAc.Pet.Ether-0.5%NH3) 
(349.5 mg, 68%). Rf (30% EtOAc-Pet.Ether-0.5%NH3) 0.21. H (400 MHz; CDCl3) 
7.34 (1H, s, 1 x aryl.CH), 7.25 (1H, d, J 7.96,  1 x aryl.CH), 7.21 (1H, t, J 7.48, 1 x 
aryl.CH), 7.05 (1H, d, J 7.36, 1 x aryl.CH), 6.67 (1H, d, J 8.04, 2-H), 6.48 (1H, d, J 
8.04, 1-H), 5.41 (1H, s, 20-OH), 4.67 (1H, s, 3-OH), 4.45 (1H, s, 5-H), 3.56 (3H, s, 
6-OCH3), 2.91 (1H, d, J 19.24, 10-H), 2.88 (1H, d, J 7.28, 9-H), 2.43-2.46 (1H, m, 
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15/16-NCH2,CH2-), 2.38 (3H, s, 1 x aryl.CH3), 2.08-2.23 (5H, m, includes 7-H,  
10-H, 15/16-NCH2,CH2-), 2.00-2.09 (1H, m, 15/16-NCH2,CH2-), 1.79-1.91 (3H, m, 
includes 8-H, 15/16-NCH2,CH2-), 1.76 (3H, s, 20-CH3), 1.02-1.11 (1H, m, 18/19-H), 
0.91-0.97 (1H, dd, J 13.2, J 8.96, 8-H), 0.68-0.77 (1H, m, 18/19-H), 0.57-0.65 (1H, 
m, N-CH2CH(CH2-CH2-)), 0.31-0.43 (2H, m, N-CH2CH(CH2-CH2-)), -0.09-0.01 (2H, 
m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; CD3OD) 150.81. 145.39, 145.14, 137.56, 
132.37, 127.94, 127.66, 127.58, 127.42, 124.03, 123.12, 119.60, 116.77, 91.62, 
64.49, 59.75 (NCH2CH(CH2)2), 58.47, 50.49, 45.85, 40.82, 36.19, 35.94, 29.33 
(CH2), 25.20, 22.81, 21.47, 18.98 (CH2), 9.19, 4.16, 3.35 (CH2).  m/z 502 (M
+ + 1), 
(Found M+ + 1, 502.2968. C32H40NO4 requires 502.2957).  
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU10092. 
Found: C, 71.10; H, 7.64; N, 2.49. C32H40ClNO4 requires C, 71.42; H, 7.49; N, 
2.60%. 
 
p-Tolyl orvinol (18) 
The thevinol 10 (155.0 mg, 0.30 mmol) was treated as in procedure F to yield orvinol 
18 after purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
(87.0 mg, 58%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.23. H (400 MHz; CDCl3) 
7.39 (2H, d, J 8.20, 2 x aryl.CH), 7.14 (2H, d, J 7.92, 2 x aryl.CH), 6.68 (1H, d, J 
8.04, 2-H), 6.49 (1H, d, J 8.08, 1-H), 5.42 (1H, s, 20-OH), 4.62 (1H, s, 3-OH), 4.51 
(1H, s, 5-H), 3.57 (3H, s, 6-OCH3), 2.91 (1H, d, J 18.88, 10-H), 2.87 (1H, d, J 
6.80, 9-H), 2.43-2.47 (1H, m, 15/16-NCH2,CH2-), 2.35 (3H, s, 1 x aryl.CH3), 2.12-
2.21 (4H, m, includes 7-H, 10-H), 2.07-2.12 (1H, m, 15/16-NCH2,CH2-), 1.95-2.02 
(1H, m, 15/16-NCH2,CH2-), 1.82-1.88 (1H, m, 15/16-NCH2,CH2-), 1.79-1.83 (1H, m, 
8-H), 1.77 (3H, s, 20-CH3), 1.00-1.09 (1H, m, 18/19-H), 0.87-0.93 (1H, m, 8-H), 
0.69-0.76 (1H, m, 18/19-H), 0.56-0.64 (1H, m, N-CH2CH(CH2-CH2-)), 0.32-0.43 (2H, 
m, N-CH2CH(CH2-CH2-)), -0.09-0.00 (2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; 
CDCl3) 145.34, 137.00, 136.03, 132.38, 128.45, 125.86, 119.45, 116.13, 80.71, 
59.41 (NCH2CH(CH2)2), 57.88, 52.72, 48.30, 47.14, 43.42 (CH2), 35.97 (CH2), 
32.49, 22.64 (CH2), 20.98, 17.86 (CH2), 9.17, 4.00 (CH2), 3.13 (CH2). m/z 502 (M
+ + 
1), (Found M+ + 1, 502.3048. C32H40NaO4 requires 502.2957).  
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Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU10135. 
Found: C, 68.80; H, 7.16; N, 2.57. C32H40ClNO4.H2O requires C, 69.11; H, 7.61; N, 
2.52%. 
 
2-Thienyl orvinol (19) 
The thevinol 11 (800.0 mg, 1.58 mmol) was treated as in procedure F to yield orvinol 
19 after purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
(324.0 mg, 42%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.19. H (400 MHz; CDCl3) 
7.25 (1H, d, J 1.12, 1 x thienyl.CH), 6.91 (1H, t, J 5.00, 1 x thienyl.CH), 6.88 (1H, d, 
J 3.52, 1 x thienyl.CH), 6.68 (1H, d, J 8.00, 2-H), 6.49 (1H, d, J 8.04, 1-H), 5.73 (1H, 
s, 20-OH), 4.61 (1H, s, 3-OH), 4.46 (1H, s, 5-H), 3.58 (3H, s, 6-OCH3), 2.92 (1H, d, 
J 18.64, 10-H), 2.88 (1H, d, J 6.48, 9-H), 2.48-2.53 (1H, m, 15/16-NCH2,CH2-), 
2.12-2.25 (6H, m, includes 7-H, 8-H, 10-H, 15/16-NCH2,CH2-), 1.80-1.89 (3H, m, 
includes, 1 x 15/16-NCH2,CH2-, 2 x 18/19-H), 1.83 (3H, s, 20-CH3), 1.59-1.62 (1H, 
m, 15/16-NCH2,CH2-), 1.02-1.10 (1H, m, 18/19-H), 0.92-0.97 (1H, m, 8-H), 0.70-
0.77 (1H, m, 18/19-H), 0.61-0.67 (1H, m, N-CH2CH(CH2-CH2-)), 0.38-0.42 (2H, m, 
N-CH2CH(CH2-CH2-)), -0.21-0.00 (2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; 
CDCl3) 153.03, 145.45, 137.10, 132.40, 128.54, 125.85, 124.58, 123.08, 119.60, 
116.27, 97.51, 80.83, 59.57 (NCH2CH(CH2)2), 58.19, 52.87, 49.68, 47.45, 43.41 
(CH2), 36.13, 35.57 (CH2), 32.64 (CH2), 29.81 (CH2), 24.13, 22.85 (CH2), 17.82 
(CH2), 9.35, 3.93 (CH2), 3.37 (CH2). m/z 494 (M
+ + 1), (Found M+ + 1, 494.2344. 
C29H36NO4S requires 494.2365). 
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU08026. 
Found: C, 63.30; H, 6.96; N, 2.42. C29H36ClNO4S.H2O requires C, 63.54; H, 6.99; N, 
2.56%. 
 
3-Methyl-2-Thienyl orvinol (20) 
The thevinol 12 (262.0 mg, 0.50 mmol) was treated as in procedure F to yield orvinol 
20 after purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
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(135.0 mg, 53%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.17. H (400 MHz; CDCl3) 
7.03 (1H, d, J 5.04, 1 x thienyl.CH), 6.76 (1H, d, J 5.12, 1 x thienyl.CH), 6.68 (1H, d, 
J 8.04, 2-H), 6.50 (1H, d, J 8.08, 1-H), 5.30 (1H, s, 20-OH), 4.51 (1H, s, 3-OH), 4.46 
(1H, s, 5-H), 3.56 (3H, s, 6-OCH3), 2.93 (1H, d, J 18.04, 10-H), 2.90 (1H, d, J 
6.36, 9-H), 2.46-2.51 (2H, m, includes 15/16-NCH2,CH2-), 2.48 (3H, s, 1 x 
thienyl.CH3), 2.15-2.31 (5H, m, includes 7-H, 10-H, 15/16-NCH2,CH2-), 1.79-1.89 
(3H, m, 15/16-NCH2,CH2-, 2 x 18/19-H), 1.87 (3H, s, 20-CH3), 1.60-1.64 (1H, m, 
15/16-NCH2,CH2-), 1.04-1.10 (1H, m, 8-H), 0.68-0.78 (1H, m, 18/19-H), 0.62-0.68 
(1H, m, N-CH2CH(CH2-CH2-)), 0.34-0.45 (2H, m, N-CH2CH(CH2-CH2-)), -0.02-0.01 
(2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; CDCl3) 145.49, 144.06, 137.18, 
133.14, 132.40, 131.75, 128.47, 121.22, 119.59, 116.35, 97.60, 80.53, 59.45 
(NCH2CH(CH2)2), 57.94, 52.78, 47.35, 43.54 (CH2), 36.09, 35.63 (CH2), 32.20 (CH2), 
29.84 (CH2), 25.61, 22.80 (CH2), 21.03, 18.00 (CH2), 16.02, 14.20, 9.30, 4.10 (CH2), 
3.22 (CH2). m/z 508 (M
+ + 1), (Found M+ + 1, 508.2572. C30H38NO4S requires 
508.2522). 
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU10093. 
Found: C, 65.30; H, 7.06; N, 2.55. C30H38ClNO4S.0.5H2O requires C, 65.14; H, 7.11; 
N, 2.53%.  
 
5-Chloro-2-Thienyl orvinol (21) 
The thevinol 13 (215.0 mg, 0.40 mmol) was treated as in procedure F to yield orvinol 
21 after purification using column chromatography (30% EtOAc.Pet.Ether-0.5%NH3) 
(149.0 mg, 71%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.12. H (400 MHz; CDCl3) 
6.72 (1H, d, J 3.80, 1 x thienyl.CH), 6.68 (1H, d, J 8.04, 2-H), 6.61 (1H, d, J 3.84, 1 x 
thienyl.CH), 6.50 (1H, d, J 8.08, 1-H), 5.69 (1H, s, 20-OH), 4.56 (1H, s, 3-OH), 4.42 
(1H, s, 5-H), 3.57 (3H, s, 6-OCH3), 2.94 (1H, d, J 18.56, 10-H), 2.90 (1H, d,          
J 6.52, 9-H), 2.52-2.57 (1H, m, 15/16-NCH2,CH2-), 2.15-2.35 (5H, m, includes 7-
H, 10α-H, 15/16-NCH2,CH2-), 1.77-1.88 (3H, m, 15/16-NCH2,CH2-, 2 x 18/19-H), 
1.76 (3H, s, 20-CH3), 1.59-1.63 (1H, m, 15/16-NCH2,CH2-), 1.00-1.10 (1H, m, 18/19-
H), 0.86-0.95 (1H, m, 8-H), 0.67-0.77 (2H, m, 18/19-H, N-CH2CH(CH2-CH2-)), 
0.36-0.47 (2H, m, N-CH2CH(CH2-CH2-)), -0.04-0.06 (2H, m, N-CH2CH(CH2-CH2-)); 
C (100.56 MHz; CDCl3) 151.81, 146.75, 141.55, 132.47, 129.06, 128.80, 124.93, 
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122.13, 119.10, 113.84, 96.91, 80.65, 59.52 (NCH2CH(CH2)2), 57.84, 56.76, 52.99, 
49.40, 47.00, 43.37 (CH2), 35.90, 35.53 (CH2), 32.59 (CH2), 29.81 (CH2), 23.41, 
22.55 (CH2), 17.69 (CH2), 9.27, 4.07 (CH2), 3.25 (CH2).  m/z 550 (M
+ + Na), (Found 
M+ + Na, 550.1774. C29H34ClNNaO4S requires 550.1795). 
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU10136. 
Found: C, 58.30; H, 6.40; N, 2.28. C29H35ClNO4S.2H2O requires C, 57.99; H, 6.55; 
N, 2.33%. 
 
3-Thienyl orvinol (22) 
The thevinol 14 (324.0 mg, 0.64 mmol) was treated as in procedure F to yield orvinol 
22 after purification using column chromatography (30% EtOAc-Pet.Ether-0.5%NH3) 
(236.0 mg, 75%). Rf (30% EtOAc.Pet.Ether-0.5%NH3) 0.11. H (400 MHz; CDCl3) 
7.26 (1H, d, J 2.96, 1 x thienyl.CH), 7.20 (1H, d, J 5.00, 1 x thienyl.CH), 7.16 (1H, d, 
J 2.88, 1 x thienyl.CH), 6.68 (1H, d, J 8.04, 2-H), 6.50 (1H, d, J 8.00, 1-H), 5.32 (1H, 
s, 20-OH), 4.59 (1H, s, 3-OH), 4.46 (1H, s, 5-H), 3.58 (3H, s, 6-OCH3), 2.93 (1H, d, 
J 18.40, 10-H), 2.86 (1H, d, J 6.16, 9-H), 2.49-2.53 (1H, m, 15/16-NCH2,CH2-), 
2.12-2.28 (6H, m, 7-H, 8-H, 10α-H, 15/16-NCH2,CH2-), 1.81-1.92 (3H, m, 15/16-
NCH2,CH2-, 2 x 18/19-H), 1.79 (3H, s, 20-CH3), 1.58-1.63 (1H, m,  15/16-NCH2,CH2-
), 1.04-1.07 (1H, m, 18/19-H), 0.89-0.97 (1H, m, 8-H), 0.70-0.80 (1H, m, 18/19-H), 
0.60-0.70 (1H, m, N-CH2CH(CH2-CH2-)), 0.34-0.45 (2H, m, N-CH2CH(CH2-CH2-)), -
0.06-0.03 (2H, m, N-CH2CH(CH2-CH2-)); C (100.56 MHz; CDCl3) 149.44, 137.04, 
126.37, 124.94, 120.41, 119.48, 116.18, 97.52, 80.63, 59.47 (NCH2CH(CH2)2), 
58.22, 52.67, 48.22, 47.29, 43.33 (CH2), 36.05, 35.57 (CH2), 32.47 (CH2), 29.76 
(CH2), 23.90, 22.85 (CH2), 17.79 (CH2), 9.27, 3.79 (CH2), 3.28 (CH2).   m/z 494 (M
+ 
+ 1), (Found M+ + 1, 494.2411. C29H36NO4S requires 494.2365). 
Phenol was converted to the corresponding hydrochloride salt as in general 
procedure G and assigned BU11001. 
Found: C, 65.90; H, 6.77; N, 2.58. C29H36ClNO4S requires C, 65.70; H, 6.84; N, 
2.64%. 
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CHAPTER 3.0: PHARMACOLOGY  
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3.1 Introduction 
 
The aim of the experiments presented in this chapter is to assess the affinity and 
efficacy of novel, newly-synthesised compounds on the mu (-), kappa (-) and 
ORL-1 receptors. Following an initial screen of compounds in cell-based radioligand 
binding and GTPS studies, we conducted a series of isolated tissue experiments. 
 
To study - and ORL-1 receptors, the rat vas deferens tissue was used, to study -
opioid receptors; the mouse vas deferens was used. 
 
3.2 Materials 
 
3.2.1 Animals 
 
Adult male albino Sprague Dawley rats weighing 300-350 g were purchased from 
Charles River UK Ltd, whereas adult male CD-1 albino mice weighing 25-30 g were 
bred in-house and obtained from Animal Facilities, University of Bath, United 
Kingdom. They were housed in colony cages and maintained under a 12 hours 
light/dark cycle (lights on 7 am) and temperature (21 ± 1°C) controlled environment 
and given free access to rodent chow and water. Experiments were carried out in 
accordance with the ethical guidelines set by Animal (Scientific Procedures) Act 
1986. 
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3.2.2 Physiological salt / buffer solution 
 
Modified Krebs solution was used as a physiological salt solution in isolated tissue 
assays. The composition of Krebs solution for rat vas deferens (RVD) was as 
follows (mM): NaCl 118, KCl 4.74, CaCl2 2.50 (1.25 for mouse vas deferens (MVD)), 
KH2PO4 1.19, MgSO4 1.20 (Mg
2+-free for mouse vas deferens), NaHCO3 25, glucose 
11.  Krebs solution was maintained at 36.9°C (30.9°C for mouse vas deferens) and 
aerated with 95% O2 and 5% CO2. 20 µM bestatin and 2 µM thiorphan (peptidase 
inhibitors) were added to Krebs solution in the organ bath reservoir 15 minutes prior 
to nociceptin addition with / without the presence of antagonist / test compound. 
 
3.2.3 Drugs 
 
Drugs were obtained from the following sources: bestatin (N-[(2S,3R)-3-Amino-2-
hydroxy-1-oxo-4-phenylbutyl]-L-leucine) from Tocris Biosciences, UK; 
buprenorphine hydrochloride from NIDA; CTAP (H-ᴅ-Phe-Cys-Tyr-ᴅ-Trp-Arg-Thr-
Pen-Thr-NH2) from Tocris, Biosciences, UK; DAMGO ([ᴅ-Ala
2,N-Me-Phe4,Gly5-
ol]enkephalin acetate) from Bachem; U-69593 ((+)-5,7,8)-N-methyl-N-[7-(1-
pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide) from Enzo Life Sciences, 
UK, Ltd; DL-Thiorphan ((±)-N-(3-Mercapto-2-benzylpropionyl)glycine,DL-3-
Mercapto-2-benzylpropanoylglycine) from Sigma Aldrich, UK; naltrexone 
hydrochloride;    Nociceptin (Phe-Gly2-Phe-Thr-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-
Ala-Asn-Gln) from Tocris Biosciences, UK; [Arg14,Lys15]nociceptin (Phe-Gly2-Phe-
Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln) from Tocris Biosciences, 
UK; nor-BNI (nor-binaltorphimine dihydrochloride) (17,17’-(Diclopropylmethyl)-
6,6’,7,7’-6,6’-imino-7,7’-binorphinan-3,4’,14,14’-tetrol dihydrochloride) from Tocris 
Biosciences, UK; SB 612111 hydrochloride (7-[[4-(2,6-Dichlorophenyl)-1-
piperidinyl]methyl]-6,7,8,9-tetrahydro-1-methyl-5H-benzocyclohepten-5-ol 
hydrochloride) from Tocris Biosciences; SCH 221510 (3-Endo-8-[bis(2-
methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol) from Tocris 
Biosciences; U-69593 ((+)-5,7,8)-N-methyl-N-[7-(1-pyrrolidinyl)-1-
oxaspiro[4.5]dec-8-yl]-benzeneacetamide) from Enzo Life Sciences, UK, Ltd. 
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BU127, BU10101, BU10136, BU10119, BU10112 were synthesised in the 
laboratory using methods as previously described.  
 
CTAP, DAMGO, nociceptin, [Arg14,Lys15]nociceptin, nor-BNI and naltrexone were 
prepared as a 10 mM stock solution in distilled water and stored at -20°C, while 
bestatin was prepared in 1 eq NaOH as a 50 mM stock in distilled water and also 
stored at -20°C. On the day of experiment, more dilute stock solutions were made 
using distilled water for these drugs. All other compounds (test compounds) were 
solubilized in dimethylsulfoxide (DMSO) at the final concentration of 10 mM, and 
stored at -20°C. Further dilutions on the day of experiment were also made in 
DMSO for the test compounds. The total amount of DMSO in the bath did not 
exceed 0.2 %. 
 
3.3 Methods 
 
All studies presented in this thesis were conducted in vitro. Three assays were used 
to pharmacologically characterize the compounds synthesised. The first two assays, 
referring to receptor binding and the [35S]GTPγS binding were performed by John 
Traynor’s group at Department of Pharmacology, University of Michigan, United 
States. The methods used by Traynor’s group and the corresponding data are 
presented in this thesis. Meanwhile, the electrically evoked isolated tissue assay in 
both rat and mouse vas deferens was conducted at the University of Bath premises 
as a part of this PhD project and will be discussed in detail. 
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3.3.1 Experimental methods 
 
3.3.1.1 Binding assay 
 
Radioligand receptor binding 
 
The receptor binding assays were performed by Traynor’s group in C6 glioma cells 
stably expressing the rat -opioid receptor and in chinese hamster ovarian (CHO) 
cells stably expressing the human -opioid or ORL-1 receptor. For the -opioid 
receptor cell cultures, the cells were grown in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 90 units/ml penicillin, 90 
µg/ml streptomycin and 0.5 mg/ml geneticin; CHO transfected cells were maintained 
in DMEM-F12 medium. All cells were grown under 5% CO2 at 37°C. Cells were 
washed in phosphate buffered saline (PBS), centrifuged and the cell pellet was 
resuspended in 50mM Tris-HCl at pH 7.4 and re-homogenized with Tissue Tearor 
(Biospec Products, Inc). The final pellet was frozen at -80°C. Protein concentration 
was determined using the Bicinchoninic acid (BCA) protein assay. Cell membranes 
(20 µg) were incubated in 50 mM Tris-HCl at pH 7.4 with [3H]diprenorphine (for - or 
-opioid receptor transfected cells) or [3H]nociceptin (for ORL-1 receptor transfected 
cells)  in the presence of varying concentrations of test compounds for 60 minutes in 
a shaking water bath at 25°C. Nonspecific binding was measured using 10 µM 
naloxone (for - and -opioid receptors) or nociceptin (for ORL-1 receptor). Samples 
were filtered through filtermats mounted on a Brandel cell harvester and rinsed four 
times with 50 mM Tris-HCl at 4°C (pH 7.4). 0.1 ml EcoLume scintillation cocktail was 
added to each sample area to soak the filter. Each filtermat (in a heat-sealed bag) 
was counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence 
Counter. IC50 values for test compounds were determined from concentration effect 
curves and converted to Ki values using GraphPad Prism Software. 
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3.3.1.2 Functional assays 
 
[35S]GTPγS binding 
 
Membranes (20 μg) from cells expressing -, - or ORL-1 receptors (same methods 
were used to prepare the cell cultures as in the previously receptor binding assays) 
are incubated in 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 100 mM NaCl, 2.2 mM 
dithiothreitol (freshly prepared), 30 μM GDP, 0.1 nM [35S]GTPγS, with or without 10 
µM of test compound or the standard agonists (10 µM DAMGO (), 10 µM U-69593 
() or 1 µM nociceptin (ORL-1) as appropriate) or H2O for 60 min at 25°C.  Samples 
were filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester 
and rinsed four times with ice-cold 50 mM Tris-HCl, pH 7.4 containing 5 mM MgCl2, 
and 100 mM NaCl.  Filtermats were processed as described for receptor binding 
above. The non-hydrolyzable GTP analogue, [35S]GTPγS was measured using a 
liquid scintillation and lumination counter. The ability of buprenorphine and its 
analogues (10 µM) to stimulate [35S]GTPγS binding was measured and is 
represented as a percentage of the maximal stimulation produced by the standard 
full agonists. 
 
Isolated tissue preparations (vas deferens assay) 
 
Tissue preparations 
 
Rats / mice were euthanized in a closed-contained CO2 environment. Both vasa 
deferentia connecting the prostate gland and testes (Figure 3.1) were dissected out 
as a single unit. The adhering fat, connective tissue and blood vessels were 
carefully removed and the tissue was gently pressed to expel the seminal contents 
(Hughes et al., 1975). About 20% of the dissected tissue connecting to the prostate 
gland was excised (Andrews et al., 2010). This part of vas deferens was removed 
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because it is believed to have a non-adrenergic component while the adrenergic 
component of the tissue predominantly sits near to the epididymal half (Kitchen, 
1984; Westfall et al., 2001). The extracted tissues were then mounted in Krebs 
solution, aerated with 95% O2 and 5% CO2 and maintained at 36.9°C for rat vas 
deferens or 30.9°C for mouse vas deferens. The tissues were then transferred into a 
3 ml organ bath. 
 
 
Figure 3.1: Dissection of the rat vas deferens. 
 
3.3.1.3 Experimental protocols (general) 
 
A single vas deferens was mounted in a 3 ml organ bath containing appropriate 
Krebs solution at 36.9°C for rat vas deferens or 30.9°C for mouse vas deferens and 
aerated with 95% O2 and 5% CO2. For electrical field stimulation, a platinum ring 
anode was placed on the top of the bath and a platinum hook cathode at the bottom. 
One end of the vas deferens was tied to the hook and the other end to the force 
transducer (Biegestab K30, Hugo Sachs Elektronik, Germany). Tissues were 
continuously stimulated (Grass S88 stimulator, Grass Medical Instruments, Quincy, 
USA) through two platinum ring electrodes and the electrically evoked contractions 
were measured isometrically and recorded with the computer-based acquisition 
system MacLab/4e (ADInstruments Pty Ltd., Castle Hill, Australia). Rat vas 
deferens: 1.0 g initial tension was applied to the tissue. Electrically evoked muscle 
contractions were induced with supramaximal voltage single square pulses, 0.1 ms 
duration and 0.1 Hz frequency. The experiments started after 60 minutes 
equilibration under direct stimulation for the ORL-1 receptor assay and after 90 
Prostate gland 
Vas deferens 
Testis 
Epididymis 
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minutes for the -opioid receptor assay (including 30 minutes of initial equilibrium 
under resting tension). Mouse vas deferens: 0.5 g initial tension was applied to the 
tissue. Electrically evoked muscle contractions were induced with supramaximal 
voltage with trains of 3 square pulses, 0.1 ms duration and 100 Hz frequency. Trains 
were repeated at a frequency of 0.05 Hz. Tissues were allowed to equilibrate for 60 
minutes under electrical field stimulation before beginning the experiment. 
 
3.3.2 Analytical methods 
 
3.3.2.1 Nonlinear regression  
 
A cumulative concentration-response curve for the standard receptor agonist was 
constructed using GraphPad Prism v5.0 software (GraphPad Software Inc, CA, 
USA) in the absence and in the presence of increasing concentrations of a selected 
standard receptor antagonist (or test compound). Data were fitted into nonlinear 
regression equation and analysed with sigmoidal dose-response (variable slope) 
model. The response of the tissue which referred to the percentage inhibition of 
smooth muscle contraction at each concentration was calculated using the equation 
as shown below: 
 
% Twitch Inhibition = Height of twitch (a-b)      x   100 
                 Height of twitch (a) 
 
where  a = baseline (prior to agonist treatment or baseline) 
            b = in the presence of antagonist           
 
The cumulative concentration-response curve for each tissue was individually fitted 
and the analysis was calculated by the four parameter nonlinear regression equation 
using GraphPad Prism v5.0 software (Kenakin, 2009; Motulsky, 2007). The 
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minimum response parameter was constrained to 0%. The equation used as stated 
below: 
 
Y = Bottom + ___(Top-Bottom)____ 
                     1 + 10(Log EC50
-X)·Hill Slope 
 
 
However, the graphs presented in this thesis were an average from multiple 
experiments unless stated otherwise as written in the legend. 
 
3.3.2.2 Schild analysis 
 
For most of the cases, we used the EC50 value to calculate the concentration ratio 
(CR). This series of CRs (at least three CR values) was plotted as log (CR-1) 
against log [B] where [B] referred to antagonist concentration. The Schild equation 
used as follows: 
 
Log (CR-1) = log [B] – Log KB 
 
The slope of the plot was analysed using linear regression. If the slope of the line of 
best-fit was not significantly different from 1, and if there was no significant 
suppression of the maximum agonist response (in the presence of antagonist, 
exceptional case when hemi-equlibria is strongly suspected), the line of best-fit was 
then recalculated, constraining the slope to 1.  
 
The x-intercept of the Schild plot is the pA2 value of the antagonist tested. 
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3.3.2.3 Schild equation (single concentration method) 
 
For the case where Schild analysis is not a valid method to estimate the antagonist 
potency (eg: slope significantly different than unity or only one concentration of 
antagonist tested per tissue), the Schild equation was used to estimate the 
antagonist potency and KB, assuming that the antagonist is following simple 
competitive behaviour and the ideal experiment condition is met (Kenakin, 2009; 
Leslie, 1987): 
 
pA2 (or log [KB]) = log (CR-1) – log [B] 
 
All data are expressed as means ± S.E.M of n experiments. For potency and 
maximum response values (Emax) the 95% confident limits are given. Some data 
have been analysed statistically using one-way ANOVA (analysis of variance), as 
specified in Table and Figure legends; P values less than 0.05 were considered to 
be significant. 
 
3.4 Results and Discussion  
 
3.4.1 Radioligand receptor binding 
 
Based on the results presented in Table 3.1, the binding affinities of the selected 
buprenorphine analogues were similar to buprenorphine at the - and -opioid 
receptors. This suggests that introducing an aromatic substituent at the C20 of 
orvinols (Figure 3.3) did not influence the binding affinity of these compounds at 
both receptors. However, there is a slight increase (3-fold) in the binding affinity of 
buprenorphine analogues compared to buprenorphine at the ORL-1 receptor (Table 
94 
 
3.1) which suggests that introducing an aromatic substituent at C20 of orvinol (Figure 
3.3) improves the binding affinity of this series at the ORL-1 receptor.  
 
Table 3.1: Binding affinities (Ki) for buprenorphine and its selected analogues derived from 
receptor binding assays using transfected C6 glioma cells (-opioid receptor) and 
transfected CHO cells (- and ORL-1 receptors). Value represents mean ± S.E.M of 
triplicates. n.d (not determined / not measured). 
Compound Binding affinity (Ki) nM 
 mu () kappa () ORL-1 
Buprenorphine 0.19 ± 0.02 0.067 ± 0.02 212 ± 7 
BU127 n.d 0.04 n.d 
BU10101 0.19 ± 0.08 0.16 ± 0.09 n.d 
BU10119 0.10 ± 0.02 0.04 ± 0.01 80.0 ± 10.0 
BU10112 0.17 ± 0.11 n.d 79.0 ± 8.0 
 
 
3.4.2 [35S]GTPγS binding 
 
[35S]GTPγS binding was used to measure the activity of buprenorphine and its 
analogues at -, -, and ORL-1 receptors. All buprenorphine analogues synthesised 
were initially screened by Traynor’s group to determine their efficacy at a single high 
concentration (10 µM) compared to standard full agonists at the individual receptors. 
Data are shown as the percentage of the maximal stimulation produced by the 
standard full agonists. The efficacy screening was conducted in triplicate and the 
results are shown (Figure 3.2 and Table 3.2).  
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Figure 3.2: [
35
S]GTPγS efficacy screening of buprenorphine and its analogues performed in 
either C6 glioma or cultured Chinese Hamster Ovarian (CHO) transfected cells. Efficacies of 
buprenorphine and its analogues at 10 µM were compared against standard receptor 
agonists (DAMGO, U-69593 and nociceptin) in triplicate (Traynor (unpublished work)). 
 
Table 3.2: Percentage receptor stimulation of buprenorphine and its analogues at 10 µM 
against standard agonists (10 µM DAMGO, 10 µM U-69593 and 1 µM nociceptin) at -, - 
and ORL-1 receptors in [
35
S]GTPγS efficacy screening. Value represents mean (%) ± S.E.M 
of triplicates (Traynor (unpublished work)). 
 Receptor stimulation (%) 
mu (-) kappa (-) ORL-1 
Standard agonist 100 ± 18 100 ± 21 100 ± 16 
Buprenorphine 33 ± 12 -12 ± 9 24 ± 9 
BU127 6 ± 0 19 ± 0 14 ± 4 
BU10101 17 ± 4 90 ± 3 45 ± 4 
BU10092 33 ± 5 102 ± 1 22 ± 4 
BU10135 50 ± 2 84 ± 7 19 ± 5 
BU08026 0 ± 1 30 ± 6 7 ± 5 
BU11001 3 ± 2 79 ± 2 6 ± 4 
BU10093 17 ± 3 81 ± 1 44 ± 6 
BU10136 45 ± 3 79 ± 6 31 ± 4 
BU10119 2 ± 4 -2 ± 1 57 ± 5 
BU10112 22 ± 5 6 ± 2 43 ± 3 
Standard (std) agonist: 
10 µM DAMGO () 
10 µM U-69593 () 
1 µM Nociceptin (ORL-1) 
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Based on the results presented in Table 3.2 above, the presence of either methyl or 
chloro on the aromatic substituent at the C20 position of the orvinol for BU127 
analogues (BU10101, BU10092, BU10135) and BU08026 analogues (BU10093, 
BU10136) appeared to change the analogues’ efficacy at -opioid receptor from low 
partial agonist to full agonist. Although there was an increase in the efficacy of the 
analogues at - and ORL-1 receptors, they still remained partial agonists at both 
receptors. The presence of a methyl group on the aromatic substituent at the 
position 2 (BU10101, BU10093) increased the analogues efficacy at ORL-1 receptor 
compared to other BU127 and BU08026 analogues in this series. This may suggest 
that introducing bulk near to the C20 position of orvinols (Figure 3.3) has the effects 
of increasing the analogue’s efficacy at the ORL-1 receptor. It appears that the 
presence of a methyl group on position 4 or 5 of the aromatic substituent has 
increased efficacy at the -opioid receptor, as can be seen in compound BU10135 
and BU10136. Moving sulphur from 2-thiophene (BU08026) to 3-thiophene 
(BU11001) also increases the efficacy of the compound at -opioid receptor to that 
of a full agonist. 
 
Compounds BU10119 and BU10112, having a methyl group at the C7 position 
(Figure 3.3), met the desired pharmacological profile at -, - and ORL-1 receptors. 
In contrast to the series discussed in the previous paragraph, these two compounds 
were antagonists at the -opioid receptor.  
 
Since the [35S]GTPγS efficacy screenings were conducted only at a single high 
concentration (10 µM), the functional evaluation of buprenorphine and the new 
analogues were further evaluated in isolated vas deferens system.  
 
3.4.3 Selection of compounds to be evaluated in isolated tissue preparation 
 
All of the test compounds were synthesised in the laboratory as part of this PhD 
project, except for compounds BU10119 and BU10112 which were synthesised by 
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another member of the Husbands’ group. These two compounds still belong to the 
orvinol series but contain a methyl group at C7 (Figure 3.3).  
 
 
Figure 3.3: Orvinol structure with the point of manipulation at C7 and/or C20 (R1 = aryl 
substitution with/without alkyl/small group side chain, R2 = CH3 / H, R3 = H / CH3.  
 
Some of the compounds were further tested to confirm their receptor efficacy 
profiles in isolated tissues preparation. Not all of the compounds synthesised in the 
chemistry part of this project were evaluated in this functional assay. The selection 
of compounds to be investigated in the isolated tissue preparation ensured that 
compounds representing the full range of structures were evaluated.  
 
3.4.4 Optimisation of experimental conditions for vas deferens assay 
 
Previously published studies were used as guidelines to develop our own 
experimental protocol (Hughes et al., 1975; Riba et al., 2010; Spagnolo et al., 2008; 
Spagnolo et al., 2007). Besides selection of species / strain that will be further 
explained throughout the thesis, the other issues that needed to be addressed were 
the standard agonist to be used, the concentration range needed, the optimal 
electrolyte concentration to measure agonist responses, the length of drug exposure 
especially for the standard agonist, and its washout time from the tissue which was 
determined by the baseline of control twitches (dose cycle). 
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3.4.4.1 ORL-1 receptor (rat vas deferens) 
 
Various concentrations of Ca2+ were tested in the Krebs solution to ensure that 
nociceptin exerted its optimum inhibition. To date, there are no studies conducted to 
evaluate the effect of varying calcium concentrations in the physiological buffer 
solution on nociceptin potency. However, it was believed that the effect might be the 
same as observed for classical opioid agonists since nociceptin also acts through 
GPCRs by inhibiting adenylyl cyclase and Ca2+ channels, and inducing K+ channel 
opening, similar to agonists at the opioid receptors (Bignan et al., 2005; Bloms-
Funke et al., 2000; Largent-Milnes et al., 2010). A previous study has shown that the 
potency of opioid agonists (eg: DAMGO (-), [D-Ala2, D-Leu5]-Enkephalin (DADLE) 
(-)) was higher in a lower extracellular Ca2+ concentration media due to the 
reduction of Ca2+ influx into the nerve terminals during depolarization (Sheehan et 
al., 1988). As a result, the effectiveness of the opioid agonist to block the Ca2+ 
entrance into the nerve terminals is potentiated which is caused by an increased in 
agonist-receptor coupling efficiency.  
 
Therefore, a test concentration of nociceptin at 3 µM was used to determine the 
calcium concentration that will produce the optimal nociceptin response (Table 3.3). 
Between 1 and 3 mM Ca2+ in the Krebs, there was no noticeable difference in 
inhibition of twitch produced by 3 µM nociceptin. We therefore decided to use 2.5 
mM Ca2+-Krebs as at concentrations lower than this, the height of the baseline 
twitch started to decrease and become more difficult to measure. Previous studies 
had used calcium concentrations of between 1.2 mM-2.5 mM in their Krebs formula 
(Fischetti et al., 2009; Riba et al., 2010). 
 
Table 3.3: The effects of 3 µM nociceptin in inhibiting electrically evoked contraction of the 
rat vas deferens in media of varying calcium concentration. Nociceptin was tested in Krebs 
medium containing 0.5 mM to 3.0 mM Ca
2+
. 
 Calcium concentration (mM) 
0.5 1.0 1.8 2.5 3.0 
% inhibition to control 36% 50% 51% 49% 46% 
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In our preliminary experiments to determine the onset and optimal length of time to 
apply at each concentration of nociceptin, nociceptin initially produced an inhibition 
of the electrically evoked contraction of the tissue. However, this response rapidly 
began to reverse after 2 minutes of nociceptin exposure (Figure 3.4). This pattern 
suggests that nociceptin is not stable. For this preliminary experiment, nociceptin 
was exposed for 10 minutes at each concentration.  
 
 
Figure 3.4: Effects of nociceptin (1 nM-3000 nM) on electrically evoked contractions of rat 
vas deferens. 
 
Therefore, we decided to minimize the nociceptin contact time to 3 minutes to solve 
this problem, since nociceptin shows rapid onset (1.5-2 minutes). The nociceptin 
induced inhibition of the smooth muscle twitch was much more stable when the 
contact time was reduced from 10 minutes to 3 minutes (Figure 3.5). 
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Figure 3.5: Effects of nociceptin (1 nM-3000 nM) on electrically evoked contractions of rat 
vas deferens.  
 
The concentration range for nociceptin was initially set to 1 nM-3 µM (Rizzi et al., 
2011; Spagnolo et al., 2007), although some studies have also used nociceptin up 
to 10 µM (Fischetti et al., 2009). The average (n = 4) Log EC50 derived was 6.67 
(5.65-7.65) and the average maximum response (Emax) calculated was 55.1% (28.8-
81.4%) (Figure 3.6 (right)). The mean value for maximum response, Emax (n = 4) was 
found to be lower than previously reported (75-85%) (Fischetti et al., 2009; Rizzi et 
al., 2011; Spagnolo et al., 2007). The 95% confidence interval for the maximum 
response was also found to be very wide (28.2-81.4%) which could lead to the wide 
error of nociceptin EC50 estimation (22.4-2238.7 nM). The individual concentration-
response curve is shown in Figure 3.6 (left)). 
LabChart Reader Window
C
h
a
n
n
e
l 
2
 (
g
)
-0.0
0.5
1.0
1.5
2.0
2.5
3.0
1
n
M
 N
o
ci
ce
p
ti
n
3
n
M
 n
o
ci
ce
p
ti
n
1
0
n
M
 n
o
ci
ce
p
ti
n
3
0
n
M
 N
o
ci
ce
p
ti
n
1
0
0
n
M
 N
o
ci
ce
p
ti
n
3
0
0
n
M
 N
o
ci
ce
p
ti
n
1
0
0
0
n
M
 N
o
ci
ce
p
ti
n
3
0
0
0
n
M
 N
o
ci
ce
p
ti
n
2:35:00 2:40:00 2:45:00 2:50:00
10 11 12 13 14 15 16 17
 2:32:45.900
3 mins 
101 
 
log[Nociceptin]
%
 
In
h
ib
it
io
n
 
o
f
e
le
c
t
r
ic
a
ll
y
-
e
v
o
k
e
d
c
o
n
t
r
a
c
t
io
n
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
Tissue 1
Tissue 2
Tissue 3
Tissue 4
log[Nociceptin]
%
 
In
h
ib
it
io
n
 
o
f
e
le
c
t
r
ic
a
ll
y
-
e
v
o
k
e
d
c
o
n
t
r
a
c
t
io
n
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
 
Figure 3.6: Inhibition of electrically evoked contractions of rat vas deferens by nociceptin     
(1 nM-3 µM). Left, individual concentration-response curve. Right, average concentration-
response curve. Points represent means, and vertical lines represent S.E.M of four 
experiments (Right). 
 
There are a few possibilities that might explain this situation. Initially, it was 
suspected that nociceptin was sticking to the glass of the organ bath, and therefore, 
the intended concentration of the agonist may not have been delivered to the tissue. 
Therefore, we decided to siliconize the organ bath to prevent nociceptin sticking to 
the glass. Additionally, the tissue was also sensitized using a low dose of nociceptin 
until consistent inhibition was established before the nociceptin response curve was 
constructed. The tissue sensitizing procedure was carried out to stimulate the 
muscles until constant twitches were established (Kitchen, 1984; McKnight et al., 
1983; Menzies et al., 1999; Sheehan et al., 1988). McKnight et al. (1983) reported 
an increase of met-enkephalin potency (IC50) when the second dose-response curve 
was constructed compare to the first curve. The IC50 for the second curve was 52.1 
± 6.43 µM compared to the first control curve which was reported to be more than 
100 µM. It was not necessary to sensitize the tissue with the same agonist since 
tissue was also reported to be sensitized with DAMGO until stable inhibition was 
obtained before a nociceptin concentration response curve was constructed 
(Menzies et al., 1999). Thus, we decided to sensitize the tissue with 30 nM 
nociceptin instead of DAMGO due to the shorter drug washout time. Since the 
previous study also reported that no increase of tissue sensitivity was observed 
when the concentration-response curve of peptide (met-enkephalin) was repeated 
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for a third time in rat vas deferens, we decided to sensitize the tissue twice before 
proceeding with the actual experiment (McKnight et al., 1983). The comparison for 
the dose response curve (n = 4) is shown in Figure 3.7. The maximum response 
(Emax) to nociceptin increased from 55.1% (28.8-81.4%) to 64.2% (59.5-68.6%) and 
the potency (EC50) of nociceptin was increased 3-fold from 213.8 nM (22.4-2238.7 
nM) to 74.8 nM (53.4-104.7 nM). Although these values were not statistically 
different, the standard error was smaller in all parameters (Emax and EC50) in the 
sensitized tissues conducted in the siliconized organ bath compared to the non-
sensitized tissues conducted in non-siliconized organ bath. Furthermore, when 
comparing the % twitch inhibition at individual concentrations, significantly increased 
responses were observed in tissue that had undergone the sensitizing procedure in 
the siliconized organ bath compared to the non-sensitized tissues at ≥ 100 nM 
nociceptin. 
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Figure 3.7: Electrically evoked contractions in rat vas deferens. Nociceptin response was 
compared between tissues that had undergone sensitizing procedure in siliconized organ 
bath to non-sensitized tissues without siliconized organ bath. Points represent means, and 
vertical lines represent S.E.M of four experiments. Statistical significance of the differences 
between mean values were determined using one-way ANOVA. *P < 0.01 compared to   
non-sensitized tissue. 
  
Although the tissue response to nociceptin was increased, we still failed to achieve 
the maximum inhibition of twitches that had been previously reported (75-85%) 
* 
* 
* 
* 
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(Fischetti et al., 2009; Rizzi et al., 2011; Spagnolo et al., 2007). Another possibility 
was that nociceptin quickly degraded once it started to produce an effect. Nociceptin 
is hydrolyzed in vivo into a few peptide fragments by aminopeptidase and 
endopeptidase, however the exact points of cleavage in the peptide varies between 
tissues (Sakurada et al., 2002; Terenius et al., 2000). According to Sakurada et al 
(2002), endopeptidase-24.11 was the enzyme responsible for the cleavage of the 
nociceptin Lys13-Leu14 bond in the mice spinal cord membranes and its activity was 
inhibited by the specific endopeptidase-24.11 inhibitors (eg: thiorphan, 
phosphoramidon). Aminopeptidase also hydrolyses nociceptin in vivo and could be 
minimized by using aminopeptidase inhibitor, bestatin. (Sakurada et al., 2002). 
Nociceptin metabolism in the plasma was also believed to be mediated mainly by 
aminopeptidase (Terenius et al., 2000). Although there have been many studies 
conducted to investigate nociceptin metabolism in vivo and in vitro in different 
tissues, to date there have been no studies performed to determine nociceptin 
metabolism in isolated vas deferens tissues. Since enkephalins were proven to be 
metabolized by enzymes in isolated vas deferens tissues, there is a strong 
possibility that nociceptin will also be greatly metabolized in this isolated tissue 
preparation in vitro. Studies performed in rat and mouse vas deferens reported that 
the potencies of [Met5]enkephalin (opioid peptides) and related peptides were 
significantly increased in the presence of enzyme inhibitors (McKnight et al., 1983). 
In rat vas deferens, [Met5]enkephalin had a roughly 178-fold higher potency in the 
presence of a cocktail of enzyme inhibitors (bestatin, thiorphan and captopril) (IC50 
of 330 ± 30 nM compared to 59 ± 14 M (McKnight et al., 1983).   
 
In order to test this hypothesis, we added endopeptidase and aminopeptidase 
inhibitors (peptidase inhibitors) into the organ bath before nociceptin addition. 20 µM 
bestatin and 2 µM thiorphan were added into the organ bath 15 minutes before the 
first concentration of nociceptin was applied to the tissue (Figure 3.8).  
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Figure 3.8: Comparison of nociceptin response between tissues treated with peptidase 
inhibitors (20 µM bestatin and 2 µM thiorphan) and non-treated tissues. Points represent 
means, and vertical lines represent S.E.M of at least four experiments. Statistical 
significance of the differences between mean values was determined using one-way 
ANOVA. *P < 0.001 compared to (-) peptidase inhibitors treated tissue.  
 
There was a significant increase in the maximum response of nociceptin in tissues 
treated with peptidase inhibitors compared to non-treated tissues from 64.2% (59.5-
68.8%) to 77.4% (74.5-80.4%) (n = 4-8). The mean responses from individual 
concentrations were significantly increased at ≥ 30 nM nociceptin. Nociceptin was 
also found to be more potent in the peptidase inhibitors pre-treated tissue with an 
EC50 value of 53.2 nM (44.6-63.3 nM) compared to the EC50 of the non-peptidase 
inhibitors pre-treated tissue, 74.8 nM (53.4-104.7 nM). However, the difference in 
the potency between these two groups was not statistically different. Although a 
higher maximum response was achieved, the response still did not reach a plateau 
and therefore, it was decided to increase the final concentration of nociceptin to 30 
µM (n = 8). The result obtained is shown in Figure 3.9. 
 
* 
* 
* 
* 
* 
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Figure 3.9: Comparison of the effects of nociceptin range on the maximum inhibition 
response of tissue inhibition in electrically evoked contractions in rat vas deferens. Points 
represent means, and vertical lines represent S.E.M of eight experiments. 
 
With the new range of nociceptin (1 nM-30 µM), there was now a more clearly 
defined maximum response that reached a plateau. Furthermore, the maximum 
response (Emax) was found to be significantly higher in the tissue treated with 
nociceptin up to 30 µM compared to tissue treated only up to 3 µM with the Emax of 
85.7% (83.2-88.2%) and 77.4% (74.5-80.4%) respectively. Based on these findings, 
we decided to use the nociceptin range of 1 nM-30 µM for the ORL-1 assays. 
 
In order to validate the dose cycle for nociceptin (washout time), four sets of 
nociceptin (n = 1) concentration-response control curves were conducted on the 
same tissue each separated by a 15 minutes wash out period (Figure 3.10).  
106 
 
log[Nociceptin]
%
 I
n
h
ib
it
io
n
 o
f
e
le
c
t
r
ic
a
ll
y
-
e
v
o
k
e
d
c
o
n
t
r
a
c
t
io
n
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
curve 1
curve 2
curve 3
curve 4
 
Figure 3.10: Comparison of tissue response of four nociceptin control curves in electrically 
evoked contractions of rat vas deferens. Experiments were conducted in a single tissue with 
dose-cycle of 15 minutes.  
 
The EC50 of nociceptin for each curve was compared in order to ensure nociceptin 
was completely washed out at each dose cycle (Table 3.4). No significant 
differences of nociceptin potency (EC50) were detected which established that 
nociceptin had completely washed out with the 15 minutes dose cycle protocol, and 
that no apparent sensitization or desensitization of the tissue occurred over this 
time-period. 
 
Table 3.4: Potency comparisons of nociceptin from a single tissue in order to evaluate the 
suitability of nociceptin washout time for each dose-cycle. 
Nociceptin Curve 1 Curve 2 Curve 3 Curve 4 
EC50 (nM) 62.6  82.9  71.4  66.4  
 
 
As these initial experiments showed that nociceptin needed to be applied at 
concentrations as high as 30 µM in order to obtain a full concentration-response 
curve, we considered using alternative ORL-1 agonists which have been suggested 
to be more potent than nociceptin. The main reason for this was to try and reduce 
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the overall cost of these experiments. These include the peptide, 
[Arg14,Lys15]nociceptin, and a synthetic non-peptide ORL-1 ligand, SCH 221510. 
The comparison of their binding affinities, Ki (receptor binding assay) and their 
relative potencies ([35S]GTPS) compared to nociceptin for the ORL-1 receptor  are 
presented in Table 3.5. 
 
Table 3.5: Comparison of ORL-1 receptor agonists profiles. 
 Nociceptin [Arg
14
,Lys
15
]nociceptin SCH 221510 
Binding affinity, 
Ki (nM) 
0.93 ± 0.50 
     (Okada et al., 2000)          
0.32 ± 0.13 
(Okada et al., 2000) 
0.3 ± 0.05        
(Varty et al., 2008) 
Type Peptide Peptide Non-peptide 
Molecular 
weight 
Relative 
potency 
1809.06 
 
1 
1909.18 
 
17 
397.55 
 
0.6 
 
 
Based on our preliminary experiments, [Arg14,Lys15]nociceptin appears to have only 
marginally greater potency than nociceptin (Figure 3.11). Although these studies 
were only performed with an n of 2, the EC50 values of nociceptin and 
[Arg14,Lys15]nociceptin were 971.2 nM (185.9-5075.0 nM) and 547.5 nM (339.4-
883.2 nM). Although previous studies (Okada et al., 2000) conducted using 
[35S]GTPS binding assay in human embryonic kidney 293 transfected cells have 
shown the former to be 17-fold more potent than nociceptin, we did not see such a 
profound effect. Moreover, the new candidate took a slightly longer time to wash out 
of the tissue.  
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Figure 3.11: Comparison of tissue response between Nociceptin and [Arg
14
,Lys
15
]nociceptin 
in electrically evoked contractions of rat vas deferens. Points represent means of two 
experiments. 
  
The other candidate, SCH 221510 was not efficiently washed out of the tissue even 
after 1 hour (Figure 3.12) and also had a very slow onset of action with a loading 
concentration of 3 µM SCH 221510 taking nearly 20 minutes to reach maximum 
effect (Figure 3.13). Furthermore, 3 µM SCH 221510 only achieved 26.6% inhibition 
of control twitches. Therefore, SCH 221510 was not a suitable ligand for this assay. 
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Figure 3.12: Effects of SCH 221510 (1 nM-3000 nM) on electrically evoked contractions of 
rat vas deferens.  
 
 
Figure 3.13: Effects of SCH 221510 (3 M) on electrically evoked contractions of rat vas 
deferens.  
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Despite testing these alternative ligands, nociceptin was still the best option. 
However, because this ligand was so expensive, it was almost impossible to screen 
all the novel compound synthesised in this project at this receptor. Therefore, we 
selected a few compounds that represent the orvinol series synthesised. 
 
Another interesting finding that was discovered during these pilot experiments was 
the strain difference in nociceptin response found between Sprague Dawley and 
Wistar rats (n = 4). Although strain-related differences in the effects of opioids in 
rodents have been widely documented (Bustamante et al., 1991; Shoaib et al., 
1995), to date there have been no studies conducted to investigate the strain 
differences of nociceptin responses in rats. In our hands, nociceptin was found to be 
significantly less potent in Wistar rats compared with Sprague Dawley rats with EC50 
values of 163.4 nM (122.4-218.1 nM) and 64.7 nM (48.8-85.8 nM) respectively 
(Figure 3.14).  
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Figure 3.14: Comparison of nociceptin response in different strain of rats, Sprague Dawley 
and Wistar. Points represent means, and vertical lines represent S.E.M of four experiments 
per strain. 
 
Such a difference in sensitivity to drug response is not uncommon, since previous 
studies have also discovered this phenomenon when the same tissue was used in 
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different strains of animals. For example, morphine was found to be significantly 
more potent in Sprague Dawley rats compared to Wistar rats in electrically evoked 
contraction of vas deferens tissue with an EC50 of 1895 µM and 3666 µM 
respectively (Bustamante et al., 1991). Although the evidence was pronounced, no 
detailed investigations were conducted by Bustamante et al (1991) to explore the 
cause. Another study conducted by Shoaib et al (1995) also found Sprague Dawley  
rats were more sensitive to morphine than Wistar rats. This study was conducted in 
vivo to determine the difference in the response to morphine in the conditioned-
place preference (CPP) model between the two strains of rat and relate it to 
dopamine release in nucleus accumbens. Morphine induced CPP was found to be 
significant at ≥ 3 mg/kg morphine in Sprague Dawley rats, but required higher doses 
in Wistar rats, where the significant effects in CPP were only seen at ≥ 5.0 mg/kg 
morphine (Shoaib et al., 1995). Morphine induced dopamine release also was found 
to be significant at ≥ 3.0 mg/kg in Sprague Dawley rats with 221 ± 16% increase in 
dopamine release compared to ≥ 10.0 mg/kg morphine required in Wistar rats to 
produce only 158 ± 16% elevation in dopamine release after 80 minutes of morphine 
administration (Shoaib et al., 1995). Overall, there is good evidence that -opioid 
agonists are more potent in Sprague Dawley rats compared with Wistar rats. 
Although the mechanism is unclear, it is likely to be due to different receptor density 
or, different effectiveness of receptor-drug coupling mechanism between the two 
strains (Bustamante et al., 1991; Shoaib et al., 1995). Although to date, no studies 
have investigated the strain differences of nociceptin responses either in vivo or in 
vitro, we provide evidence of a similar strain-dependent effect whereby nociceptin is 
more potent in Sprague Dawley rather than Wistar rats (Figure 3.14). For this 
reason all future experiments were conducted in Sprague Dawley rats. 
 
3.4.4.2 -opioid receptor (rat vas deferens)  
 
[D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin acetate (DAMGO), a selective -opioid 
receptor agonist, was used as the standard -opioid receptor agonist (control) in this 
isolated rat vas deferens assay. DAMGO has higher affinity at the -opioid receptor 
compared to the - and -opioid receptors with about 200 and 1200-fold differences 
in the binding affinities respectively (Table 3.6) (Zhao et al., 2003). Moreover, a 
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recent study measuring the operational efficacies of 22 -opioid agonists has shown 
that DAMGO is the most efficacious -opioid agonist available to date (McPherson 
et al., 2010). Operational efficacy is a parameter used to measure the relative 
intrinsic efficacy of a series of agonists using the concentration-effects data.  
 
Table 3.6: Binding affinity (Ki) of DAMGO over classical opioid receptor, -, - and - opioid 
receptor (Zhao et al., 2003). 
 Binding Affinity, Ki (nM) 
  
DAMGO 1.18 ± 0.12 213 ± 28 1430 ± 20 
 
 
The vas deferens assay using DAMGO is widely published, however we initially 
struggled to get an optimal response with this -agonist in rat tissue. The underlying 
issue is still unclear. Although a preliminary experiment had shown a robust effect of 
10 µM DAMGO to inhibit the muscle twitch by 70% (Figure 3.15 (left)), we were 
unable to reproduce this effect later. Instead, a greater concentration of 30 µM 
DAMGO produced only a 28% inhibition of the muscle twitch (Figure 3.15 (right)). 
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Figure 3.15: Electrically evoked contraction in rat vas deferens. (Left), tissue inhibition after a 
concentration of 10 µM DAMGO was given. (Right), tissue inhibition after a concentration of 
30 µM DAMGO was given. Experiments were conducted in a different tissue at different time 
period. 
 
Several attempts were made in order to get a more robust DAMGO effect including 
using newly purchased DAMGO, reducing the tension applied to the tissue, 
switching rat strain to Wistar and also adjusting the stimulator settings, however the 
result was still not reproducible. The final attempt taken was by reducing the Ca2+ 
concentration in Krebs solution since DAMGO was reported to be more potent in rat 
vas deferens when the Ca2+ concentration in the Krebs formula was reduced to half 
the normal concentration (Sheehan et al., 1988). The cumulative concentration-
response curve was constructed with 1.25 mM Ca2+-Krebs concentration (Figure 
3.16). DAMGO potency (EC50) derived from this experiment was 280.5 nM (218.5-
360.1 nM) with the maximal response (Emax) of 92.5% (88.1-96.8%). The mean 
inhibition obtained at 30 µM DAMGO from our experiment using 1.25 mM Ca2+-
Krebs formula was 91% compared to the 28% inhibition achieved using 30 µM 
DAMGO loading concentration in 2.5 mM Ca2+-Krebs (Figure 3.15 (right)). These 
results were in line with Sheehan et al (1988) when 1.25 mM Ca2+-Krebs was used, 
where the DAMGO potency (IC50) reported was 366 ± 32 nM with 100% maximal 
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response. Although we did not perform a full concentration-response curve for 
DAMGO in 2.5 mM Ca2+-Krebs to compare DAMGO potency between two different 
calcium concentrations, Sheehan et al (1988) reported a 10-fold increase in 
DAMGO potency after the calcium concentration was reduced to 1.25 mM which 
was 366 ± 32 nM compared to 3780 ± 610 nM. 
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Figure 3.16: Electrically evoked contractions of rat vas deferens for DAMGO (10 nM-100 µM) 
in 1.25 mM Ca
2+
-Krebs. Points represent means, and vertical lines represent S.E.M of four 
experiments. 
 
It is believed that the increase of opioid agonists potency (eg: DAMGO) in lower 
calcium is due to the increased efficiency of receptor-effector coupling in a lower 
extracellular calcium media (Sheehan et al., 1988). The influx of calcium into the 
nerve terminals during depolarisation is reduced in a lower extracellular calcium 
environment and therefore the effectiveness of the opioid agonist to block calcium 
from entering the nerve terminals is potentiated compared to in a higher extracellular 
calcium environment (Sheehan et al., 1988). 
                             
The cycle for DAMGO was determined using the same method as used for 
nociceptin, by comparing the EC50 of four DAMGO concentration-response curve 
conducted on the same tissue with a 30 minute wash between curves (n = 1). The 
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result is shown in Figure 3.17 and the EC50 derived from each curves are presented 
in Table 3.7. 
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Figure 3.17: DAMGO concentration-response curve conducted in the same tissue to 
determine the suitability of DAMGO dose-cycle in electrically evoked contraction of rat vas 
deferens. 
 
Table 3.7: Potency comparisons of DAMGO from a single tissue in order evaluate the 
suitability of DAMGO washout time for each dose-cycle. 
DAMGO Curve 1 Curve 2 Curve 3 Curve 4 
EC50 (nM) 1031.0  592.8  945.3 890.8 
 
Although there is some variability between each of the four concentration response 
curves, the effect is not statistically significant, and there is no consistent pattern to 
suggest either that DAMGO does not wash-out fully between cycles (which would 
appear as an apparent increase in DAMGO potency over time) or that DAMGO 
induces desensitization of the response (which would appear as an apparent 
decrease in DAMGO potency over time). For future experiments we therefore used 
this protocol: a dose cycle of 30 minutes and contact time of 5 minutes at each 
concentration.  
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Similar to when using the rat vas deferens to study ORL-1 receptors, the vas 
deferens was sensitized with nociceptin for the same reason as previously 
discussed (Chapter 3.4.4.1). No peptidase inhibitors were used in the -opioid 
receptor assay since DAMGO was found to be stable peptide (Van Dorpe et al., 
2010) compared to nociceptin in this tissue even though each concentration was 
applied for 5 minutes (Figure 3.15). 
 
3.4.4.3-opioid receptor (mouse vas deferens)  
 
-opioid receptors are not present in the rat vas deferens (Sheehan et al., 1988; 
Smith et al., 1983), but are present in the mouse vas deferens (Miller et al., 1983; 
Ward et al., 1982).  
 
Out of the few candidates tested (U-69593, (±)U-50488, (-)U-50488)), compound U-
69593, a selective -opioid receptor agonist was finally selected to be used as a 
standard agonist in these assays. In rat brain membranes, U-69593 was found to 
have 300 and 800-fold higher affinity at the -opioid receptor (Ki = 10.40-18.46 nM) 
compared to the -opioid receptor (3191 ± 661 nM), and -opioid receptor (8534 ± 
1577 nM) respectively (La Regina et al., 1988).   
 
Although they have comparable binding affinities and selectivities for the -opioid 
receptors, the reason both compounds (±)U-50488 and its single enantiomer,          
(-)U-50488 were not selected was because of very slow washout (incomplete after 2 
hours). U-69593 had faster washout, but still took 90-120 minutes. For this reason, 
and because the electrically-evoked twitch response in the mouse vas deferens 
tends to deteriorate over time (Enna et al., 1998), it was not feasible to conduct 
these experiments in the same manner as the ORL-1 and -opioid receptor assays. 
So, affinity constants for each compound tested at the -opioid receptor were 
determined using the single concentration of antagonist method, rather than Schild 
plot analysis. 
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Our pilot experiment demonstrated that the washout time used was sufficient based 
on the similar EC50 of the four U-69593 control curves (Table 3.8) obtained from the 
same tissue (n = 1) suggesting U-69593 had completely washed out after each dose 
cycle (Figure 3.18).   
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Figure 3.18: U-69593 concentration-response curve conducted in the same tissue to 
determine the suitability of U-69593 dose-cycle in electrically evoked contractions of mouse 
vas deferens. 
 
Table 3.8: Potency comparisons of U-69593 from a single tissue in order to evaluate the 
suitability of U-69593 washout time for each dose-cycle. 
U-69593 Curve 1 Curve 2 Curve 3 Curve 4 
EC50 (nM) 21.6  40.7  24.4 14.4 
 
There were no significant differences in potencies between the four U-69593 control 
curves except for the last curve (curve 4) which suggested U-69593 was completely 
removed after a 90-120 minutes washout interval.  
 
For the -opioid receptor assays conducted in mouse vas deferens, all tissues were 
pre-treated with 1 µM CTAP (a selective -opioid receptor antagonist) 15 minutes 
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before the administration of U-69593 (for control curves) and test compound (for 
antagonist curves). Since mouse vas deferens has significantly larger -opioid 
receptor population compared to rat vas deferens (Smith et al., 1983), CTAP was 
administered to the tissue to block any -opioid receptor mediated response 
induced by test compounds. For example, a previous study has shown the ability of 
buprenorphine to inhibit the electrically evoked contraction of mouse vas deferens 
with EC50 of 21.4 nM (20.4-22.9 nM) and achieved 63 ± 4% maximal response 
(Emax) (Spagnolo et al., 2008). Based on Spagnolo et al (2008) studies, this inhibition 
was proven to be mediated by -opioid receptor activity of buprenorphine. In the 
results section as will be discussed later, 1 µM CTAP was proven to successfully 
block any -opioid receptor efficacy mediated by buprenorphine on mouse vas 
deferens tissue. Therefore, in order to standardize the experimental protocol for     
-opioid receptor assays, all tissues were pre-treated with 1 µM CTAP. 
 
3.4.5 Isolated tissue preparation (vas deferens assay)   
 
Functional assays were carried out in either rat vas deferens to evaluate the ORL-1 
and -opioid receptor activity of the compounds or in mouse vas deferens to 
evaluate the -opioid receptor activity. Initially, a single high concentration (10 µM) 
of buprenorphine and its analogues was tested to determine if the compounds had 
any efficacy at the different receptors in either the rat or mouse vas deferens 
system.  
 
3.4.5.1 ORL-1 receptor rat vas deferens assays 
 
Buprenorphine and five of its analogues (BU127, BU10101, BU10136, BU10112 
and BU10119) showed no agonist response in this tissue and so were evaluated at 
the ORL-1 receptor against nociceptin, a selective ORL-1 receptor agonist. A 
synthetic non-peptide compound, SB 612111 was used as a standard ORL-1 
receptor antagonist in these assays. SB 612111 is > 1000-fold more selective for 
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the ORL-1 receptor compared to the - and -opioid receptors (Spagnolo et al., 
2007). 
 
Using Sprague Dawley rats, the average potency (EC50) for nociceptin derived from 
our experiments (n = 45) was 138.0 nM (109.6-166.0 nM), slightly less potent 
compared to the value previously reported, 56.2 nM (38.1-83.2 nM) (Fischetti et al., 
2009). Fischetti et al (2009) also found that nociceptin was slightly more potent in 
mouse vas deferens compared to rat vas deferens as shown in Table 3.9. Although 
nociceptin was less potent in our experiment, this was not a critical issue since the 
compound’s potency was calculated based on individual tissue responses and was 
analyzed using individual concentration-ratio values to determine the antagonist 
potency values (pA2) and binding affinities (KB). 
 
Table 3.9: Potency, EC50 (nM) of nociceptin in rats and mouse vas deferens (Fischetti et al., 
2009). Data marked * derived from our experiments. 
 Potency, EC50 (nM) 
Mouse vas deferens Rat vas deferens 
Swiss  
(n = 5) 
CD1  
(n = 5) 
Sprague Dawley  
(n = 5) 
Sprague Dawley*  
(n = 45) 
Nociceptin 42.7 nM      
(33.9-53.7 nM) 
24.0 nM       
(20.9-27.5 nM) 
56.2 nM       
(38.1-83.2 nM) 
138.0 nM    
(109.6-166.0 nM) 
 
 
Results 
 
SB 612111 
SB 612111, the standard ORL-1 receptor antagonist used in this assay, caused a 
parallel rightward shift of the nociceptin control curves (n = 4-8) (Figure 3.19 (left)).  
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Figure 3.19: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of SB 612111 (1-100 nM); the corresponding Schild plot is shown on the 
right. The straight line (red) is after the slope was constrained to 1 and the dotted line (black) 
is the best fit line. Points represent means, and vertical lines represent S.E.M. of at least four 
experiments.  
 
No significant diminution of the maximum inhibition to the control curve was 
observed by SB 612111, even at the highest concentration used. A Schild plot was 
constructed (n = 4-8) (Figure 3.19 (right)) to evaluate the antagonist pattern of      
SB 612111 and gave a straight line with a slope of 0.967 ± 0.0724 (95% confidence 
interval of 0.816-1.118) that was not significantly different to unity. As discussed 
earlier (Chapter 3.3.3.2), this situation permitted the straight line to be constrained to 
1. The x-intercept of the Schild plot (when the slope was constrained to 1) gave the 
pA2 value of 8.046 (7.957-8.136) for SB 612111. Therefore, SB 612111 was shown 
to be a competitive reversible antagonist in this system. The pA2 value derived from 
this assay is in line with the value that has been previously reported (8.20-9.70) 
(Spagnolo et al., 2008; Zaratin et al., 2004). 
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Buprenorphine 
A 10 µM concentration of buprenorphine did not inhibit the electrically evoked 
contractions of rat vas deferens, demonstrating that buprenorphine had no efficacy 
in this system (Kajiwara et al., 1986) up to 10 µM (Figure 3.20). 
 
 
Figure 3.20: Effects of buprenorphine (10 M) on electrically evoked contractions of rat vas 
deferens.  
 
Increasing concentrations of buprenorphine (1 µM, 3 µM and 10 µM) were used and 
a Schild plot (n = 4) was constructed to evaluate the ORL-1 receptor antagonist 
characteristics of buprenorphine in this system (Figure 3.21). 
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Figure 3.21: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of buprenorphine (1-10 µM); the corresponding Schild plot is shown on the 
right. The straight line (red) is after the slope was constrained to 1 and the dotted line (black) 
is the best fit line. Points represent means, and vertical lines represent S.E.M. of four 
experiments.  
 
The best fit slope obtained from the straight line was 0.869 ± 0.248 (0.316-1.421) 
and was not significantly different to unity. The pA2 value derived from the Schild 
plot for buprenorphine was 5.976 (5.760-6.191) with the slope constrained to 1.  
Therefore, in this case, pA2 was equal to pKB. Similar to SB 612111, buprenorphine 
was also shown to be a competitive reversible antagonist in this system with no 
significant difference in the maximum response (Emax) compared to the control even 
in the presence of 10 µM buprenorphine. In this experiment, buprenorphine was 
100-fold less potent at the ORL-1 receptor compared to the standard ORL-1 
antagonist used in this assay, SB 612111, with a binding affinities of 1056.8 nM 
(644.2-1737.8 nM) and 9.0 nM (7.3-11.0 nM) respectively. The inability of 10 µM 
buprenorphine to inhibit the electrically evoked contraction of the rat vas deferens 
and also the parallel rightward shift of the nociceptin concentration-response curves 
in the presence of buprenorphine (Figure 3.21) demonstrates that buprenorphine 
acts as an ORL-1 antagonist in rat vas deferens.  
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BU127 
A 30 µM concentration of BU127 did not inhibit electrically evoked contractions of rat 
vas deferens, indicating that BU127 has no efficacy in this system up to 30 µM 
(Figure 3.22). 
 
 
Figure 3.22: Effects of BU127 (30 µM) on electrically evoked contractions of rat vas 
deferens. 
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Figure 3.23: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of BU127 (1-30 µM); the corresponding Schild plot is shown on the right. The 
dotted line (black) is the best fit line. Points represent means, and vertical lines represent 
S.E.M. of at least three experiments.  
 
Although there is no diminution of the maximal response to the control nociceptin 
curves observed, the Schild analysis (n = 3-8) gave a slope value of 0.761 ± 0.0877 
with 95% CI significantly less than 1 (0.578-0.944). Therefore, a different approach 
was used to empirically estimate the pA2 value of this compound since the              
x-intercept of the Schild plot is no longer valid to obtain this value (Kenakin, 2009).  
From the Schild equation (single concentration method), the pA2 value calculated 
based on the procedure described in the methods section was 5.884 ± 0.108 (5.594-
6.104). Based on the parallel rightward shift of the concentration-response curves 
and the fact that the maximum agonist response did not decrease (Figure 3.23 
(left)), BU127 seems to behave as a competitive reversible antagonist. Both the lack 
of activity of 30 µM BU127 on its own and also the parallel rightward shift of 
nociceptin concentration-response curves in the presence of BU127 (Figure 3.23) 
demonstrate that BU127 acts as an ORL-1 antagonist in rat vas deferens.  
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BU10101 
A 10 µM concentration of BU10101 did not inhibit electrically evoked contraction of 
rat vas deferens, which means that BU10101 had no efficacy in this system up to 10 
µM (Figure 3.24). 
 
 
Figure 3.24: Effects of BU10101 (10 M) on electrically evoked contractions of rat vas 
deferens.  
 
Compound BU10101 was evaluated at the ORL-1 receptor to determine if the 
presence of a methyl group on the phenyl substituent at the C20 position improves 
the potency of BU127 analogue (BU10101) at this receptor. Based on Figure 3.25  
(left), the concentration-response curves showed a significant suppression of the 
maximal response compared to the control at 30 µM BU10101 (n = 4-8) with an Emax 
value of 42.4% (37.8-46.9%) and 77.2% (72.2-82.2%) respectively. This suggests 
either a pseudo-irreversible action of BU10101 or hemi-equilibrium.  
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Figure 3.25: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of BU10101 (1-10 µM); the corresponding Schild plot is shown on the right. 
The dotted line (black) is the best fit line. Points represent means, and vertical lines 
represent S.E.M. of at least four experiments.  
 
From the Schild analysis, the slope derived from the regression line was 1.703 
(1.248-2.159), which was significantly greater than 1. This Schild analysis has 
further proved that either BU10101 is a pseudo-irreversible ORL-1 antagonist 
(based on the fact that the presence of antagonist cause a parallel shift of the dose-
response curve, but the maximal response was significantly suppressed) or that 
equilibrium of agonist and antagonist with the receptors was not achieved (based on 
the fact that the slope was significantly greater than 1) (Kenakin, 2009). As the 
regression line on the Schild plot was significantly different from unity, we used the 
single concentration method in order to empirically estimate the potency (pA2) value 
of compound BU10101 in this system. The nociceptin concentration-response curve 
in the presence of the lowest concentration of antagonist that caused the shift at 
each individual experiment was used to estimate the pA2 value of compound 
BU10101. The estimated pA2 value calculated using the Schild equation (single 
concentration method) for compound BU10101 was 5.872 ± 0.180 (5.446-6.297). 
Compound BU10101 was found to be a pseudo-irreversible antagonist in this 
system or the assay is in hemi-equilibrium as demonstrated by the reduction of the 
maximal response in the presence of 10 µM BU10101 (Figure 3.25 (left)), and the 
fact that the slope was significantly greater than 1 (Figure 3.25 (right)). Both the lack 
127 
 
of activity of 10 µM BU10101 on its own and also the rightward shift of nociceptin 
concentration-response curves in the presence of BU10101 (Figure 3.25 (left)) 
demonstrate that BU10101 acts as an ORL-1 antagonist in rat vas deferens.  
 
BU10136 
A 10 µM concentration of BU10136 did not inhibit electrically evoked contraction of 
rat vas deferens, suggesting BU10136 has no efficacy in this system up to 10 µM 
(Figure 3.26). 
 
 
Figure 3.26: Effects of BU10136 (10 M) on electrically evoked contractions of rat vas 
deferens.  
 
Compound BU10136 has a 5-chlorothiophene at the C20 position of the orvinol. This 
compound was selected to see if it would retain its functional activity with the 
presence of a heteroatom rather than carbon in the aromatic system. Based on 
structure, thiophene is smaller compared to phenyl, which may be an advantage 
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during synthesis, however its pharmacological implications still needed to be 
investigated.  
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Figure 3.27: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of BU10136 (1-10 µM); the corresponding Schild plot is shown on the right. 
The straight line (red) is after the slope was constrained to 1 and the dotted line (black) is the 
best fit line. Points represent means, and vertical lines represent S.E.M. of four experiments.  
 
From the concentration-response curves shown in Figure 3.27 (left) (n = 4), the 
maximal response of nociceptin in the presence of 3 µM and 10 µM of BU10136 
was suppressed compared to the control with the Emax value of 74.5% (68.0-80.9%) 
for the control, and 52.3% (49.2-55.3%) and 50.6% (45.7-55.4%) in the presence of 
3 µM BU10136 and in the presence of 10 µM BU10136,respectively. The decrease 
in the maximal response was statistically significant which indicates that compound 
BU10136 is a pseudo-irreversible ORL-1 receptor antagonist in this system, possibly 
due to the slow offset of BU10136 from the receptor during pre-equilibria period. The 
Schild slope derived from the Schild analysis for this compound was 1.732 (0.978-
2.486) which was not significantly different to unity. Therefore hemi-equilibria rather 
than a true non-competitive nature of the antagonist is suspected. In this case, 
where a hemi-equilibria condition was suspected, Schild analysis still can be used to 
estimate the pKB (= pA2) of compound BU10136 (Kenakin, 2009). The pA2 value 
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derived from the Schild plot for this compound was 6.140 (5.789-6.491) after the 
slope was constrained to 1. Both the lack of activity of 10 µM BU10136 on its own 
and also the parallel rightward shift of nociceptin concentration-response curves in 
the presence of BU10136 (Figure 3.27 (left)) demonstrates that BU10136 acts as an 
ORL-1 antagonist in rat vas deferens.  
 
BU10119 
A concentration of 10 µM of BU10119 did not inhibit electrically evoked contraction 
of rat vas deferens, which means BU10119 has no efficacy in this system up to 10 
µM (Figure 3.28). 
 
 
Figure 3.28: Effects of BU10119 (10 M) on electrically evoked contractions of rat vas 
deferens.  
 
Compound BU10119 has a similarity in the chemical structure with compound 
BU127, except the presence of a methyl group at the C7 position and a proton at the 
C20 position of orvinol. 
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Figure 3.29: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of BU10119 (3-30 µM); the corresponding Schild plot is shown on the right. 
The straight line (red) is after the slope was constrained to 1 and the dotted line (black) is the 
best fit line. Points represent means, and vertical lines represent S.E.M. of five experiments.  
 
The pA2 value derived for compound BU10119 was based on the value obtained 
from Schild plot (n = 5) since the concentration-response curve for this compound 
showed no significant decrease in the maximal response at all of the concentration 
of BU10119 tested and the slope for the best fit line was not significantly different to 
1 (0.851 ± 0.111 (0.612-1.089)) which allowed the slope to be constrained to 1. Both 
the lack of activity of 10 µM BU10119 on its own and also the parallel rightward shift 
of nociceptin concentration-response curves in the presence of BU10119 (Figure 
3.29 (left)) demonstrate that BU10119 acts as an ORL-1 antagonist in rat vas 
deferens with the pA2 value of 5.745 (5.646-5.845) after the slope was constrained 
to 1.   
 
BU10112 
A 30 µM concentration of BU10112 did not inhibit electrically evoked contraction of 
rat vas deferens, which means BU10112 had no efficacy in this system up to 30 µM 
(Figure 3.30). A single concentration of 30 µM BU10112 was tested since this was 
the highest dose range used in the actual assay (Figure 3.31 (left)). 
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Figure 3.30: Effects of BU10112 (30 M) on electrically evoked contractions of rat vas 
deferens.  
 
Compound BU10112 has a similarity in structure to BU10101. Compound BU10112 
also has a modification at the C7 and C20 position of the orvinol as seen in 
BU101119.  
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Figure 3.31: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to nociceptin obtained in the absence and in the presence of increasing 
concentrations of BU10112 (1-30 µM); the corresponding Schild plot is shown on the right. 
The straight line (red) is after the slope constraint to 1 and the dotted line (black) is the best 
fit line. Points represent means, and vertical lines represent S.E.M. of at least three 
experiments. 
  
Unlike BU10101, compound BU10112 (n = 4-8) did not decrease the maximal 
nociceptin response even at 30 µM BU10112 (Figure 3.31 (left)). This was different 
to compound BU10101, where the decrease of the maximal response was detected 
at 10 µM (Figure 3.25 (left)). The pA2 value derived from the Schild plot for BU10112 
(n = 3-8) was 5.539 (5.385-5.693) after the slope was constrained to 1. The slope 
obtained from the best fit line was 1.223 ± 0.152 (0.906-1.540). Although there was 
not a significant difference the potency of compounds BU10112 and BU10101, 
5.539 (5.385-5.693) and 5.872 ± 0.180 (5.446-6.297) respectively, these two 
compounds showed different antagonistic behaviour in this system. Compound 
BU10112 showed a competitive reversible antagonist pattern based on both 
concentration-response curves and Schild analysis, whereas compound BU10101 
acted as a pseudo-irreversible antagonist at the ORL-1 receptor. Both the lack of 
activity of 30 µM BU10112 on its own and also the parallel rightward shift of 
nociceptin concentration-response curves in the presence of BU10112 (Figure 3.31 
(left)) demonstrate that BU10112 acts as an ORL-1 antagonist in rat vas deferens.   
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Discussion 
 
Are buprenorphine and its analogs ORL-1 agonists or antagonists ? 
 
Although the [35S]GTPγS initial screening (Figure 3.2 and Table 3.2) has shown all 
buprenorphine analogues evaluated have partial efficacy at the ORL-1 receptor (14-
57%), none of them show any efficacy when tested in rat vas deferens. This was not 
surprising since a number of previous studies have also reported similar trends 
(Butour et al., 1998). For example, [F/G]N/OFQ(1-13)NH2, a nociceptin peptide 
fragment was previously reported to be an ORL-1 receptor antagonist due to its 
failure to inhibit the electrically evoked contraction of mouse vas deferens and 
guinea pig ileum. However it was found to show partial efficacy at the ORL-1 
receptor in [35S]GTPγS assay system (Burnside et al., 2000; Guerrini et al., 1998). 
Moreover, in cAMP accumulation assay, this same peptide was found to exert a full 
efficacy at the ORL-1 receptor (Butour et al., 1998). These inconsistencies were 
believed to happen due to the different capacity of receptor reserve available 
between different assay systems (Spagnolo et al., 2008).  
 
Spagnolo et al (2008) has compared the profile of two different compounds with 
mixed ORL-1/-opioid receptor agonist activities (SR14150 and SR16476) and has 
found the relevance of this hypothesis. These studies suggest both compounds 
have similar affinity for ORL-1 receptor with Ki value of 1.39 ± 0.42 nM and 3.96 ± 
1.55 nM respectively. Compound SR14150 however has 20-fold receptor selectivity 
for ORL-1 receptor over the -opioid receptor, significantly higher than SR16476 
which only has 2-fold receptor selectivity. Surprisingly, only compound SR16476 
which has slightly lower binding affinity and much lower selectivity for ORL-1 
receptor, managed to maintain its agonist activity at this receptor in mouse vas 
deferens in the presence of naloxone while the efficacy of SR14150 at ORL-1 
receptor was completely abolished by naloxone which shows that the inhibition of 
the mouse vas deferens contraction by compound SR14150 was mainly -opioid 
receptor mediated  (Spagnolo et al., 2008). When traced backward, it was found that 
although both compounds were equipotent at the ORL-1 receptor in [35S]GTPγS 
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functional assay with EC50 of 20.8 ± 3.1 nM (SR14150) and 26.5 ± 4.3 nM 
(SR16476),  only SR16476 managed to 100% stimulate ORL-1 receptor in this 
assay system compared to SR14150 which only partially stimulated the receptor 
(54.2% ORL-1 receptor stimulation) (Spagnolo et al., 2008). Therefore, it is 
suggested that the GTPγS assay system which was conducted using CHO cells 
transfected with ORL-1 receptor might have a significantly higher ORL-1 receptor 
reserve compared to the vas deferens system (Spagnolo et al., 2008). Therefore, a 
compound with low efficacy has an increased capability to stimulate the ORL-1 
receptor in GTPγS assay might be due to the saturated number of ORL-1 receptors.  
 
Thus, in order for a compound to show efficacy at ORL-1 receptor, especially in a 
system with a lower receptor reserve, a compound must possess a full agonist 
efficacy in a system with higher receptor density, such as in [35S]GTPγS assay. In 
our case, since buprenorphine and all of its analogues only managed to partially 
stimulate the ORL-1 receptor in the [35S]GTPγS assay, it was predicted that they 
would also be ORL-1 antagonists in mouse vas deferens. Any efficacy that may 
appear in the mouse vas deferens is believed to be mediated by the -opioid 
receptor. In conclusion, only compounds that show full ORL-1 efficacy in the 
[35S]GTPγS assay can potentially show efficacy in a system with a lower receptor 
reserve, such as vas deferens (Spagnolo et al., 2008).  
 
In the current work, all of the compounds evaluated at the ORL-1 receptor in the rat 
vas deferens assay were compared against the standard ORL-1 receptor 
antagonist, SB 612111. SB 612111 was found to be 100-300-fold more potent 
antagonist at ORL-1 receptor compared to buprenorphine and its analogues, with 
pA2 value of 8.046 (7.957-8.136). In previous studies SB 612111 was shown to be a 
pure ORL-1 receptor antagonist and inactive as an agonist at this receptor across a 
wide range of assay systems including the cAMP accumulation assay, [3H]Leucyl-
N/OFQ and [35S]GTPγS binding assays, CRE-luciferase gene reporter assay and in 
electrically evoked isolated tissues assays (mouse / rat vas deferens and guinea pig 
ileum) (Spagnolo et al., 2007; Zaratin et al., 2004). pA2 values ranged between 8.20-
9.70 and therefore agreed with the value obtained in the current work. SB 612111 
was confirmed to be a competitive reversible ORL-1 antagonist in rat vas deferens 
system (Figure 3.19).  
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Although we were unable to detect any existence of ORL-1 receptor efficacy of 
either buprenorphine or its analogues in rat vas deferens assays, previous studies 
have suggested that the activation of ORL-1 receptor by buprenorphine has 
potential as a new target in relapse prevention associated with drug addiction 
(McCann, 2008). The potential role of ORL-1 receptor in relapse prevention due to 
opioid, cocaine and alcohol consumption has been discussed in an earlier chapter. 
Thus, we aimed to design buprenorphine analogues that have certain profiles at 
targeted opioid receptors, which includes having high efficacy and potency at ORL-1 
receptor. 
 
One aspect of buprenorphine’s profile that is believed to be beneficial in the 
treatment of drug addiction is its ability to activate ORL-1 receptors (McCann, 2008). 
From Traynor’s finding, buprenorphine acted as a partial ORL-1 agonist in the 
[35S]GTPγS assay with 24 ± 9% receptor stimulation at 10 µM. Previous studies 
show that buprenorphine displays inconsistent efficacy at the ORL-1 receptor at the 
cellular level, believed to highly rely on the sensitivity of the assay system which will 
influence the capacity of receptor reserve. For example, in one case buprenorphine 
was totally inactive as an agonist at the ORL-1 receptor in [35S]GTPγS binding 
assay which was in contrast to Traynor’s findings (Spagnolo et al., 2008). In another 
study, buprenorphine shows higher partial ORL-1 receptor efficacy with 50 ± 4% 
receptor stimulation in [35S]GTPγS assay conducted using ORL-1 transfected CHO-
K1 cell lines (Bloms-Funke et al., 2000). The higher ORL-1 receptor stimulation by 
buprenorphine obtained by Blooms-Funke (2000) compare to Traynor’s results is 
suspected to be due to the different sensitivity of the GTPS assay system used. 
Besides varying the amount of GDP added during their preliminary assay in order to 
optimize the measurement of the [35S]GTPS binding, Blooms-Funke’s lab also has 
added the SPA-beads into their assay kit. SPA-bead (Scintillation proximity assay 
beads) is a sensitive microscopic size bead containing scintillant used to detect 
radioactivity signal (Park et al., 1999) (eg: 35S from the GTPS species). This 
component is not present in Traynor’s assay which is believed to contribute to the 
different extent of receptor stimulation seen in buprenorphine between these two 
lab. The most extreme case was reported from the reporter gene assay system 
where buprenorphine exerts its full and potent ORL-1 agonist efficacy with an IC50 
value of 8.4 ± 2.8 nM and an Emax of 82.9 ± 2.1%, which was as efficacious as 
nociceptin. The IC50 value for nociceptin was 0.81 ± 0.5 nM with Emax of 81.9 ± 8.6% 
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at 10 µM in the same assay (Wnendt et al., 1999). This assay that used reporter 
gene system has incorporated a cAMP-sensitive luciferase gene into the CHO-K1 
transfected cells under the control of a promoter. Since the receptor activation by 
nociceptin inhibits the cAMP, this biochemical event can be detected and measured 
by the gene-reporter that was incorporated into the cell lines (inhibition of fosrskolin-
induced luciferase expression). Therefore, sensitivity is not only different within 
similar assay system but with different receptor reserve, but the sensitivity of the cell 
lines and the variability in the experimental protocols is also believed to have a 
significant impact on the results (Harrison et al., 2003; Kenakin, 2002; Leslie, 1987).  
 
Synthetic chemistry approaches to increasing efficacy at ORL-1 receptor 
 
Among all the buprenorphine analogues evaluated by Traynor’s [35S]GTPγS 
functional screening, the aromatic analogues of buprenorphine that have extra bulk 
near to the C20 position show significantly higher efficacy at the ORL-1 receptor 
compared to others in the series (Figure 3.32). This includes compounds BU10101, 
BU10093, BU10119 and BU10112 with ORL-1 receptor stimulation between 43-
57%. 
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Figure 3.32: [
35
S]GTPγS efficacy screening of buprenorphine and its analogues performed in 
cultured Chinese Hamster Ovarian (CHO) transfected cells. Efficacies of buprenorphine and 
its analogues at 10 µM were compared against standard ORL-1 receptor agonist (nociceptin) 
in triplicate. BU10101, BU10093, BU10119 and BU10119 (marked in red) shows significantly 
higher efficacy at ORL-1 receptor compared to the rest of the orvinol series (Traynor 
(unpubished work). 
 
Compounds BU10101, BU10093 and BU10112 have a methyl group attached to the 
ortho position of the aromatic substituent (phenyl / thiophene) at the C20 position. 
Although compound BU10119 did not have such a methyl group, it is believed that 
the efficacy of this compound at the ORL-1 receptor is high due to the presence of a 
methyl group at the C7 position of the orvinol. The presence of a methyl group at C7 
increases the steric bulk of this orvinol series near to C20. BU10112 has both a 
methyl group at the ortho position of phenyl ring and at C7 but does not have even 
higher efficacy for BU10119 suggesting that the effect of adding methyl groups is 
not additive, or that the C18-C19 bridge (double bond in BU10112 and single bond in 
BU10119) also affects efficacy. Of all the analogues, compounds BU08026 and 
BU11001 have the lowest efficacies at the ORL-1 receptor. Both compounds have a 
thiophene substituent at the C20 position of the orvinol but have no alkyl or small 
groups attached to the thiophene ring compared to BU10093 (3-methyl-2-thienyl) 
and BU10135 (5-chloro-2-thienyl). In terms of the aromatic system, thiophene (5 
membered ring) is smaller compared to phenyl (6 membered ring). Therefore, these 
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2 compounds (BU08026 and BU11001) have slightly lower efficacy compared to 
BU127 (phenyl). In terms of the efficacy at the ORL-1 receptor, there were no 
differences seen by relocating sulphur from 2-thiophene to 3-thiophene (Figure 
3.32). 
 
In conclusion, neither buprenorphine nor the newly synthesised buprenorphine 
analogues display agonist activity at ORL-1 receptors in a functional in vitro assay, 
although cell-based assays show that they may be agonists with very low intrinsic 
efficacy (Figure 3.32). Although these compounds appear to act functionally as 
ORL-1 antagonists, there is still evidence that a component of buprenorphine’s 
action in vivo are caused by activation of ORL-1 receptors. This level of efficacy is 
not likely to play a major role in their actions in vivo, and so they would act as ORL-1 
antagonists. This is based on buprenorphine in vivo effects seen in mice, where the 
bell-shaped dose response curve for buprenorphine induced antinociception (using 
high light intensity) was converted to a sigmoidal dose-response curve when the 
ORL-1 antagonist, J-113397 was administered (Lutfy et al., 2003b). J-113397 is 600 
times more selective at the ORL-1 receptor compared to the -opioid receptor, 1000 
times compared to -opioid receptor and inactive at -opioid receptor (Kawamoto et 
al., 1999). 
 
Antagonist potency of compounds at the ORL-1 receptor 
 
In terms of antagonist potency, buprenorphine was found to be 117-fold less potent 
at the ORL-1 receptor compared to SB 612111 with pA2 value of 5.976 (5.760-
6.191). The affinity (KB) of buprenorphine in rat vas deferens was found to be about 
5-fold lower than the binding affinity (Ki) at the ORL-1 receptor reported by Traynor’s 
group using radioligand binding in transfected CHOORL-1 cells (212 ± 7 nM) (Table 
3.1). Similar to SB 612111, buprenorphine also behaved as a competitive reversible 
antagonist at the ORL-1 receptor in the rat vas deferens system. 
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The effect on antagonist potency of increasing the steric bulk near to the C20 
position of the orvinol series was the opposite to the effect on efficacy. Introducing 
bulk near to C20 slightly reduces the antagonist potency of analogues for the ORL-1 
receptor compared to buprenorphine, although the differences were not statistically 
significant except for compound BU10112 (Table 3.10). Compound BU10112 has 
about 3-fold less affinity for the ORL-1 receptor than buprenorphine with a KB value 
(≈ Ki) of 2890.7 nM (2027.7-4121.0 nM) and 1056.8 nM (644.2-1737.8 nM) 
respectively (Table 3.10). 
 
As mentioned, although introducing phenyl at C20 (BU127) slightly reduces the 
analogue potency at ORL-1 receptors compared to buprenorphine, the differences 
were not statistically proven, which suggests that the presence of a methyl on the 
phenyl substituent at the C20 position of orvinol has little effect on this parameter. 
However the slight difference in chemical structure causes BU10101 to be pseudo-
irreversible as can be seen in the concentration-response curve in Figure 3.25 (left). 
One possible explanation is the difference in lipophilicity between these compounds 
which is calculated by measuring log P. High lipophilicity ensures the compounds 
are able to diffuse through the tissue, however it can also cause the compounds to 
have slow receptor kinetics, making it difficult to remove from the active site. Log P 
is a quantitative descriptor of compound lipophilicity and it helps to understand 
pharmacological behaviour of compounds in a biological system (Riba et al., 2010). 
It measures the partition coefficient of a compound in octanol-water. Higher values 
indicate higher lipophilic properties of the compound (Riba et al., 2010). The log P 
calculated using Chemdraw software for compound BU10101 was 4.45, higher than 
compound BU127 which was 3.96. This means that BU10101 is more lipophilic than 
BU127 which might explain the pseudo-irreversible behaviour of this compound. In 
addition, BU10136 (5-chloro-2-thienyl orvinol) (log P = 4.32) was also found to be 
more lipophilic than BU127 and also displayed a pseudo-irreversible behaviour of 
antagonism at the ORL-1 receptor. Unfortunately, compound BU08026 (2-thienyl 
orvinol) was not tested in this assay as a comparison. Log P calculations show that 
compound BU10136 was slightly more lipophilic than BU08026 with calculated log P 
to be 4.32 and 3.95 respectively, suggesting that BU08026 would be reversible.  
 
All findings at the ORL-1 receptor in rat vas deferens are summarized in Table 3.10.  
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Compound pA2 KB (nM) Log P Potency vs. 
Buprenorphine 
Antagonist Behaviour 
SB 612111 
(Standard ORL-1 antagonist) 
 
 
8.046  
(7.957-8.136) 
9.0 
(7.3-11.0) 
6.24 117 Competitive reversible 
 
 
 
 
 
 
 
 
 
Buprenorphine 
 
 
5.976 
(5.760-6.191) 
1056.8  
(644.2-1737.8) 
3.99 1 Competitive reversible 
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BU127 
 
 
5.884 ± 0.108  
(5.594-6.104) 
1305.9 
(787.0-2546.8) 
3.96 0.8 Competitive reversible 
 
 
 
 
 
 
 
BU10101 
 
 
5.872 ± 0.180 
(5.446-6.297) 
1342.8 
(504.7-3581.0) 
4.45 0.8 Pseudo-irreversible 
 
 
 
 
 
 
 
BU10136 
 
 
6.140  
(5.789-6.491) 
724.4 
(322.8-1625.5) 
4.32 1.5 Pseudo-irreversible 
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BU10119 
 
 
5.745 
(5.645-5.845) 
1762.0  
(1429.0-2259.4) 
4.37 0.6 Competitive reversible 
BU10112 
 
 
5.539 
(5.385-5.693) 
2890.7  
(2027.7-4121.0) 
4.86 0.4 Competitive reversible 
 
Table 3.10: Summary of ORL-1 receptor assays conducted in rat vas deferens. 
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3.4.5.2 -opioid receptor rat vas deferens assays 
 
Based on the initial [35S]GTPS efficacy screening done by Traynor’s lab (Figure 
3.2), only three buprenorphine analogues (BU127, BU10101 and BU10119), in 
addition to buprenorphine, were selected to be evaluated at the -opioid receptor 
against DAMGO, a selective -opioid receptor agonist in the rat vas deferens 
system. BU127 and BU10119 were selected because these two analogues have 
shown successful profile at all the targeted receptors. Compound BU10101 was 
selected as the representative of the analogues having small substituent group at 
the C20 aromatic ring, and also due to the high partial efficacy shown at the ORL-1 
receptors (Figure 3.2).  
 
Cumulative DAMGO concentration-response curves (10 nM-100 µM) were 
constructed in the presence and in the absence of increasing concentrations of the 
test compounds. Instead of naloxone, we used naltrexone as the standard -opioid 
receptor antagonist in this assay. Both naloxone and naltrexone are universal opioid 
receptor antagonists. Naloxone is relatively more selective than naltrexone for the -
opioid receptor compared to - and -opioid receptors (Table 3.11) (Magnan et al., 
1982). However, since the compounds synthesised are -antagonists and rat vas 
deferens (which does not have -opioid receptor population) (Smith et al., 1983) 
was used to evaluate their -opioid receptor activity, this will not cause a problem. 
 
Table 3.11: The opioid receptor selectivity of naltrexone and naloxone. 
Compound Binding affinity, Ki (nM) 
  
Naltrexone 1.08 ± 0.17 6.6 ± 0.08 8.5 ± 0.82 
Naloxone 1.78 ± 0.25 27.0 ± 6.1 17.2 ± 3.5 
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Results 
 
In the current studies, naltrexone showed no efficacy in rat vas deferens at 10 µM 
as expected (Figure 3.33).  
 
 
Figure 3.33: Effects of naltrexone (10 M) on electrically evoked contractions of rat vas 
deferens.  
 
Naltrexone caused a parallel rightward shift to the control DAMGO curves (n = 5) 
with no suppression of the maximal response at all concentrations used (1 nM,      
10 nM, 30 nM) (Figure 3.34 (left)). The slope for the best fit line was not significantly 
different to 1 (0.869 ± 0.179 (0.482-1.255) (Figure 3.34 (right)). The Schild plot was 
constructed with the slope constrained to 1 and gave the pA2 value of 8.898 (8.665-
9.131) for naltrexone. This was similar with the previous pKB value reported (9.04) 
for naltrexone (single concentration method) in rat vas deferens (Riba et al., 2010). 
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Figure 3.34: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to DAMGO obtained in the absence and in the presence of increasing 
concentrations of naltrexone (1-30 nM); the corresponding Schild plot is shown on the right. 
The straight line (red) is after the slope was constrained to 1 and the dotted line (black) is the 
best fit line. Points represent means, and vertical lines represent S.E.M. of five experiments.  
 
From both graphs, naltrexone was shown to be a competitive reversible -opioid 
receptor antagonist in this system. 
 
Buprenorphine 
As shown in the previous ORL-1 receptor assay, buprenorphine does not show any 
agonist activity in the rat vas deferens tissue at ≤ 10 µM (Figure 3.20). Although 
buprenorphine is a partial -opioid agonist, the inability of this drug to inhibit the 
twitches is due to the low -receptor reserve in the rat vas deferens system (Liao et 
al., 1981; Smith et al., 1983) compare to the mouse vas deferens (Huidobro-Toro et 
al., 1981; Maldonado et al., 2001), where the agonist activity of buprenorphine was 
seen (Spagnolo et al., 2008). The concept of receptor reserve has already been 
introduced in the first chapter (Chapter 1.7.2.2) and been discussed extensively in 
the previous   ORL-1 discussion’s section.  
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To investigate buprenorphine’s activity in this system, DAMGO concentration-
response curves were performed in the presence of increasing buprenorphine 
concentrations (1 nM, 3 nM and 10 nM) (n = 3-4). The results are presented in 
Figure 3.35.  
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Figure 3.35: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to DAMGO obtained in the absence and in the presence of increasing 
concentrations of buprenorphine (1-10 nM); the corresponding Schild plot is shown on the 
right. The straight line (red) is after the slope was constrained to 1 and the dotted line (black) 
is the best fit line. Points represent means, and vertical lines represent S.E.M. of at least 
three experiments.  
 
Although DAMGO shows a parallel rightward shift of the concentration-response 
curves in the presence of increasing concentration of buprenorphine (1-10 nM) 
(Figure 3.35 (left)), the graph pattern clearly suggesting buprenorphine is a pseudo-
irreversible antagonist in this system. This is based on the decreasing pattern of the 
maximal response of DAMGO when buprenorphine is presence. This suppression is 
however is not significantly different from the control curve, except at 3 nM 
buprenorphine (Emax; control 100.0%, 1 nM (83.6% (65.7-100.0%), 3 nM (80.2% 
(62.8-97.6%), 10 nM (95.0% (64.7-100.0%)) (calculated Emax), which technically 
allows Schild analysis to be used to get the pA2 value of buprenorphine. The slope 
of the linear regression line derived from the Schild plot for buprenorphine (Figure 
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3.35 (right)) was 1.432 ± 0.321 (0.691-2.172) which was not significantly different to 
unity. This has permitted the slope to be constrained to 1 to estimate the pA2 value 
(= pKB) of buprenorphine which was 9.665 (9.468-10.100). The pA2 value of 
buprenorphine has also been estimated using the Schild equation. Although the 
slope of the linear regression is not significantly different from unity, the confidence 
interval is wide. Using the Schild equation, the estimated pA2 value for 
buprenorphine was 9.837 ± 0.057. These two values have shown to be not 
statistically different. Based on the graph pattern seen in Figure 3.39(left), 
buprenorphine appears to behave as a pseudo-irreversible antagonist at the µ-
opioid receptor in this system. This could be explained by the slow dissociation 
kinetics of buprenorphine, which will be discussed in further detail in the discussion 
section. The parallel rightward shift of DAMGO concentration-response curves in the 
presence of buprenorphine (Figure 3.35 (left)) and the previously shown lack of 
activity of 10 µM buprenorphine on its own (Figure 3.20) demonstrate that 
buprenorphine acts as a -opioid receptor antagonist in rat vas deferens.  
 
BU127 
Up to 10 experiments were performed to evaluate the activity of compound BU127 
at the -opioid receptor in rat vas deferens. Unfortunately, on some days, the tissue 
was less responsive to DAMGO than usual as evidenced by the wide range in the 
EC50 of the DAMGO control curves (219.7-4705.0 nM). When the tissue was less 
responsive, a higher concentration of DAMGO (300 µM) was needed to define the 
maximal response (Emax). Because such high concentrations of DAMGO were 
required, theoretically more -opioid receptors needed to be activated in order to 
produce the response. This situation is likely to be due to lower receptor reserve in 
the tissues where DAMGO was seen as less potent. Indeed, there is good evidence 
that the rat vas deferens has a lower -opioid receptor density compared to mouse 
vas deferens and guinea pig ileum as discussed earlier (Smith et al., 1983). This 
problem becomes more prominent when the control curve in the presence of 1 nM 
BU127 was constructed where the maximal response cannot be defined even when 
300 µM DAMGO was used. Figure 3.36 represents traces from a single tissue 
where the EC50 for DAMGO was 4705.0 nM.  
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Figure 3.36: Electrically evoked contractions of rat vas deferens. Concentration-response 
curve to DAMGO obtained in the absence and in the presence of increasing concentrations 
of BU127 (0.1-1 nM) conducted from a single experiment. 
 
Based on the results obtained (Figure 3.36), it was not possible to determine the 
maximal response to DAMGO, and so it was not possible to derive accurate EC50 
values required to construct the Schild plot. Therefore, we decided to exclude data 
from tissues where the DAMGO maximal response could not be empirically 
determined (Figure 3.37 (left)). This excluding criteria is only applied for BU127, 
since no similar problem (Figure 3.36) was observed on days when other 
compounds were tested in the rat vas deferens assay.  
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Figure 3.37: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to DAMGO obtained in the absence and in the presence of increasing 
concentrations of BU127 (0.1-1 nM); the corresponding Schild plot is shown on the right. The 
straight line (red) is after the slope was constrained to 1 and the dotted line (black) is the 
best fit line. Points represent means, and vertical lines represent S.E.M. of at least seven 
experiments.  
   
Based on the results presented in Figure 3.37 (left), no decrease in the maximal 
response was detected in the presence of compound BU127 at all concentrations 
used (n = 7-10). This suggests that BU127 acts as a competitive reversible 
antagonist. This was supported by the findings revealed from the Schild plot (n =    
7-10, Figure 3.37 (right)) where the slope from the best fit line was found to be not 
significantly different to unity (1.217 ± 0.196 (0.810-1.624)). The pA2 value for 
compound BU127 was 10.33 (10.17-10.50) when the slope was constrained to 1.  
 
BU10101 
Similar to compound BU127, BU10101 was also found to be a competitive 
reversible antagonist at this receptor with the pA2 value of 9.846 (9.644-10.050) 
derived from the Schild plot (n = 3-4). The slope obtained from the best fit line was 
1.014 ± 0.240 (0.471-1.558) which was not significantly different to unity.  No 
decrease in the maximal response was detected in the presence of increasing 
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concentrations of BU10101 compared to control. The results are presented in Figure 
3.38. 
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Figure 3.38: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to DAMGO obtained in the absence and in the presence of increasing 
concentrations of BU10101 (0.1-1 nM); the corresponding Schild plot is shown on the right. 
The straight line (red) is after the slope was constrained to 1 and the dotted line (black) is the 
best fit line. Points represent means, and vertical lines represent S.E.M. of at least three 
experiments.  
 
BU10119 
Compound BU10119 was slightly different in structure compared to its closest 
analogue (BU127). As presented in Figure 3.39, compound BU10119 was also 
found to be a competitive reversible antagonist in nature with no suppression of the 
maximal DAMGO response compared to control (n = 6) in the presence of 
increasing concentrations of BU10119 (0.1-1 nM). 
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Figure 3.39: Electrically evoked contractions of rat vas deferens. Left, concentration-
response curve to DAMGO obtained in the absence and in the presence of increasing 
concentrations of BU101119 (0.1-1 nM); the corresponding Shild plot is shown on the right. 
The straight line (red) is after the slope was constrained to 1 and the dotted line (black) is the 
best fit line. Points represent means, and vertical lines represent S.E.M. of six experiments.  
 
The best fit line gave a slope of 0.878 ± 0.277 (0.288-1.468) which was not 
significantly different to unity. The pA2 value for compound BU10119 was 10.08 
(9.847-10.310) when determined from the correspondence Schild plot (n = 5-6) after 
the slope was constrained to 1.  
 
Discussion 
 
Are buprenorphine and its analogs -opioid receptor agonists or antagonists ? 
 
Buprenorphine has a high affinity at the -opioid receptor (subnanomolar to 
nanomolar concentrations) and has a wide range of efficacy from a complete 
antagonist to a partial -opioid receptor agonist (0-65% receptor stimulation) in vitro 
across various assay systems (Huang et al., 2001; Kajiwara et al., 1986; Lee et al., 
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2011; Lutfy et al., 2003b; Spagnolo et al., 2008). This was in line with our findings 
where in both [35S]GTPγS and rat vas deferens assays, buprenorphine shows high 
affinity for the -opioid receptors, with the binding affinity values of 0.195 ± 0.02 nM 
and 0.15 nM (0.10-0.23 nM) respectively. In term of efficacy, buprenorphine shows 
partial efficacy in the [35S]GTPS assay at the -opioid receptor with 33 ± 12% 
receptor stimulation, obtained from Traynor’s lab (Figure 3.2 and Table 3.2). A 
similar [35S]GTPγS experiment conducted in CHO transfected cells also found 
buprenorphine to be a potent partial -opioid receptor agonist with an EC50 of 24.9 ± 
14 nM and an Emax of 17.7 ± 0.4% (Spagnolo et al., 2008). Further functional 
experiments conducted in mouse vas deferens have shown that buprenorphine was 
as potent as nociceptin in inhibiting the electrically evoked contraction, but produced 
different maximal response, with Emax of 63 ± 4% and 92 ± 1% respectively. 
Although buprenorphine has partial efficacy at both the ORL-1 and -opioid 
receptors, the inhibition seen in mouse vas deferens was believed to be mediated 
by the -opioid receptor (Spagnolo et al., 2008). A different assay system which 
measures opioid activity through the activation of mitogen-activated protein kinase 
(MAP kinase) in vitro also showed that buprenorphine is a partial agonist, with low 
efficacy but high affinity at the -opioid receptor with an Emax of 42.97 ± 4.65% (Lutfy 
et al., 2003b). However in our assay, conducted in rat vas deferens, buprenorphine 
did not show any efficacy even at 10 µM (Figure 3.20). This was supported by a 
previous study where buprenorphine also failed to show any efficacy in the rat vas 
deferens system when tested at doses ranging from 10 nM-10 µM (Kajiwara et al., 
1986). The failure of buprenorphine and its analogues to show any efficacy in rat 
vas deferens system is related to the lower -opioid receptor population in rat vas 
deferens and therefore a lower capacity of receptor reserve as compared to the 
other systems. Despite this limitation, in that it is not possible to determine agonist 
potency of lower efficacy agonists in the rat vas deferens, it can actually be 
considered as an advantage in our assays since it allows the affinity of 
buprenorphine at the -opioid receptor to be easily measured.  
 
In our assay, buprenorphine was an antagonist at the -opioid receptor and caused 
a parallel rightward shift of the DAMGO control curves (Figure 3.35 (left)) with  pA2 
value of 9.782 (9.468-10.100) derived from Schild plot and estimated pA2 value of 
9.837 ± 0.057 calculated using Schild equation. Based on the concentration-
response curve constructed in the presence of increasing concentration of 
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buprenorphine (Figure 3.35 (left)), buprenorphine appeared to behave as a pseudo-
irreversible antagonist. Although there is no significant suppression of the maximal 
response of DAMGO in the presence of buprenorphine, the decreasing pattern 
visibly observed from the concentration-response curve of DAMGO and the 
maximum parallel shift at ≥ 3 nM buprenorphine suggest that buprenorphine is not a 
competitive reversible antagonist at this receptor (Kenakin, 2009). Previous studies 
conducted in mouse vas deferens have proven buprenorphine to have a slow onset 
and also difficult removal from the tissue (slow receptor off-set) even after repeated 
prolonged washing (Kajiwara et al., 1986; Kosterlitz et al., 1975). As a result, there 
will be fewer -opioid receptor site left for the agonist to occupy, which could explain 
the decreasing in the maximal response of agonist, especially after the tissue was 
pre-treated with a high concentration of buprenorphine (≥ 3 nM) (Englberger et al., 
2006). Kajiwara et al (1986) believed that the difficulties to wash off buprenorphine 
from the tissues were due to the high lipophilicity of buprenorphine, where 
buprenorphine was believed to be trapped in the tissue membranes. As reported by 
Kajiwara (1986), buprenorphine took 2 hours to be completely removed from the 
mouse vas deferens tissue while it failed to be removed from the guinea pig ileum 
even after 2 hours washing. Although Kajiwara (1986) has postulated that this 
incidence was due to the high lipophilicity of buprenorphine, our recent findings with 
the buprenorphine analogues suggest that besides lipophilicity, there could be other 
factors that also contribute to the pseudo-irreversibility behaviour of buprenorphine. 
From our assay, compounds BU10101 (log P = 4.45) and BU10119 (log P = 4.37) 
were more lipophilic than buprenorphine (log P = 3.99), as shown with the 
calculated log P value, however were proven to be competitive reversible 
antagonists in this system (Table 3.12). Moreover, compound BU127 which has 
similar lipophilicity value with buprenorphine (3.96 and 3.99 respectively), has 
shown a competitive reversible behaviour in this assay system. It is not surprising 
that buprenorphine has different antagonist behaviour than its analogue, BU127, 
since buprenorphine and fentanyl which have similar physicochemical properties 
(lipophilicity), also were proven to have different receptor kinetics 
(pharmacodynamics) profiles in vivo (Yassen et al., 2005). This suggests that there 
are other factors that could explain the pseudo-irreversibility behaviour of 
buprenorphine compared to the rest of the analogues tested at this receptor in this 
assay system. Based on their chemical structures, buprenorphine has a t-butyl 
group attached at the C20 position of orvinol (Figure 1.3(c)), while BU127 and other 
analogues tested (BU10101 and BU101119) has a phenyl ring with only one small 
group attach to the phenyl at most (Figure 2.3 and Figure 3.3). Buprenorphine has 
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been shown to have a restricted rotation ability about the C7 and the C20 position 
due to the t-butyl moeity (Loew et al., 1979), compared to other analogues tested. 
This could theoretically suggest that the chemical structures at this region (C7,C20) 
could contribute to the different antagonist behaviour of buprenorphine compared to 
its analogues, for example by tightly locking buprenorphine to the -opioid receptor 
binding sites once it was bound to the receptors compared to others.  
 
Furthermore, it is interesting to note that although buprenorphine appears to be 
pseudo-irreversible at the -opioid receptor, it is fully reversible at the ORL-1 
receptor, in the same tissue. Again, suggesting that the mechanism for its pseudo-
irreversible effects at the -opioid receptor are by a mechanism other than high 
lipophilicity. 
 
Similar to the results seen previously in the ORL-1 receptor assays, none of the 
compounds evaluated (including buprenorphine) show efficacies at the -opioid 
receptors in the rat vas deferens whereas these compounds manage to stimulate 
the ORL-1 receptor in the [35S]GTPγS as reported by Traynor’s lab (2-33% receptor 
stimulation) (Table 3.2). Again, this is likely to be due to the different receptor 
reserve in these two assay system. 
 
Structure modification and effects on -opioid receptor efficacy 
 
In the current work, our aim was to synthesise buprenorphine analogues with very 
low partial efficacy or antagonism at the -opioid receptor. Based on Traynor’s 
results, replacing the aliphatic alkyl group (as in buprenorphine) with a simple 
aromatic substituent at the C20 position of the orvinol has decreased the efficacy of 
analogues at the -opioid receptor compared to the parent drug, buprenorphine. 
This can be seen in compound BU127, BU08026, BU11001 and BU10119 (Figure 
3.40). 
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Figure 3.40: [
35
S]GTPγS efficacy screening of buprenorphine and its analogues performed in 
C6 glioma transfected cells. Efficacies of buprenorphine and its analogues at 10 µM were 
compared against the standard -opioid receptor agonist (DAMGO) in triplicate. BU127, 
BU08026, BU11001 and BU10119 (marked in blue) shows significantly lower efficacy at the 
µ-opioid receptor compared to the rest of the orvinol series (Traynor (unpublished work)). 
 
However, unlike the ORL-1 receptor, introducing a small group on the aromatic 
substituent appears to increase the efficacy of analogues at the -opioid receptor 
(BU10101, BU10093, BU10112, BU10092 and BU10136 and BU10135). These 
effects in increasing the -opioid receptor efficacy were most obviously seen when a 
small group was attached at the furthest position on the aromatic substituent as can 
be seen in compounds BU10136 and BU10135. Compound BU10136 has a chloro 
attached to the 5-position of the thiophene substituent, while compound BU10135 
has a methyl group attached at para position of the phenyl substituent. The smallest 
effects were seen in compounds BU10101, BU10093 and BU10112 when a small 
group was attached at the 2-position of the thiophene (BU10093) or at the ortho 
position of the phenyl substituent (BU10101 and BU10112). The size of the aromatic 
system (5/6 members ring) does not influence the analogues efficacy at the -opioid 
receptor as was seen previously at the ORL-1 receptor. 
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Affecting antagonist potency of compounds at the -opioid receptor 
 
The binding affinity (KB) obtained for naltrexone was 1.26 nM (0.74-2.16 nM) which 
was similar to the value previously reported using the same assay system in Wistar 
rats (0.91 ± 0.10 nM) (Al-Khrasani et al., 2007). The KB value for naltrexone at the  
-opioid receptor derived from this functional assay was also close to the binding 
affinity (Ki) obtained from the receptor binding assays performed in mouse brain 
which were 1.26 nM (0.74-2.16 nM) and 2.57 ± 0.48 nM respectively (Uwai et al., 
2004). 
 
All of the compounds evaluated were found to be at least 2 times more potent than 
naltrexone, the standard -opioid receptor antagonist used in this assay. Out of all 
the buprenorphine analogues analyzed at this receptor, only compound BU127 
showed a significantly higher potency compared to buprenorphine with pA2 value of 
10.33 (10.17-10.50) and 9.814 (9.631-9.995) respectively. Compared to BU127, the 
introduction of a methyl group at the ortho position of the phenyl substituent 
(BU10101) has decreased the potency towards the -opioid receptor almost 3-fold, 
with the comparative pA2 value of 10.33 (10.17-10.50) and 9.846 (9.664-10.050) 
respectively (Table 3.12). From the rat vas deferens assay, it was also found that 
the presence of a methyl at C7 position of the orvinol did not affect the potency of 
this orvinol series towards the -opioid receptor as was seen at the ORL-1 receptor. 
There was no evidence to suggest any relation between the lipophilicity of the 
compound and their antagonistic behaviour at the -opioid receptor in rat vas 
deferens (Table 3.12). All analogues evaluated at the -opioid receptor in this 
system displayed competitive reversible behaviour, except for the parent drug 
buprenorphine.  
 
The summary of the results are presented in Table 3.12. 
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Compound pA2 KB (nM) Log P Potency vs. 
Buprenorphine 
Antagonist Behaviour 
Naltrexone 
 
8.898 
(8.665-9.131) 
1.26 
(0.74-2.16) 
0.82 0.1 Competitive reversible 
 
 
 
 
 
 
Buprenorphine 
 
9.782 
(9.468-10.100) 
or 
9.837 ± 0.057 
 
0.15 
(0.10-0.23) 
or 
0.15 
(0.13-0.17) 
 
3.99 1 Pseudo-irreversible 
 
 
 
 
 
 
BU127 
 
10.33 
(10.17-10.50) 
0.047 
(0.032-0.068) 
3.96 3.3 Competitive reversible 
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BU10101 
 
9.846 
(9.644-10.050) 
0.14 
(0.089-0.23) 
4.45 1.1 Competitive reversible 
 
 
 
 
 
 
BU10119 
 
10.08 
(9.847-10.310) 
0.083 
(0.049-0.14) 
4.37 1.8 Competitive reversible 
 
 
 
 
 
 
 
Table 3.12: Summary of -opioid receptor assays conducted in rat vas deferens. 
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3.4.5.3 -opioid receptor mouse vas deferens assays 
 
While the previous two assays were performed in rat vas deferens, mouse vas 
deferens was used to evaluate the compounds functional activity at the -opioid 
receptors. Buprenorphine and two of its analogues (BU127 and BU10119) were 
evaluated against U-69593, a selective -opioid receptor agonist. Since this was the 
final assay used, the selection of buprenorphine analogues to be evaluated were 
based on their successful profile at all opioid receptors shown during the [35S]GTPS 
initial efficacy screening (Figure 3.2), especially at the -opioid receptors. BU127 
was included since this compound is the lead in this project. 
 
The potency of buprenorphine and its analogues at the κ-opioid receptor were 
compared against norbinaltorphimine (nor-BNI), a selective -opioid receptor 
antagonist. In guinea pig brain membranes, nor-BNI is about 150-fold more selective 
at -opioid receptor compared to - and -opioid receptors with binding affinities (Ki) 
of 0.28 ± 0.07 nM, 47.2 ± 3.3 nM and 42.9 ± 11.0 nM respectively (Takemori et al., 
1988). 
 
Due to the reasons mentioned previously in the methods section, we decided to use 
just one antagonist concentration per tissue. The Schild equation (single 
concentration method) was used to determine the pA2 value of the test compounds. 
The disadvantage of performing assays using only one single concentration of 
antagonist was that it only gave an empirical estimation of the potency (pA2) and 
affinity constant (KB). The antagonist behaviour of the test compounds (eg: whether 
the antagonist is competitive or pseudo-irreversible) also cannot be determined. 
Therefore, we only aimed to compare the potency of the analogues to 
buprenorphine through this assay. 
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As previously mentioned, all tissues were pre-incubated with 1 µM CTAP (a 
selective -opioid receptor antagonist) 15 minutes before U-69593 or test 
compounds were administered in order to standardize the experimental protocol.  
 
Results 
 
nor-BNI 
Nor-BNI at 1 µM concentration has been previously reported to cause a slight 
inhibition of the electrically evoked contraction in mouse vas deferens with Emax of 
16 ± 6% (Portoghese et al., 1987). The receptor mediating the agonist response 
observed in the mouse vas deferens tissue was not discussed in this paper. 
However, in our experiment, nor-BNI did not show any efficacy in the mouse vas 
deferens even at 10 µM (Figure 3.41). 
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Figure 3.41: Effects of nor-BNI (10 M) on electrically evoked contractions of mouse vas 
deferens.  
. 
1 µM CTAP was used to block any -opioid agonist mediated activity of the 
compounds evaluated. A previous study has shown that although CTAP is a           
-opioid selective antagonist, at 10 µM concentration it has ability to significantly 
block the -opioid agonist activity (2-opioid receptor subtype) of U-69593 at 10 µM 
concentration (Heyliger et al., 1999). However this study, conducted using 
[35S]GTPγS binding technique performed in guinea pig caudate membranes, also 
proved that at a 1 µM concentration CTAP did not reduce the efficacy of U-69593 at 
the -opioid receptor.  
 
The trace obtained with 10 µM nor-BNI in the presence of 1 µM CTAP is shown in 
Figure 3.42. 
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Figure 3.42: Effects of nor-BNI (10 M) in the presence of CTAP (1 M) on electrically 
evoked contractions of mouse vas deferens.  
 
Concentration-response curves of U-69593 (1 nM-3 µM) were constructed in the 
absence and in the presence of single concentrations of nor-BNI (Figure 3.43).  
 
 
 
LabChart Reader Window
C
h
a
n
n
e
l 
2
 (
g
)
0.2
0.3
0.4
0.5
0.6
22
1
0
m
cM
 n
o
r-
B
N
I
o
ff
 &
 d
o
n
e
5:00:00 5:05:00 5:10:00 5:15:00
24
 4:55:26.830
5 mins 
163 
 
log[U-69593]
%
 
In
h
ib
it
io
n
 
o
f
e
le
c
t
r
ic
a
ll
y
-
e
v
o
k
e
d
c
o
n
t
r
a
c
t
io
n
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
control
1 nM nor-BNI
log[U-69593]
%
 
In
h
ib
it
io
n
 
o
f
e
le
c
t
r
ic
a
ll
y
-
e
v
o
k
e
d
c
o
n
t
r
a
c
t
io
n
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
control
5 nM nor-BNI
 
Figure 3.43: Electrically evoked contractions of mouse vas deferens. Concentration-
response curve to U-69593 obtained in the absence and in the presence of 1 nM nor-BNI 
(left) and 5 nM nor-BNI (right). Points represent means from two separate experiments. 
 
An individual pA2 was calculated for each set of experiments (n = 4) and gave the 
average value of 9.545 ± 0.123 (9.155-9.935).  
 
Buprenorphine 
A previous study has shown that buprenorphine inhibits the electrically evoked 
contraction of mouse vas deferens at a concentration ≥ 1 µM, which is shown to be 
-opioid receptor mediated (Spagnolo et al., 2008). Therefore, instead of testing the 
effects of buprenorphine alone in this tissue, we decided to directly block any         
-opioid receptor mediated efficacy of buprenorphine in this assay by pre-incubating 
the tissue with the selective -opioid receptor antagonist, CTAP (Heyliger et al., 
1999), in order to more accurately determine the affinity of buprenorphine at the     
-opioid receptor. 
 
A 10 µM concentration of buprenorphine (in the presence of 1 µM CTAP) does not 
inhibit electrically evoked contraction of the mouse vas deferens, which confirmed 
buprenorphine has no efficacy at the -opioid receptors in this system up to 10 µM. 
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1 µM CTAP sufficiently blocked any -opioid agonist mediated response induced by 
buprenorphine  (Figure 3.44). 
 
 
Figure 3.44: Effects of buprenorphine (10 M) in the presence of CTAP (1 M) on electrically 
evoked contractions of mouse vas deferens.  
 
The functional assays conducted for buprenorphine (n = 6) gave the average pA2 
value of 9.245 ± 0.105 (8.975-9.515). The concentration-response curves in the 
presence and in the absence of buprenorphine are presented in Figure 3.45 as 
follows: 
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Figure 3.45: Electrically evoked contractions of mouse vas deferens. Concentration-
response curve to U-69593 obtained in the absence and in the presence of 1 nM 
buprenorphine (left) and 3 nM buprenorphine (right). Points represent means, and vertical 
lines represent S.E.M. of three experiments.  
 
There is no significant decrease in the maximal response and hill slope of the 
agonist concentration-response curve in the presence of buprenorphine at both 
concentrations, which at this point suggests that buprenorphine might be a 
competitive antagonist. However, it is important to highlight that the single 
concentration method cannot be used to estimate the antagonist behaviour of the 
compound (Kenakin, 2009). In addition, the single concentration method assumes 
that the antagonist is competitive and the equilibrium between the agonist, 
antagonist and the receptors has been achieved (Leslie, 1987).  
 
Both the lack of activity of 10 µM buprenorphine (in the presence of 1 µM CTAP) 
and also the parallel rightward shift of U-69593 concentration-response curves in the 
presence of buprenorphine (pre-incubated with 1 µM CTAP) (Figure 3.45) 
demonstrated that buprenorphine acts as a -opioid receptor antagonist in mouse 
vas deferens.  
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BU127 
Similar to buprenorphine, in order to standardize the assay protocol, the tissue was 
directly pre-incubated with CTAP without testing the effects of BU127 alone in the 
tissue. A 10 µM loading concentration of BU127 (in the presence of 1 µM CTAP) did 
not inhibit the electrically evoked contraction of mouse vas deferens, which 
confirmed BU127 has no -opioid receptor efficacy in this system up to 10 µM 
(Figure 3.46). However a slight increase in the amplitude of baseline twitches (33%) 
was detected after 2 minutes of BU127 administration. The reason for this elevation 
was still unclear. There is the possibility that BU127 might be an inverse agonist, but 
in order to ensure this possibility, an extensive investigation needs to be done (Cruz 
et al., 1996). An ‘inverse agonist’ refer to a compound that is able to spontaneously 
formed a new receptor active sites once it is bound to the receptors (Kenakin, 2009). 
An inverse agonist compound will have a higher binding affinity towards an inactive 
receptor site compared to the active receptor sites, thus cause opposite response of 
the agonist (de Ligt et al., 2000). Since the baseline twitch was unaffected in the 
presence of lower concentration of BU127 (1 nM) that was used in this assay 
(Figure 3.47), no further investigation is done for compound BU127 to establish its 
inverse agonism activity. 
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Figure 3.46: Effects of BU127 (10 M) in the presence of CTAP (1 M) on electrically evoked 
contractions of mouse vas deferens.  
 
 
Figure 3.47: Effects of BU127 (1 nM) in the presence of CTAP (1 M) on electrically evoked 
contractions of mouse vas deferens.  
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An individual concentration-response curve of U-69593 in the presence of various 
concentrations of compound BU127 (n = 5) caused a parallel rightward shift of the 
control curve as low as at 0.5nM BU127. The graphs as shown in Figure 3.48: 
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Figure 3.48: Electrically evoked contractions of mouse vas deferens. Concentration-
response curve to U-69593 obtained in the absence and in the presence of 0.5 nM BU127 
(top, left), 1 nM BU127 (top, right) and 3nM BU127 (bottom). Points represent means from 
two separate experiments (except only one experiment at 1 nM BU127).  
 
Using the Schild equation (single concentration method), the average pA2 value 
calculated for compound BU127 was 9.591 ± 0.086 (9.317-9.865). Both the lack of 
apparent agonist activity of 10 µM BU127 (in the presence of 1 µM CTAP) and also 
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the parallel rightward shift of U-69593 concentration-response curves in the 
presence of BU127 (pre-incubated with 1 µM CTAP) (Figure 3.48) demonstrated 
that BU127 acts as a -opioid receptor antagonist in mouse vas deferens.   
 
BU10119 
A 10 µM concentration of BU10119 (in the presence of 1 µM CTAP) did not inhibit 
the electrically evoked contraction of mouse vas deferens, which confirmed 
BU10119 has no efficacy in this system at least up to 10 µM (Figure 3.49). Similar to 
compound BU127, a slight increase (13%) of baseline twitches was also detected 
after 2 minutes of BU10119 administration. However, no baseline elevation was 
detected when lower concentration of BU10119 (0.5 nM) was used (Figure 3.50). 
 
 
Figure 3.49: Effects of BU10119 (10 M) in the presence of CTAP (1 M) on electrically 
evoked contractions of mouse vas deferens.  
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Figure 3.50: Effects of BU10119 (0.5 nM) in the presence of CTAP (1 M) on electrically 
evoked contractions of mouse vas deferens.  
 
Five individual experiments using the various concentrations of compound BU10119 
between 0.1-3 nM were conducted in order to estimate the pA2 value of this 
compound (Figure 3.51).  
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Figure 3.51: Electrically evoked contractions of mouse vas deferens. Concentration-
response curve to U-69593 obtained in the absence and in the presence of 0.1 nM BU10119 
(top, left), 0.5 nM BU10119 (top, right) and 3 nM BU10119 (bottom). Points represent means 
from two separate experiments (except only one experiment at 3 nM BU10119).  
 
From these assays, compound BU10119 was found to have an average pA2 value 
of 9.831 ± 0.235 (9.084-10.58), calculated using the Schild equation (single 
concentration method). Both the lack of activity of 10 µM BU10119 (in the presence 
of 1 µM CTAP) and also the parallel rightward shift of U-69593 concentration-
response curves in the presence of BU10119 (pre-incubated with 1 µM CTAP) 
(Figure 3.51) demonstrated that BU10119 acts as a -opioid receptor antagonist in 
mouse vas deferens.  
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Discussion 
 
An individual pA2 value for nor-BNI was calculated from each set of experiments 
giving the average pA2 value of 9.545 ± 0.123 (9.155-9.935). The potency of       
nor-BNI at the -opioid receptor estimated from our mouse vas deferens assay 
using the Schild equation (single concentration method) (0.29 nM (0.12-0.70 nM)) 
was similar to the value reported from a radioligand binding assay conducted using 
guinea pig brain membranes (0.28 ± 0.07 nM) (Takemori et al., 1988). Other studies 
have reported a slightly higher binding affinity of nor-BNI in their assay systems. For 
example, a previous study conducted in the [35S]GTPγS binding assay using guinea 
pig caudate membranes has reported a higher binding affinity of     nor-BNI (Ki = 
0.03 nM) (Heyliger et al., 1999). This was similar to the value reported by the other 
study performed in the mouse vas deferens using a single antagonist concentration 
per tissue, which estimates the potency of nor-BNI to be 0.06 ± 0.02 nM (Bell et al., 
1998). However, the differences were only about 5-fold compared to the values 
obtained from our experiments and the study conducted by Takemori (1998) which 
were in the subnanomolar range. 
 
Buprenorphine was proven to be a -opioid receptor antagonist in the mouse vas 
deferens assay with an estimated potency (pA2) of 9.245 ± 0.105 (8.975-9.515) 
(Figure 3.45). From Traynor’s [35S]GTPγS initial efficacy screening, 10 µM 
buprenorphine totally failed to stimulate the -opioid receptor in this system (% 
stimulation = -12 ± 9%). Traynor’s result was in line with the previous published 
data, where buprenorphine also failed to stimulate the -opioid receptor at < 10 µM 
(Spagnolo et al., 2008). A subnanomolar to nanomolar potency of the buprenorphine 
at the -opioid receptor predicted from our assay (0.57 nM (0.31-1.06 nM)) was not 
much different from buprenorphine binding affinity (Ki) that has been previously 
reported which (between 0.11-1.5 nM), conducted in CHO transfected cells stably 
expressing the -opioid receptor (Huang et al., 2001; Spagnolo et al., 2008; Toll et 
al., 1998). While most of the studies have confirmed the non-existence of -opioid 
receptor efficacy mediated by buprenorphine, Huang et al (2001) have reported 
otherwise. Through [35S]GTPγS binding assays using similar cell lines, (-)-
buprenorphine was reported to produce 10 ± 4% maximal response with an EC50 
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value of 0.04 ± 0.01 nM, while no stimulation was reported when (+)-buprenorphine 
was tested (Huang et al., 2001). From this study, Huang et al (2001) concluded 
buprenorphine behaves as a pure antagonist to low partial agonist at the -opioid 
receptor.  
 
Structure modification and effects on -opioid receptor efficacy 
 
For this receptor, our aim was to synthesise buprenorphine analogues that have no 
efficacy (antagonist) at the -opioid receptor. Together, with having efficacy at ORL-
1 receptor, -opioid receptor antagonism may hold the major key in preventing 
relapse to drug addiction as mentioned earlier in this thesis as evidenced through 
buprenorphine/naltrexone combination therapy (Spagnolo et al., 2008). 
Unfortunately, as can be seen from Traynor’s initial screening, the majority of the 
buprenorphine analogues show full efficacy at -opioid receptor with > 80% receptor 
stimulation (Figure 3.52).  
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Figure 3.52: [
35
S]GTPγS efficacy screening of buprenorphine and its analogues performed in 
chinese hamster ovarian (CHO) transfected cells. Efficacies of buprenorphine and its 
analogues at 10 µM were compared against a standard -opioid receptor agonist (U-69593) 
in triplicate. BU127, BU10119, and BU10112 (marked in red) shows significantly lower 
efficacy at the -opioid receptor compared to the rest of the orvinol series (Traynor 
(unpublished work)). 
 
Only compounds BU10119 and BU10112 have met the desired profile at the          
-opioid receptor with almost no receptor stimulation for BU10119 (0 ± 1% 
stimulation) and 6 ± 2% stimulation (BU10119). Compound BU127 can also be 
considered as having a potential profile at the -opioid receptor with a comparatively 
low receptor stimulation (19 ± 0 %) in the [35S]GTPγS assay compared to the 
majority of the analogues synthesised. From this initial efficacy screening, few 
modifications seem to efficiently sustain buprenorphine analogues profile at the -
opioid receptor as seen in the parent drug, buprenorphine. The presence of a methyl 
group at the C7 position of orvinol has maintained the -opioid antagonistic profile of 
compounds BU10119 and BU10112. For example, compound BU10119 which is an 
analogue of BU127; both have a simple phenyl substituent group attach to the C20 
position of the orvinol. However, it is suggested that compound BU10119 has zero 
efficacy at the -opioid receptor due to the presence of a methyl group at the C7 
position, as compared to a proton at this position in BU127. Another example is 
compound BU10112 which is an analogue of BU10101. Both have a methyl group 
175 
 
attached at the ortho position of the phenyl substituent at the C20 position of the 
orvinol. Based on Figure 3.52, compound BU10112 only shows 6 ± 2% stimulation 
at the -opioid receptor compared to compound BU10101 which highly stimulates 
the -opioid receptor in this system (90 ± 3%). Although compound BU10112 has an 
unsaturated bridge at C18-C19 in the morphinan ring, the ability of this compound to 
display antagonistic properties at the -opioid receptor is believed to be due to the 
presence of a methyl group at the C7 position. On the other hand, introducing a 
small aromatic system seems to be unhelpful in optimizing the analogue’s profile at 
the -opioid receptor as can be seen with compound BU08026 (2-thiophene). 
Moreover, relocating sulphur from 2-thiophene to 3-thiophene seems to drastically 
increase the efficacy from a partial to a full -opioid receptor agonist. Therefore the 
thiophene substituent was not ideal at this receptor. Since only a few analogues 
were evaluated at this receptor, the structure activity relationships being developed 
are only preliminary. 
 
Affecting antagonist potency of compounds at the -opioid receptor 
 
In terms of potency, there is little difference between buprenorphine and the 
analogues evaluated at the -opioid receptor in mouse vas deferens, suggesting 
that neither the modification at C7 nor C20 of orvinols had significant impact on 
buprenorphine’s potency at the -opioid receptor.  
 
The summary of the findings are shown in Table 3.13. 
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Compound pA2 KB (nM) Log P Potency vs. Buprenorphine 
nor-BNI 
 
9.545 ± 0.123 
(9.155-9.935) 
0.29 
(0.21-0.38) 
N.D 2 
Buprenorphine 
 
9.245 ± 0.105 
(8.975-9.515) 
0.57  
(0.31-1.06) 
3.99 1 
BU127 
 
9.591 ± 0.086 
(9.317-9.865) 
0.26 
(0.14-0.48) 
3.96 2.2 
177 
 
BU10119 
 
9.831 ± 0.235 
(9.084-10.58) 
0.15 
(0.026-0.82) 
4.37 3.9 
 
Table 3.13: Summary of -opioid receptor assays conducted in mouse vas deferens. 
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CHAPTER 4.0: CONCLUSION 
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Compounds 
 
Profiles Opioid receptors Relative potency  
to buprenorphine 
Antagonist behaviour  
(Reversibility) 
ORL-1   ORL-1   ORL-1 
Buprenorphine [
35
S]GTPS efficacy 
pA2 
Binding affinity, KB (nM) 
24 ± 9* 
5.976 
1056.8 
33 ± 12* 
9.782 or 9.837 ± 0.057 
0.15 
-12 ± 9* 
9.245 ± 0.105 
0.57 
 
1 
 
1 
 
1 
 
C 
 
P 
BU127 [
35
S]GTPS efficacy 
pA2 
Binding affinity, KB (nM) 
14 ± 4* 
5.884 ± 0.108 
1305.9 
6 ± 0* 
10.33 
0.047 
19 ± 0* 
9.591 ± 0.086 
0.26 
 
0.8 
 
3.3 
 
2.2 
 
C 
 
C 
BU10101 [
35
S]GTPS efficacy 
pA2 
Binding affinity, KB (nM) 
45 ± 4* 
5.872 ± 0.180 
1342.8 
17 ± 4* 
9.846 
0.14 
90 ± 3* 
n.d 
n.d 
 
0.8 
 
1.1 
 
n.d 
 
P 
 
C 
BU10119 [
35
S]GTPS efficacy 
pA2 
Binding affinity, KB (nM) 
57 ± 5* 
5.745 
1762.0 
2 ± 4* 
10.08 
0.083 
-2 ± 1* 
9.831 ± 0.235 
0.15 
 
0.6 
 
1.8 
 
3.9 
 
C 
 
C 
BU10136 [
35
S]GTPS efficacy 
pA2 
Binding affinity, KB (nM) 
31 ± 4* 
6.140 
724.4 
45 ± 3* 
n.d 
n.d 
79 ± 6* 
n.d 
n.d 
 
1.5 
 
n.d 
 
n.d 
 
P 
 
n.d 
BU10112 [
35
S]GTPS efficacy 
pA2 
Binding affinity, KB (nM) 
43 ± 3* 
5.539 
2890.7 
22 ± 5* 
n.d 
n.d 
6 ± 2* 
n.d 
n.d 
 
0.4 
 
n.d 
 
n.d 
 
C 
 
n.d 
Table 4.1: Pharmacological profiles ([
35
S]GTPS binding (Traynor (unpublished work))*, potency (pA2) and binding affinity (KB) of all compounds evaluated in 
the vas deferens tissues (RVD (ORL-1 and ) and MVD ()); n.d, not determined; C, Competitive reversible; P = Pseudo-irreversible.  
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The difference in kinetics observed with buprenorphine at different opioid receptor 
types (ORL-1 and -opioid receptors) within the same strain was an interesting 
finding. Unfortunately, buprenorphine antagonist behaviour at the -opioid receptor 
cannot be determined since the assay on this tissue was based on the single 
concentration method. However, it has recently been shown that buprenorphine’s 
activity at the -opioid receptors in vivo is of much shorter duration than at the        
-opioid receptors (Paronis et al., 2011). In the rat vas deferens assays, 
buprenorphine was a competitive reversible antagonist at the ORL-1 receptor, but a 
pseudo-irreversible antagonist at the -opioid receptors. The pseudo-irreversibility of 
buprenorphine in vitro and in vivo has been widely published, and is related to its 
slow receptor off-rate (slow receptor dissociation) once it is bound to the receptors 
(Boas et al., 1985; Kajiwara et al., 1986; Kosterlitz et al., 1975). However in previous 
work, the focus was towards the -opioid receptor kinetics, whereas no work has 
been done to determine its ORL-1 receptor reversibility.  
 
It is not unusual for a compound to have different receptor kinetics at different 
receptor types. Previous studies have shown that an analogue of buprenorphine, 
BU74 (a full -opioid receptor agonist, partial opioid receptor agonist and -opioid 
receptor antagonist), has different receptor kinetics at the - and -opioid receptors 
in isolated tissues (Husbands et al., 2005). The -agonist activity of BU74 could not 
be reversed by nor-BNI (a selective -opioid receptor antagonist) or with a repeated 
prolonged washing in GPI, but was reversible by naltrindole (-opioid receptor 
antagonist) in the mouse vas deferens, suggesting the different receptor kinetics of 
BU74 at different opioid receptors. It is, however, still debatable since these assays 
were conducted in different species whether variability of the tissue environment 
could be a contributing factor (Kajiwara et al., 1986).    
 
In this project, seven orvinols related to the lead BU127 had been successfully 
synthesised by using the standard techniques for orvinol synthesis with one 
significant improvement being the use of ethyl acetate as a solvent in the catalytic 
hydrogenation. The aim of this project is to find a single compound (buprenorphine 
analogue), having a similar profile as seen with the buprenorphine/naltrexone 
combination (Gerra et al., 2006; Rothman et al., 2000). This profile has been 
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suggested to be an ideal pharmacological profile for relapse prevention to drug 
taking, including as a potential intervention for polydrug abuse (McCann, 2008). The 
intended profiles for these analogues are antagonist / very low efficacy for the        
-opioid receptor, partial efficacy at the ORL-1 receptor and antagonist at the         
-opioid receptor.  
 
Although only the analogues with the general structure A (Figure 4.1) were 
synthesised in this project, a few analogues from Husbands’ group with the general 
structure B (Figure 4.1) were also selected for evaluation in this project due to their 
interesting profiles seen during an initial [35S]GTPS efficacy screen (Figure 4.2). 
Particularly interesting was their -efficacy (relatively lower -efficacy compared to 
analogues with general structure A).  
 
 
 
 
Figure 4.1: Orvinol series with general structure (A) and (B) (Ar = aromatic substituent). 
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Figure 4.2: [
35
S]GTPγS efficacy screening of buprenorphine and its analogues performed in 
either C6 glioma or cultured chinese hamster ovarian (CHO) transfected cells. Efficacies of 
buprenorphine and its analogues at 10 µM were compared against the standard receptor 
agonists (DAMGO, U-69593 and nociceptin) in triplicate. BU127 and BU10119 (marked in 
red) shows optimum profiles at targeted opioid receptors compared to the rest of the orvinol 
series (Traynor (unpublished work)). 
 
For the series of compounds that was synthesised in this project (Figure 4.1 (A)), 
the aim was to introduce bulk around C7 and C20, by introducing a small group to the 
aromatic system in the hope of increasing the efficacy of the analogues at the ORL-
1 receptors, while retaining the -opioid antagonist activity (Husbands (personal 
communication)) and very low - efficacy as seen with the lead compound (BU127) 
(Figure 4.2). Although the relative efficacy of the analogues at the ORL-1 receptors 
did increase (compared to the unsubstituted aromatic analogues, BU127, 
BU08026), unfortunately all the analogues with a small group attached to the 
aromatic substituents also showed sudden increase in their -opioid receptor 
efficacy ( > 75% receptor stimulation relative to U-69593) (Figure 4.2). Also a 
surprise was that BU11001, an analogue of BU08026, with no group attached to the 
thiophene ring, showed completely different efficacy at the -opioid receptors. 
BU11001 (3-thiophene orvinol) has shown nearly full efficacy at the -opioid 
receptors (79 ± 2%) compared to BU08026 (2-thiophene) which had relatively lower 
-opioid receptor stimulation (30 ± 6%). Although increasing bulk by introducing a 
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small group on the aromatic substituent (C20) has had the desired effect in 
increasing the efficacy of the analogues at the ORL-1 receptors, overall this 
modification has had a negative impact due to the increase in efficacy at the -
opioid receptor. Related to the ORL-1 activity, only the efficacy of the analogues 
was increased with this modification, while the binding affinity was not greatly 
affected compared to buprenorphine and the lead compound (BU127). Although the 
binding affinity at ORL-1 of buprenorphine and its analogues was 1000-times lower 
than their binding affinity at the - and -opioid receptors, the in vivo effects on 
buprenorphine profile of ORL-1 stimulation are believed to be significant. For 
example, the bell-shaped-buprenorphine dose-response curve for buprenorphine-
induced antinociception in the wild type mice was eliminated in the presence of 
ORL-1 antagonist (Lutfy et al., 2003b). At the -opioid receptor, in general the 
binding affinity of the analogues with aromatic substituent increased compared to 
buprenorphine, but only to minimal extent (1-3 fold). The efficacy of the analogues 
towards the -opioid receptors has also decreased relative to buprenorphine with 
the aromatic substituent without the small group attached to their aromatic ring 
(BU127, BU08026, BU11001). Introducing a small group into the aromatic 
substituent has increased the efficacy of this series towards the µ-opioid receptors 
(lower efficacy to partial agonist). From these findings, it shows that in order to 
achieve the optimum opioid pharmacological profiles as mentioned before, at this 
point, the moiety needed with the analogues with general structure A is having at 
least 6-membered aromatic ring without any small group attach to the aromatic 
substituent.  
 
For the orvinol with the general structure B (Figure 4.1), the important structure 
modification is the introduction of methyl at the C7 position. From the [
35S]GTPS 
efficacy screenings (Figure 4.2), compound BU10119 has shown the highest 
efficacy at the ORL-1 receptor among the rest of the analogues tested. This 
suggests that it is not necessary to have a group attached to the aromatic 
substituent in order to improve the efficacy of the analogues at the ORL-1 receptor. 
As shown by compound BU10119 (phenyl substituent), the methyl at C7 also can act 
as bulk in place of the small group (eg: BU10101). Although it is hard to make 
definitive conclusions based on only a small number of compounds, BU10112 also 
provides evidence that the C7-methyl group is beneficial in increasing ORL-1 
efficacy and minimising stimulation of -opioid receptors. There is no big difference 
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in terms of binding affinity of this series compared to the series with general 
structure A (Figure 4.1). Therefore, it is suggested that for the orvinol with general 
structure B, essential features is having a small group at C7 (eg: methyl).  
 
Of all the analogues synthesised and evaluated, only compounds BU127 and 
BU10119 (Figure 4.3) have technically met the desired pharmacological profile at all 
targeted opioid receptors (Table 4.2) (Gerra et al., 2006; McCann, 2008; Rothman et 
al., 2000). The combined opioid profiles for the optimum buprenorphine analogues 
are partial efficacy at ORL-1 receptor, low efficacy or antagonism at the -opioid 
receptor and antagonism at the -opioid receptor (Figure 4.1). Although compound 
BU127 displayed some efficacy at the -opioid receptor in a [35S]GTPS assay, 
further in vivo studies (unpublished) conducted by Traynor’s group has confirmed 
the lack of agonist activity of this compound. The assay (mouse tail withdrawal) was 
conducted in warmed water at 48°C, a very low stimulus intensity that would have 
allowed even a low efficacy -agonist to be found (Husbands (personal 
communication)). 
 
 
Figure 4.3: Compound BU127 (15) and BU10119. 
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Table 4.2: Pharmacological profile of compound BU127 (15) and BU10119 at µ-, - and 
ORL-1 receptors. The [
35
S]GTPS data were obtained from Traynor’s group (unpublished 
work). 
 BU127 (15) BU10119 
 
[
35
S]GTPS efficacy 
- - ORL-1 - - ORL-1 
6 ± 0%* 19 ± 0%* 14 ± 4%* 2 ± 4%* -2 ± 1% * 57 ± 5% * 
Binding affinity, KB 
(nM) 
0.05 0.3 1306 0.08 0.2 1762 
Relative potency to 
standard antagonist 
3.3 2.2 0.8 1.8 3.9 0.6 
 
 
In this project, we rely on the shift in the agonist concentration-response curve in the 
presence of increasing concentration of antagonists, followed by Schild analysis to 
predict the reversibility of the compound synthesised (Kenakin, 2009). Schild 
analysis is a powerful tool to determine the affinity constant of an antagonist, while it 
indirectly evaluates the pharmacological behaviours of the compound such as the 
competitive / non-competitive receptor interaction and also the reversibility 
(dissociation) of the compound from the receptor. However, the evaluation of the 
pharmacological behaviours of the compound can also be misleading. The outcome 
of this assay system is highly reliant on the receptor reserve available in the tissue 
used. For example, a high affinity, potent antagonist does not need high receptor 
occupancy to exert its effects. In this case, this antagonist could actually be a     
non-competitive antagonist, however it can appear to show competitive reversible 
behaviour if there is sufficient unoccupied receptor left for the agonist. As a result, 
the parallel shift of the agonist concentration-response curve with no suppression of 
the maximal response still can be observed, unless a high dose of antagonist is 
used. Therefore, in future work another method that can be used to validate the 
competitive reversible antagonist behaviour of buprenorphine analogues evaluated 
from this project is by comparing the EC50 value of the standard agonist after 
repeated washing (Spagnolo et al., 2007).  
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Due to time constraints and limited resources, only limited work was done at the     
-opioid receptor. From the [35S]GTPS result, most of the compounds synthesised 
in this project had substantial efficacy at the -opioid receptor. Although in general 
this could be related to the small group attached to the aromatic system, the 
different -opioid receptor efficacy shown by both BU08026 (2-thiophene) and 
BU11001 (3-thiophene) suggests further investigation. Therefore, the GPI 
preparation is suggested in order to evaluate the -opioid receptor efficacy in the 
isolated tissue preparation. GPI is a more sensitive tissue and commonly used to 
evaluate the compounds with -opioid receptor efficacy. Although the mouse vas 
deferens also has -opioid receptor, the receptor population is lower than in the GPI 
(Leslie, 1987). 
 
 
Finally, since the introduction of C7-methyl (orvinol with general structure B, Figure 
4.1) has shown a promising overall pharmacological profile, further exploration of 
this series should be done to further our knowledge of the SAR, especially related to 
-opioid receptor efficacy. 
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Appendix I: 
Definition for pharmacology parameters (Sheehan et al., 1993) 
 
EC50 The molar concentration of an agonist which produces 50% of the 
maximum possible response for that agonist. 
ED50 Dose of drug which produces 50% of its maximum response effect. 
IC50 The molar concentration which produces 50% of its maximum possible 
inhibition (for functional assay). 
or 
The concentration of competing ligand which displaces 50% of the 
specific binding of the radioligand (for receptor binding assay). 
KB The dissociation equilibrium constant for a competitive antagonist; the 
concentration which could occupy 50% of the receptors at equilibrium. 
Ki The inhibition constant for a drug; the concentration of competing ligand 
in a competition assay which would occupy 50% of the receptors if no 
radioligand were present. 
pA2 A logarithmic measure of the potency of an agonist; the negative log of 
the concentration of antagonist which would produce a 2-fold shift in the 
concentration-response curve for an agonist. 
pKB A measure of the potency of a competitive antagonist; the negative log of 
the molar concentration which at equilibrium would occupy 50% of the 
receptors in the absence of agonist. 
pEC50 The negative log of EC50 
 
